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General Introduction and Outline
PROLOGUE: HIPPOCRATES’ LEGACY
“The physician must be able to tell the antecedents, know the present, and foretell the future 
– must mediate these things, and have two special objects in view with regard to disease, 
namely, to do good or to do no harm.” 
So wrote Hippocrates – the father of modern Western medicine – in his monumental 
work Epidemics. Ever since there have been doctors caring for ill patients, the most per-
tinent question has been: will the patient get better, and – if yes – by what therapeutic 
means? Prognosis and treatment: they are fundamental pillars in medicine, reflecting imme-
diate needs of the ill patient. However, the first step towards successfully treating an illness 
is finding out what is wrong. This process referred to as “diagnosis” is derived from the 
Greek word διαγιγνώσκειν, meaning “to discern, or to distinguish”. 
Diagnosis
Making a diagnosis involves the identification of the nature and cause of a certain phe-
nomenon. Accordingly, patients are categorised as having a disease based on a common 
aetiology, pathogenesis, or symptoms.
In the early days of medicine, the limited availability of diagnostic tools challenged the 
process of making a diagnosis. Hippocrates used whatever he could take in from his 
environment in making a diagnosis: from dietary habits, the season, prevailing winds, the 
water supply at the patient’s home, to the tasting of urine and smelling of sweat.1 In 
modern medicine, more advanced diagnostic methods have come at hand. In spite of these 
advanced methods, the process of diagnosis may currently still be challenging. First, doctors 
must agree on a definition of a specific disease. However, diagnosis and disease do not 
represent an unchangeable truth: with expanding knowledge about disease mechanisms 
and increasingly sophisticated diagnostic tools, definitions and boundaries of disease conti-
nue to shift. These shifting disease definitions do not only reflect advancing knowledge, but 
also the need for doctors to incorporate developments with a practical means to group 
patients assisting in clinical decision making. In some instances, the discovery of a mutation 
in a single gene associated with a consistent phenotype results in a clear-cut definition of 
disease and a corresponding gold standard diagnostic test, as is the case in, for instance, 
cystic fibrosis and sickle cell disease. However, in most instances the cause is not found 
in a single gene, but seems to be a complex multifactorial interplay between genes and 
environment. In more complex cases, a clear-cut definition and gold standard diagnostic 
tool may never be found.  
In making a diagnosis, the underlying concept of disease as a dichotomous state is chal-
lenged by the nature of many diseases. The clinical symptoms and laboratory indicators 
chosen to define a disease in reality represent a continuum. Disease is usually acquired by 
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degrees, starting with exposure to a particular risk factor, followed by the development 
of subclinical pathologic changes and evolution of symptoms and signs. Clearly, there is 
a smooth transition from low to high values of the diagnostic indicators with increasing 
degrees of dysfunction. Thus, most distributions of clinical variables are not easily divided 
into normal and abnormal. In reality, most diagnoses are defined by a cut-off, chosen at 
some point in the continuum between health and disease. This cut-off may be based on 
a laboratory abnormality, but may also more abstractly be seen as a combination of diffe-
rent laboratory test results and clinical signs and symptoms, of which certain sets have to 
be present to meet the diagnosis. If the cut-off of the diagnostic indicator is set too high, 
patients with the disease may be missed, thereby decreasing the sensitivity of the indicator. 
However, if the cut-off is set too low, individuals without the disease may be incorrectly 
identified as being ill, decreasing the specificity of the diagnostic indicator. In formulating 
disease definitions, there is a constant trade-off between sensitivity and specificity. 
Prognosis
Traditionally, diagnosis is seen as the primary guide to treatment and prognosis. However, 
the continuum between health and disease does not resolve once a certain cut-off is 
chosen and a patient fulfils the criteria for a particular diagnosis. Ultimately, prognostic 
implications are of primary importance to the patient. Because patients diagnosed with 
a disease may have various degrees of the disease, there is a need to stratify patients by 
prognosis. Prognosis, derived from the Greek “πρόγνωσις” (fore-knowing, foreseeing), is 
the likelihood of future outcomes in a patient with a given disease. Predicting an individual’s 
prognosis can involve a wide range of relevant and available information, including disease, 
patient, demographic, and socioeconomic factors. Thus, prognosis offers an alternative 
starting point with wider incorporation of factors relevant to patient outcomes than 
diagnosis alone. By this approach, multiple “sub-diagnoses” of prognostic subgroups can 
be made among patients with a given diagnosis. Personalised medicine, also coined preci-
sion medicine, patient-tailored medicine, or stratified medicine, is the approach in clinical 
medicine that attempts to incorporate the prognosis of individual patients. The goals of 
personalised medicine are to optimise treatment efficacy for the individual patient, and to 
minimise the risk of adverse effects due to ineffective treatment.
In this thesis, issues relating to the diagnosis and prognosis of systemic lupus erythematosus 
(SLE) were investigated, a condition in which the aforementioned understanding of disease 
as a clinical and pathologic spectrum with prognostic subgroups is clear. In the first part 
of this introduction, SLE as a heterogeneous disease will be portrayed, demonstrating 
areas from which the challenges in diagnosis and prognosis arise. In the second part, two 
of the most severe visceral manifestations of SLE – lupus nephritis and neuropsychiatric 
lupus – will illustrate that the concept of SLE as a spectrum extends to these specific 
organ manifestations. Specific challenges in the accurate diagnosis and prognosis of these 
manifestations will be pointed out. 
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PART 1: SYSTEMIC LUPUS 
ERYTHEMATOSUS
SLE is an autoimmune disease characterised by loss of tolerance against nuclear autoan-
tigens, lymphoproliferation, production of autoantibodies, immune complex disease, and 
multiorgan tissue inflammation.2 SLE is a systemic disorder that ranges from a limited 
cutaneous disorder to life-threatening multisystemic disease with major organ involvement. 
The heterogeneous manifestations of SLE and the overlap of symptoms with various other 
diseases can make its diagnosis extremely challenging. Because SLE may be accompanied 
by significant morbidity that can be fatal, prompt diagnosis and subsequent selection of 
the most effective therapy is of utmost importance for patients suffering from this disease. 
Here, diagnostic and prognostic challenges in SLE will be demonstrated by review of the 
clinical heterogeneity and aetiopathogenic complexity of this disease. First, review of the 
history will reveal how SLE with its myriad manifestations became established as an entity 
over time.
Historic background 
Disease definitions of SLE have shifted considerably throughout history, reflecting advan-
cing knowledge and increasingly sophisticated diagnostic tools. The term “lupus” (Latin for 
“wolf ”) was first used during the Middle Ages to describe erosive skin lesions reminiscent 
of a wolf ’s bite.3 The first clear description of lupus is credited to Biett of the Paris School 
of Dermatology, referring to centrifugal erythema.4 His student, Cazenave, published Biett’s 
work and coined the term “lupus érythémateux” (lupus erythematosus) in 1833. Cazen-
ave classically described lupus as a rare condition, appearing most frequently in young 
females who were otherwise healthy, mainly affecting the face. In 1846, the Viennese 
physician Ferdinand von Hebra introduced the butterfly metaphor to describe the malar 
rash characteristic of SLE.5 He and his son-in-law Moritz Kaposi also first recognised lupus 
as having a cutaneous form as well as a systemic form characterised by subcutaneous 
nodules, arthritis with synovial hypertrophy of both small and large joints, lymphadenopathy, 
fever, weight loss, anaemia, and central nervous system involvement.6 Over the next thirty 
years, pathologic studies recognised the existence of nonbacterial verrucous endocarditis 
(Libman-Sacks endocarditis),7 and wire-loop lesions in individuals with glomerulonephritis.8 
Osler wrote three papers during the years 1895–1904 in which he described the visceral 
complications of lupus erythematosus with cutaneous involvement. Retrospectively, only 
two out of the 29 patients he described definitely appear to have had SLE, while the other 
patients likely suffered from Henoch-Schönlein purpura and a number of other conditions.9 
Clearly, the early diagnosis of SLE depended largely on the finding of skin lesions, which may 
show overlap with currently known conditions including cutaneous tuberculosis, syphilis, 
vasculitis, and others. The introduction of antibiotic treatment assisted in the distinction 
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of patients with true SLE from those with confounding conditions. In 1948, the ability to 
more specifically define SLE allowed Hargraves and colleagues to study bone marrow 
preparations of 25 patients with SLE in which they revealed nuclei derived from dead 
cells that were phagocytosed by mature polymorphonuclear cells and were being digested. 
This phenomenon resulted in a distinct appearance by light microscopy coined the “LE 
cell”.10 In 1954, Miescher and Fauconnet observed that when serum from SLE patients 
was incubated with a suspension of cell nuclei, the ability to induce the LE cells was elimi-
nated. This observation indicated that either the serum factor responsible for the LE cell 
phenomenon was destroyed by exposure to the nuclei, or removed from the serum by 
reacting with the nuclei.11 In 1958, Friou demonstrated that the serum factor of patients 
with SLE that reacted with the nuclei of cells was gamma globulin, and the target in the 
nucleus was DNA forming complexes with histones.12 The serum factor was called the 
“antinuclear factor” and could be detected by an indirect immunofluorescence technique. 
These observations in the late 1950s clearly demonstrated an autoimmune pathogenic 
process underlying SLE, and paved the way for the modern era of diagnosing SLE. 
Epidemiology and symptomatology
In modern times, the reported prevalence of SLE ranges from 20 to 150 cases per 
100,000.13 SLE predominantly affects women, with a male-to-female ratio ranging from 
1:3 in children, 1:7–15 in adults, and 1:8 in older individuals.14, 15 The peak age of onset of 
SLE is between 20–40 years of age.13 African Americans and Hispanics are affected more 
frequently than Caucasians, and have higher morbidity.13
SLE can affect any part of the body, as demonstrated by its numerous clinical manifestations. 
The most common clinical signs and symptoms of SLE are shown in Figure 1. 
Because of its heterogeneous manifestations, SLE often mimics other diseases. Therefore, 
SLE is frequently coined the “great imitator”, and is thereby a classic diagnostic conside-
ration in the differential diagnosis of many diseases. Since diagnostic criteria for SLE are 
lacking, the diagnosis of SLE is usually made clinically after exclusion of other diagnoses. 
In clinical practice, classification criteria for SLE are frequently used as diagnostic criteria, 
although they serve a different purpose (Box 1).
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Figure 1 Clinical manifestations of SLE.





Diagnostic versus classification criteria 
Diagnostic criteria are a set of signs, symptoms, and tests for use in routine clinical practice to guide the care of individual 
patients.17 To be successful, diagnostic criteria must reflect the broad spectrum of different features of a disease, with the 
objective to accurately identify as many patients with the disease as possible, including those with atypical phenotypes 
of the disease. In contrast, classification criteria are primarily intended to create well-defined, homogeneous cohorts of 
patients for clinical research. Classification criteria do not aim to capture the entire population of possible patients, but 
rather to capture the majority of patients with the principal features of the condition. Hence, the goal of classification 
criteria differs from the goal of diagnostic criteria. As a consequence, classification criteria generally tend to be more 
specific, but less sensitive than diagnostic criteria. Because SLE is a very heterogeneous disease and a gold standard 
for its diagnosis is lacking, diagnostic criteria with sufficient sensitivity and acceptable specificity remain unattainable. 
Although SLE classification criteria may support a diagnosis of SLE, clinicians today are still compelled to diagnose SLE 
based upon the totality of patients’ disease manifestations. 
 
Classification of SLE
An accurate and validated set of classification criteria is critical to the interpretation of 
study findings and to the comparison of results between studies. Existing classification 
criteria for SLE have traditionally been developed with the aim to distinguish patients with 
SLE from patients with various other diseases that are mainly encountered in rheumatology 
clinics.18-20 In the development of the 1982 and 1997 American College of Rheumatology 
(ACR) and 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification 
criteria for SLE, the approach has been to include a cohort of patients recruited from 
rheumatology clinics with putative SLE as well as with other diseases that might appear 
in the differential diagnosis in that setting. In the process of the derivation of the set of 
classification criteria, experienced rheumatologists – assisted by mainly dermatologists 
and neurologists – then reached a consensus on a “reference-standard” clinical diagnosis 
for each patient in the cohort. Subsequently, various combinations of classification criteria 
were tested to investigate which have the optimal sensitivity and specificity to distinguish 
patients with SLE from those with other rheumatic diseases while at the same time do 
not falsely classify patients with other rheumatic diseases as having SLE.
The original criteria for the classification of SLE established by the American Rheumatism 
Association (ARA) in 1971 have been revised in 1982 by Tan et al.20 and updated by Hoch-
berg et al.18 in 1997 under the auspices of the ACR, resulting in a list of 11 items (Table 1). 
Accordingly, a patient can be classified as having SLE if any four or more of the criteria are 
present, serially or simultaneously, during any interval of observation. 
These ACR criteria were long used as inclusion criteria for clinical trials involving patients 
with SLE. When tested against patients with other rheumatic diseases in the derivation 
cohort of this classification, these criteria had a sensitivity of 86% and a specificity of 
93%.20 However, over the years a general consensus was reached that the ACR criteria 
over-represent cutaneous lupus, may not capture early lupus, and do not capture some 
patients with lupus nephritis and neuropsychiatric lupus.21
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Table 1 ACR classification criteria for SLE.18, 20
Criterion Definition
1. Malar Rash Fixed erythema, flat or raised 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight
4. Oral ulcers Oral or nasopharyngeal ulceration
5. Nonerosive arthritis Involving two or more peripheral joints, characterised by tenderness, swelling, 
or effusion
6. Serositis Pleuritis: typical pleurisy or pleural rub or evidence of pleural effusion or
Pericarditis: documented by electrocardiogram or pericardial rub or evidence of 
pericardial effusion
7. Renal disorder Persistent proteinuria >0.5 grams per day or >3+ or
Cellular casts (red cell, haemoglobin, granular, tubular, or mixed)
8. Neurologic disorder Seizures (in the absence of other causes) or
Psychosis (in the absence of other causes)
9. Hematologic disorder Haemolytic anaemia or
Leukocytopenia (<4.0*109/L on ≥2 occasions) or
Lymphocytopenia (<1.5*109/L on ≥2 occasions) or
Thrombocytopenia (<100*109/L in the absence of offending drugs)
10. Immunologic disorder Anti-dsDNA: antibody to native DNA in abnormal titre or
Anti-Sm: presence of antibody to Sm nuclear antigen or
Positive finding of antiphospholipid antibodies:
• an abnormal serum level of IgG or IgM anticardiolipin antibodies or
• a positive test result for lupus anticoagulant using a standard method or
• a false-positive test result for at least six months confirmed by Treponema 
pallidum immobilisation or fluorescent treponemal antibody absorption test
11. Antinuclear antibody An abnormal titre of antinuclear antibody by immunofluorescence or an equivalent 
assay at any point in time and in the absence of drugs
A group of experts on SLE, unified as the SLICC, more recently proposed revised criteria 
for SLE (Table 2).19 In order for a patient to be classified as SLE according to the SLICC 
criteria requires either that the patient fulfils at least four of 17 criteria, including at least 
one of the 11 clinical criteria and one of the six immunologic criteria, or that the patient 
has biopsy-proven nephritis compatible with SLE in the presence of antinuclear antibodies 
(ANA) or anti-double-stranded DNA (dsDNA) antibodies.
The SLICC criteria were validated in 690 patients with SLE and other rheumatic diseases. 
The SLICC revised criteria had a greater sensitivity but lower specificity than the 1997 ACR 
classification criteria (sensitivity of 97 vs. 83 percent and specificity of 84 vs. 96 percent, 
respectively).19
Reflected by the high but still suboptimal sensitivity of the different SLE classification criteria, 
some patients are clinically diagnosed with SLE without fulfilling SLE classification criteria. 
Sometimes these patients are designated as having “incomplete” or “latent” SLE, and may 
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presumably be encountered at a relatively early time point in the course of their disease. 
A substantial proportion of these patients may develop “complete” SLE according to clas-
sification criteria during follow-up,22 particularly in the presence of discoid lupus, positive 
anti-dsDNA and/or anti-Sm antibodies.23
Aetiology
Making a diagnosis based on clinical symptoms alone may adversely affect outcomes by 
obscuring important information about the aetiology and pathogenesis of the disease. For 
instance, infectious diseases such as borreliosis, leishmaniasis, and those caused by parvovirus 
and human immunodeficiency virus may mimic systemic symptoms of SLE, and may even 
result in a patient fulfilling clinical classification criteria for SLE.24-27 However, the underlying 
aetiology and pathogenesis of these conditions are different and thereby the indicated tre-
atment and outcome are also expected to be different. As seen in the classification criteria 
for SLE, the demonstration of antinuclear autoantibodies plays a central role in the diagnosis 
of SLE. Antinuclear autoantibodies are omnipresent in SLE and are typically present many 
years before the clinical diagnosis with a progressive accumulation of specific autoantibodies.28 
However, the aetiology of the break in tolerance and subsequent production of autoantibo-
dies in SLE is not clear-cut and appears to be multifactorial. Multiple genetic predispositions 
and gene-environment interactions have been identified in the setting of SLE.  A longstan-
ding proposed mechanism for the development of autoantibodies involves a dysregulation 
of various cell death processes (including apoptosis, necrosis, and NETosis29) with defective 
clearance of dying cells. Either there is excess cell death or failure to clear debris from dying 
cells efficiently. Exposure of the immune system to these hidden antigens can result in a break 
of tolerance and an autoimmune response directed to these nuclear antigens – ultimately 
resulting in the production of autoantibodies characteristic of SLE. Excess exposure to these 
nuclear antigens can be seen in the case of exposure to ultraviolet radiation,30 and mass cell 
death associated with physiologic processes, or effects of viruses and medication. Defective 
clearance of debris from dying cells consisting of antigens that are normally hidden from the 
immune system, such as nuclear antigens (chromatin and histone proteins) and components 
of cell membranes (phospholipids), can occur with e.g. defective phagocytosis, a deficiency 
of early complement components,31 and defective DNase.32 In addition, aberrant antigen 
presentation and defects in T and/or B cell selection or regulation may be involved in the 
development and perpetuation of autoimmunity in SLE.33
The high concordance rate of SLE among monozygotic twins34 and the increased risk of 
SLE in first-degree relatives35 suggest a strong genetic component in the aetiology of SLE. 
Genome-wide association studies (GWAS) have identified approximately 50 genes that 
predispose to SLE.36 However, these genes account for only a limited part of susceptibility 
to SLE, suggesting a large influence of environmental factors. The most common genetic 
predisposition for SLE is found at the locus of the major histocompatibility complex (MHC). 
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Table 2 SLICC classification criteria for SLE.19
Clinical criteria
1. Acute cutaneous lupus a. Lupus malar rash (not if discoid) or
b. Bullous lupus or
c. Toxic epidermal necrolysis variant of SLE or
d. Maculopapular lupus rash or
e. Photosensitive lupus rash (in the absence of dermatomyositis) or
f. Subacute cutaneous lupus
2. Chronic cutaneous lupus a. Classic discoid rash localised/generalised or
b. Hypertrophic (verrucous) lupus or
c. Lupus panniculitis (profundus) or
d. Mucosal lupus or
e. Lupus erythematosus tumidus or
f. Chilblain lupus or
g. Discoid lupus/lichen planus overlap
3. Oral/nasal ulcers Oral or nasopharyngeal ulceration 
(In the absence of vasculitis, Behçet’s disease, infection (herpes), inflammatory bowel 
disease, or acidic foods)
4. Non-scarring alopecia Diffuse thinning or hair fragility with visible broken hairs 
(In the absence of other causes such as alopecia areata, drugs, iron deficiency, and 
androgenic alopecia)
5. Synovitis (≥2 joints) a. Swelling or effusion or
b. Tenderness in ≥2 joints and at least 30 minutes of morning stiffness
6. Serositis a. Typical pleurisy >1 day or pleural effusion or pleural rub or
b. Typical pericardial pain >1 day or pericardial effusion or pericardial rub or 
pericarditis by electrocardiography
(In the absence of other causes, such as infection, uraemia, or Dressler’s pericarditis)
7. Renal disorder a. Urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500 
mg protein/24 hours or 
b. Red blood cell casts
8. Neurologic disorder a. Seizures or
b. Psychosis or 
c. Mononeuritis multiplex (in the absence of other known causes such as primary 
vasculitis) or
d. Myelitis or
e. Peripheral or cranial neuropathy (in the absence of other known causes such as 
primary vasculitis, infection, and diabetes mellitus) or 





a. Leukocytopenia: at least once (<4000/mm3) 
(In the absence of other known causes such as Felty’s syndrome, drugs, and portal 
hypertension) or
b. Lymphocytopenia: at least once (<1000/mm3)  
(In the absence of other known causes such as corticosteroids, drugs, and 
infection)
11. Thrombocytopenia At least once (<100,000/mm3)  






1. Antinuclear antibody Level above the laboratory reference range
2. Anti-dsDNA Antibody level above laboratory reference range (or 2-fold the reference range if 
tested by ELISA)
3. Anti-Sm Presence of antibody to Sm nuclear antigen
4. Antiphospholipid antibody a. Positive test for lupus anticoagulant
b. False-positive test for rapid plasma reagin
c. Medium- or high-titre anticardiolipin antibody level (IgA, IgG, or IgM)
d. Positive test result for anti-2-glycoprotein I (IgA, IgG, or IgM)
5. Low complement C3, C4, or CH50
6. Direct Coombs’ test In the absence of haemolytic anaemia
T cells and B cells recognise self and foreign peptides presented on the cell surface 
by human leukocyte antigens (HLA) encoded by genes of the MHC. A breakdown of 
immunologic tolerance to self-antigens may be mediated by aberrant presentation of self 
or foreign peptides to autoreactive T cells via HLA molecules. Notably, the HLA genes 
HLA-A1, -B8, and -DR3 have been linked to SLE.37 
It is thought that in certain individuals with a genetic immunologic background that predis-
poses them to SLE, exposure to a specific environmental factor may trigger SLE. Possible 
triggers may include exposure to sunlight, infection, surgery, or pregnancy.  The observations 
that (i) SLE is a disease predominantly affecting women; (ii) SLE particularly affects women 
of fertile age; and (iii) SLE may flare during pregnancy,38 implicate pregnancy as an intriguing 
aetiologic factor. Possibly, the antibodies in SLE are not only directed to nuclear autoantigens, 
but also to nuclear antigens derived from chimeric cells that are acquired during pregnancy. 
In this thesis, the relationship between pregnancy, chimerism, and SLE was investigated further. 
Pregnancy-derived chimerism in SLE
In the 1990s, the discovery of bi-directional cell trafficking during human pregnancy resul-
ting in the persistence of fetal cells in the mother and of maternal cells in her offspring 
for decades after birth shed new light on the relationship between pregnancy and SLE.39 
Consequently, a role for pregnancy-acquired chimerism as an aetiologic factor in SLE was 
postulated, which was investigated further in this thesis.
The term chimerism stems from the Greek mythical beast “chimera” (Χίμαιρα): a creature 
with the head of a lion, the body of a goat, and the tail of a dragon. In medicine, (micro)
chimerism refers to the occurrence of (small) numbers of cells of a distinct genetic con-
stitution in an individual. 
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Pregnancy is presumed to be the most important physiologic source of microchimerism in 
women. During pregnancy, fetal cells can enter the maternal circulation across the placenta 
(fetal microchimerism), and maternal cells can enter the fetal circulation vice versa (mater-
nal microchimerism).  A pregnant woman can acquire chimeric cells from the fetus as a 
consequence of completing pregnancy, but chimeric cells may also be exchanged during 
a miscarriage or abortion.40, 41 Transplacental exchange of cells is possible because the 
placenta contains microscopic disruptions, which become more permeable as pregnancy 
progresses.42 Implantation of embryonic chorionic villi in the functional endometrium 
results in a primitive fetomaternal circulation by the end of the third week of embryonic 
development.43 As pregnancy progresses, the placental barrier becomes increasingly thin-
ner, while fetal blood flow and blood pressure increase, and the villous tree expands.42 Small 
quantities of chimeric cells (ranging from 1 to up to 400 per 106 cells) can be detected 
in nearly all pregnant women, starting as early as 4 weeks after gestation.44 Fetal chime-
ric cells may be present in mothers as hematopoietic progenitor cells, trophoblast cells, 
nucleated erythrocytes, T lymphocytes, as well as other leukocytes.45-52 Pregnancy has also 
been shown to leave a long-term legacy: chimeric cells may persist in healthy women for 
up to 27 years after pregnancy.39  
While microchimerism during pregnancy is common in healthy individuals and may 
even assist in tissue repair and maintenance, fetal microchimerism has been implicated 
in various adverse phenomena, including autoimmune disease, pregnancy complications, 
malignancy, infectious disease and the production of donor-specific antibodies in the setting 
of organ transplantation. Maternal microchimerism is studied less frequently, but may be 
of pathogenic significance in neonatal lupus syndrome,53 juvenile idiopathic inflammatory 
myopathies,54 and juvenile dermatomyositis.55 Few studies have looked at microchimerism 
in relation to SLE. Typically, studies have focused on the detection of male microchimerism 
of presumably fetal origin as identified by the Y chromosome in whole blood or in tissues 
of female patients.  At the tissue level, an increased occurrence of male microchimerism 
has been demonstrated in women with SLE as compared to healthy women.56-58 A number 
of studies have shown that in peripheral blood, there is also an increased frequency of 
male microchimerism in SLE patients compared to controls,59, 60 whereas other studies 
have found no difference.61, 62 Interestingly, although pregnancy is presumed to be the 
main source of chimerism in these cases, a clear-cut relationship between microchimerism 
in tissues and pregnancy was not found. To substantiate ongoing research in the field of 
chimerism and SLE and other autoimmune diseases with a female preponderance, the 
significance of chimerism in pregnancy must be established first. 
A crucial finding pointing towards a role for chimerism in SLE came from a mouse model 
for graft-versus-host disease developed by Via and Shearer in the late 1980s.63 In this model, 
the injection of a specific type of parental T lymphocytes into F1 recipients resulted in a 
condition resembling human SLE.  This was accompanied by proliferative glomerulonephri-
tis with deposition of immune complexes similar to lupus nephritis, lymphoid hyperplasia, 
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and production of antibodies against nuclear antigens, erythrocytes, and thymocytes. In this 
model, donor parental T helper cells were able to continuously stimulate F1 host B cells 
because of a low frequency of cytotoxic T cell precursors. This landmark study led to the 
hypothesis that a graft-versus-host phenomenon may also be involved in human SLE, as 
well as in other autoimmune diseases. In this setting, the host must accept the presence 
of chimeric cells, chimeric cells must be immunocompetent T cells, chimeric cells must 
recognise the host as foreign, and there must be a lack of a cytotoxic T cell response against 
the host. Intriguingly, these conditions all seem to hold true in human SLE.64
Another possible mechanism that may involve chimerism in the pathogenesis in SLE is the 
occurrence of a host-versus-graft reaction, similar to rejection after solid organ transplan-
tation. The host must recognise the chimeric cell as foreign for a host-versus-graft reaction 
to occur. During and after pregnancy, anti-paternal HLA antibodies have been found in up 
to 30% of women.65 Several mechanisms prevent the immune system from the mother 
to react against the paternal antigens during pregnancy.66 However, when these tolerance 
mechanisms are no longer in effect after delivery, it is possible that the immune system 
from the mother reacts against the fetal cells that may have been incorporated into various 
tissues by that time. Because a host-versus-graft reaction would expectedly result in the 
elimination of chimeric cells, the disease manifestations would be localised and limited. 
This may parallel the clinical situation of an SLE patient who experiences a relatively short 
and limited course of the disease. If however, the removal of chimeric cells fails, e.g. due to 
an inadequate response of cytotoxic T cells or NK cells, the chimeric cells may be able to 
continuously stimulate the immune system leading to persistent inflammation resembling 
autoimmune disease.64 Apart from a direct response to the chimeric cells, the immune 
response can also be sustained by molecular mimicry.  In this case, the chimeric cell induces 
a host-versus-graft reaction, which in itself is self-limited, but because of cross-reactivity 
between antigens on chimeric cells and self-antigens of the host, autoimmunity occurs.64 
In contrast to the proposed effects of chimerism mentioned above, chimeric cells may 
also be involved in tissue repair. As previously mentioned, pregnancy may result in the 
acquisition of fetal chimeric cells with the capacity for multilineage differentiation and 
tissue repair. Studies in mice have demonstrated that fetal chimeric cells migrate to sites 
of maternal injury.67, 68 In a human autopsy study, Kremer Hovinga et al.57 found significantly 
more microchimerism in organs from women with SLE that showed either SLE-related or 
non-SLE-related injury, than in organs from women with SLE without injury and in uninju-
red organs from controls. No difference in the occurrence of microchimerism was found 
between uninjured organs from SLE patients and uninjured organs from controls, indicating 
that SLE patients did not have a higher “background” level of chimerism. Because chimeric 
cells also seem to occur in tissues without apparent injury,69, 70 normal tissue maintenance 
may also be responsible for the occurrence of microchimerism in tissues.
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Other than having either a pathogenic or a beneficial role, it is also possible that chimeric 
cells are innocent bystanders that do not react with the immune system of the host. If 
one assumes that chimeric cells are distributed equally across tissues, and the cell density 
increases in inflamed tissue, more chimeric cells would reasonably be found in injured 
tissues. This hypothesis was investigated in an autopsy study by Kremer Hovinga et al.57 
Although a tendency towards an increased occurrence of microchimerism was found when 
an inflammatory infiltrate was present, the occurrence of microchimerism could not be 
solely explained by an influx of inflammatory cells. 
Because pregnancy is very common and SLE is relatively rare, it is likely that only cer-
tain subsets of chimeric cells are pathogenic. This may depend on the phenotype of the 
chimeric cells and HLA relationships between the chimeric cell and the host.  Also, micro-
chimerism may not be only beneficial or pathogenic, but rather a combination of both 
depending on the circumstances. Probably, only some chimeric cells with an immunocom-
petent phenotype have pathogenic potential, whereas others, such as CD34+ cells found 
in pregnancy, may be innocent bystanders. In the setting of fetomaternal cell trafficking, 
it is important to realise that the proportion of cell phenotypes is different between the 
mother and fetus. The different subpopulations of chimeric cells in the mother and fetus 
may explain why many autoimmune diseases are less common in neonates and young 
children than in adults, but further research is warranted. 
Pathogenesis 
As previously mentioned, pathogenic autoantibodies against nuclear components currently 
form an important pillar in the classification of SLE and may be of pivotal importance 
in making the diagnosis. Many clinical manifestations of SLE are mediated by circulating 
immune complexes that form when autoantibodies bind nuclear antigens and deposit in 
various tissues or by direct binding of autoantibodies to antigens on resident cell surfaces 
or extracellular components in various organs. Both situations result in the attraction 
and activation of infiltrating leukocytes resulting in the release of various inflammatory 
mediators, including cytokines, growth factors, vasoactive substances, complement, and 
coagulation factors. Receptors for the Fc portion of deposited immunoglobulin are present 
on many immune cells.  Activation of Fc receptors induces a number of responses, including 
Fc receptor-mediated phagocytosis and antibody-dependent cell-mediated cytotoxicity.71 
However, the complement system appears to be a key mediator of immunoglobulin-in-
duced tissue injury in SLE. 
The complement system, an essential component of the innate immune system, is a 
complex cascade of activation of plasma and membrane-bound proteins that are divided 
according to their respective surface recognition patterns into three major pathways: the 
classical pathway, the lectin pathway, and the alternative pathway.72 Immune complexes 
formed by autoantibodies and antigens lead to the activation of the classical pathway.  Acti-
vation of the classical pathway is initiated by the binding of complement factor C1q and 
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activation of the C1 complex, leading to the formation of C3 convertase and the cleavage 
of complement component C3. Cleavage of C3, the most abundant serum complement 
protein, results in the release of the chemotactic factor C3a and covalent attachment of 
C3b to host cells, which is also important for the amplification of the cascade through the 
alternative pathway and for continued activation of the complement system. In the process, 
the anaphylatoxins C3a and C5a attract neutrophils and monocytes by means of a strong 
chemotactic signal, which in turn propagate further tissue injury. Finally, the complement 
cascade results in the formation of the terminal membrane attack complex, C5b-9. C5b-9 
causes cytolysis of the target cell by insertion in cell membranes in lytic quantities.
Importantly, while the activation of complement is apparently deleterious in the propa-
gation of tissue injury, it was mentioned earlier that a deficiency of early complement 
components is associated with SLE itself. The latter is due to impaired clearance of immune 
complexes and/or apoptotic debris in patients lacking C1, C2, and C4, leading to a break 
of tolerance.31 Clearly, the complement system plays a dual role in SLE. 
Treatment and Prognosis
Given the clinical heterogeneity of SLE, treatment is highly variable depending on disease 
manifestations, disease activity and severity, comorbidities, and patient preferences. 
Generally, all patients with SLE receive treatment with the antimalarial drug hydroxy-
chloroquine.73 The benefits of hydroxychloroquine in the treatment of SLE are broad, 
including the amelioration of constitutional symptoms, musculoskeletal manifestations, and 
mucocutaneous manifestations; as well as the reduction of flare rates, thrombotic events, 
organ damage accrual, and mortality.74 Additional therapy depends on the severity of 
specific manifestations. Patients with mild to moderate manifestations may be treated 
conservatively with nonsteroidal anti-inflammatory drugs, and/or (low-dose) corticos-
teroids. Occasionally, a steroid-sparing agent such as azathioprine may be indicated to 
maintain control of symptoms.73 Patients with severe or life-threatening major organ invol-
vement of SLE, such as lupus nephritis and neuropsychiatric lupus, usually require intensive 
cytotoxic immunosuppression to induce remission including high doses of intravenous 
corticosteroids in combination with other immunosuppressive agents, such as mycop-
henolate mofetil or cyclophosphamide.  As will be discussed in more detail in Part 2 of this 
introduction, these immunosuppressive agents are associated with severe and potentially 
lethal adverse effects,75 and selection of patients for whom such treatment is indicated is 
therefore of utmost importance. The phase of intensive treatment is usually followed by 
a second phase of less toxic treatment to maintain remission.73
Partly attributed to these intensive schemes of treatment that were developed during 
the past decades, the prognosis of SLE has improved from less than 50% 5-year survival 
in 195576 to more than 90% 10-year survival in recent years.77, 78 Several other factors 
may have contributed to this increased survival rate, including the improved capability to 
diagnose patients with (early) SLE, the increased recognition of patients with mild disease, 
 25
1
General Introduction and Outline
and the improved treatment of comorbid and secondary conditions, such as hypertension, 
infection, and renal failure.79 Despite these improvements, mortality rates of patients with 
SLE are on average still two to five times higher than in the general population.80 Given 
the heterogeneous manifestations and corresponding heterogeneous clinical course, the 
prognosis of individual patients largely depends on the presence of adverse prognostic 
factors, including lupus nephritis,78 hypertension,81 male sex, older age at presentation,81 low 
socioeconomic status,13 Afrocaribbean race,13 presence of antiphospholipid antibodies,82 
and high overall disease activity.81
The decrease in overall mortality attributed partly to immunosuppressive therapy has 
resulted in a shift in causes of death among patients with SLE. Whereas in earlier days 
patients with SLE frequently died of causes relating to active SLE and infections, today 
the most frequent causes of death – including cardiovascular disease and malignancy – 
are not directly related to SLE. Immunosuppressive therapy may now be included as an 
adverse prognostic factor for these long-term outcomes.  Various studies have indicated 
that besides SLE itself, also its treatment, especially corticosteroids and cytotoxic drugs, may 
play a role in these causes of death.83-85 As mentioned earlier, these medications are given 
primarily to patients with major organ involvement of SLE – patients who are already at 
increased risk of adverse outcomes.
PART 2: FOCUS ON MAJOR ORGAN  
MANIFESTATIONS OF SLE
Lupus nephritis
Renal involvement due to lupus nephritis (LN) occurs in approximately one half of patients 
with SLE at some time in the course of their disease.86 Clinical manifestations of LN 
range from asymptomatic urinary findings (microscopic haematuria or proteinuria) to 
the nephrotic syndrome and progressive renal dysfunction. Given the relatively frequent 
occurrence of LN in SLE and its potentially severe consequences, patients with SLE should 
undergo regular testing for renal involvement by evaluation of the urinary sediment, pro-
teinuria, and serum creatinine. Elevated anti-dsDNA titres and low complement levels may 
indicate active SLE, and particularly LN, although the utility of serologic assessment differs 
among patients. Laboratory abnormalities indicating renal dysfunction in a patient with 
SLE require further diagnostic workup: they may indicate LN as well as an unrelated form 
of renal disease.  A renal biopsy serves as a central diagnostic asset in LN. Not only can a 
renal biopsy confirm the diagnosis of LN and sometimes exclude other causes in a patient 
with clinical suspicion of LN, but it can also guide treatment decisions and predict outcome. 
The pathogenic mechanisms contributing to LN have been studied extensively and form 
the foundation of its tissue diagnosis. In turn, the tissue diagnosis guides the prognosis.
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The kidney as a site of injury in SLE
The anatomy and physiology of the kidney make it highly susceptible to inflammatory 
insults caused by autoantibodies.  A number of factors contribute to the nonspecific 
trapping of immune complexes in the kidney.87 First, immune complexes in the circulation 
are delivered at a high rate to the kidney because the kidney receives roughly 25% of the 
cardiac output. Second, intraglomerular pressure is higher than in other capillary beds, 
and more protein than usual may be forced across the glomerular capillary wall. Third, the 
glomerular capillaries provide a large and highly permeable surface through which immune 
complexes circulate. Lastly, the capillary walls comprise a negatively charged surface, faci-
litating the binding of positively charged macromolecules. Initiation of renal disease in SLE 
caused by preformed circulating immune complexes is likely due to the deposition of 
immune complexes in the mesangium or subendothelial spaces, since these complexes 
are too large to cross the capillary wall. Alternatively, immune deposits may form in situ 
when antibodies bind to intrinsic antigens in the kidney, such as extracellular matrix compo-
nents or cell surface glycoproteins. In situ formation may also occur when soluble antigens 
become independently localised in the kidney due to charge interactions with anionic 
sites in the glomerular basement membrane. In the setting of LN, cationic histone parts 
of nucleosomes are bound to anionic glomerular basement membrane components such 
as heparan sulphate or collagen IV, resulting in binding of anti-dsDNA antibodies in situ.88 
Since the in situ formation of immune deposits depends on the location of the intrinsic 
antigen or the site where the extrinsic antigen is deposited, this type of immune complex 
deposition may occur in the mesangium, subendothelial, or subepithelial space. The reaction 
that these immune complexes elicit depends, in part, on the nature of the autoantibody 
(its ability to activate complement or to bind to Fc receptors).89 Furthermore, depending 
on the site of immune complex deposition, different patterns of injury may be observed. 
Immune deposits at sites accessible to the circulation, such as the subendothelial region 
or mesangium (Figure 2), tend to cause an inflammatory or proliferative form of glome-
rulonephritis. Mesangial deposits (Figure 2) result in activation of mesangial cells causing 
mesangial hypercellularity and production of extracellular matrix, generally resulting in 
microscopic haematuria and subnephrotic proteinuria along with a preserved glomerular 
filtration rate (GFR).90, 91 Subendothelial deposits may elicit inflammatory nephritis charac-
terised by influx of leukocytes, endothelial cell injury, and endocapillary hypercellularity.  This 
pattern is often associated with capillary wall destruction and varying degrees of crescent 
formation.90 Because the mesangium is in direct continuity with the subendothelial space, 
various degrees of mesangial proliferation may also be observed – in its ultimate form 
recognised as mesangiocapillary or membranoproliferative nephritis. This pattern of injury 
may also be observed in the absence of immune complexes in the case of shear stress due 
to malignant hypertension, or thrombotic microangiopathy in SLE-associated antiphospho-
lipid syndrome. The subendothelial pattern of injury is generally accompanied by a marked 
decrease in GFR, haematuria, and mild to moderate proteinuria.91 In contrast, subepithelial 
deposits, secluded from inflammatory cells by the barrier formed by the glomerular base-
 27
1
General Introduction and Outline
ment membrane, tend to produce a non-inflammatory form of complement-mediated 
podocyte injury that manifests mainly with (nephrotic-range) proteinuria.90, 91
The detection of immune deposits by immunofluorescence at various glomerular locations 
as well as along tubular basement membranes and in vascular walls forms an essential 
diagnostic test in LN.  The immune deposits predominantly contain polyclonal IgG, as well 
as C3, and in most instances C1q.  A hallmark finding is the so-called “full house” staining 
pattern by immunofluorescence, defined as concurrent positivity for IgA, IgG, and IgM, as 
well as the complement components C3 and C1q.91 The finding of this pattern is the result 
of nonspecific activation of autoreactive B cells resulting in the formation of autoantibodies 
with many specificities, as well as the activation of multiple pathways of complement. The 
immune deposits may also be detected by electron microscopy, giving an electron-dense 
appearance varying in size and distribution. 
Figure 2 Localisations of immune complexes in the glomerulus in lupus nephritis.
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Sequelae of immune complex-mediated injury in the kidney
Damage to renal parenchymal cells triggers healing responses that contribute to renal 
pathology. Focal necrosis in the glomerular tuft may be followed by migration of parie-
tal epithelial cells towards the visceral epithelial cells forming cellular bridges and their 
subsequent production of extracellular matrix, contributing to focal segmental glome-
rulosclerosis, which may eventually progress to global glomerulosclerosis.92 In addition, 
cellular crescent formation may also result from activation of parietal epithelial cells that 
fill Bowman’s space by proliferation.93, 94 This process can be triggered by breaks in the 
glomerular basement membrane that allow plasma to leak into Bowman’s space.95 In later 
stages, the parietal epithelial cells initiate a process of extensive matrix production, creating 
a “honeycomb” matrix in Bowman’s space that turns cellular crescents into fibrocellular 
crescents and eventually fibrous crescents and glomerulosclerosis.
Histopathologic classification of LN
Since the introduction of the renal biopsy in the 1950s, a number of efforts have been 
made to classify LN based on the knowledge about immune complex-mediated pathoge-
nesis and evidence indicating the clinical significance of various lesions. A histopathologic 
classification serves to implement the histopathologic diagnosis with prognostic infor-
mation in clinical practice, as well as providing a means for communication between 
pathologists and clinicians and allowing risk stratification of patients included in clinical 
intervention studies. Following the World Health Organisation (WHO) classifications,96, 97 
the International Society of Nephrology and Renal Pathology Society (ISN/RPS) working 
group construed a new classification of LN in 2003, which has presently gained world-wide 
acceptance.90  The ISN/RPS 2003 classification of LN categorises the spectrum of lesions 
occurring in LN into discrete entities, consisting of six classes based on a mesangial (clas-
ses I/II), proliferative (classes III/IV), membranous (class V), or a globally sclerotic (class VI) 
pattern of injury (Table 3).
Treatment and prognosis
LN is associated with considerable morbidity and mortality. The cumulative 5-year survival 
of LN has improved from 50% in the 1960s to 80% in the 1990s, reflecting the implementa-
tion of immunosuppressive therapy.98 Even though immunosuppressive treatment is clearly 
beneficial for some patients with LN, patients eligible for such therapy should be selected 
with great caution due to severe and potentially lethal adverse effects.75 Many clinical trials 
on therapy in LN have been published over the past 40 years. The conclusions from these 
trials have been incorporated in a set of currently employed national and international 
treatment guidelines for LN.99-103 Because of a poor correlation between clinical and biopsy 
findings,104, 105 and because early diagnosis and treatment have been shown to improve 
outcomes in LN,106-108 the threshold for a renal biopsy is set relatively low. Thus, the guide-
lines uniformly recommend a renal biopsy in patients with SLE and any suspicion of renal 
involvement. Specifically, this is meant to indicate a decrease in renal function, reproducible 
proteinuria (>500 mg/24h), and/or the presence of an active urinary sediment. Importantly, 
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guidelines base therapeutic decisions in LN solely on the histopathologic diagnosis of LN 
class according to the ISN/RPS classification.90
Table 3 ISN/RPS 2003 classification of lupus nephritis.90
Class I Minimal mesangial LN
Normal glomeruli by light microscopy, but mesangial immune deposits by immunofluorescence
Class II Mesangial proliferative LN
Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with 
mesangial immune deposits
A few isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or 
electron microscopy, but not by light microscopy
Class III Focal proliferative LN
Active or inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving <50% of 
all glomeruli, typically with focal subendothelial immune deposits, with or without mesangial alterations
Class IV Diffuse proliferative LN
Active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving 
≥50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial 
alterations. This class is divided into diffuse segmental (IV-S) LN when ≥50% of the involved glomeruli 
have segmental lesions, and diffuse global (IV-G) LN when ≥50% of the involved glomeruli have global 
lesions. Segmental is defined as a glomerular lesion that involves less than half of the glomerular tuft. This 
class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation.
Class V Membranous LN
Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy 
and by immunofluorescence or electron microscopy, with or without mesangial alterations
Class V LN may occur in combination with class III or IV in which case both will be diagnosed
Class V LN may show advanced sclerosis
Class VI Advanced sclerotic LN
≥90% of glomeruli globally sclerosed without residual activity
LN, lupus nephritis.
Treatment for class II 
Due to lack of evidence, guidelines for LN are inconsistent with regard to therapy for 
class II LN.109 There is consensus that proteinuria should be controlled with renin-an-
giotensin-aldosterone system (RAAS) inhibitors. As to immunosuppressive therapy, it is 
generally accepted that class II LN does not require such therapy, although corticosteroids 
may be indicated in patients with proteinuria over 1 g/24h, particularly in the presence of 
glomerular haematuria.99  
Treatment for classes III and IV 
Based on evidence from a number of landmark randomised controlled trials (RCTs), tre-
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atment guidelines for LN uniformly recommend immunosuppressive therapy for patients 
with class III or IV LN.109 A series of RCTs in the 1970s indicated that long-term use of 
a combination of corticosteroids and high-dose intravenous cyclophosphamide (0.5–1 
g/m2 monthly for 6 months) was superior to steroids alone to prevent renal impair-
ment.110-112 Based on this finding, the so-called “NIH regimen” became the standard of 
care for induction of remission of classes III and IV LN for two decades, despite its many 
side effects including a high rate of severe infections and premature ovarian failure. More 
recently, two different approaches for induction of remission of classes III and IV LN have 
been investigated. First, the “Euro-Lupus” regimen was proposed to potentially decrease 
the burden of cytoxic immunosuppression by lowering doses of intravenous cyclophosp-
hamide for induction of remission (500 mg fortnightly for 3 months). In the Euro-Lupus 
trial, this regimen was shown to achieve results comparable with high-dose intravenous 
cyclophosphamide.113 Second, mycophenolate mofetil (MMF) was shown to be at least as 
efficacious as intravenous cyclophosphamide to induce a satisfactory renal remission at 6 
months in several studies,114, 115 with the advantage that this drug conveys a lower risk of 
premature ovarian failure.116 On account of these studies, current guidelines recommend 
intravenous cyclophosphamide (either Euro-Lupus or NIH regimen) or MMF (2–3 g total 
daily dose) in combination with oral corticosteroids with or without three pulses of intra-
venous methylprednisolone at the start of induction treatment. In the maintenance phase 
of treatment, MMF (1–2 g/day) or azathioprine (1.5–2.5 mg/kg/day) is recommended, 
supported by low-dose oral corticosteroids.99-103
Treatment for class V
Immunosuppressive treatment for class V LN is generally not recommended, unless a 
patient has nephrotic-range proteinuria (>3 g/24h).109 With sub-nephrotic proteinuria, 
anti-proteinuric treatment with RAAS inhibitors is indicated. Evidence on the efficacy 
of immunosuppressive treatment for class V LN is limited; therefore the recommended 
management of class V LN differs between guidelines.99-103 However, there is an agreement 
that corticosteroids should be included in the immunosuppressive regimen for patients 
with nephrotic-range proteinuria. In addition, MMF,73, 100, 101, 103 cyclophosphamide,101, 103 
azathioprine,101, 103 rituximab,101, 103 or calcineurin inhibitors101, 103 are generally advised. 
 31
1
General Introduction and Outline
Neuropsychiatric lupus
Neuropsychiatric involvement in SLE (NP-SLE) is observed in 10-80% of patients.117-121 
The manifestations of NP-SLE represent a spectrum of disorders, both with focal and 
diffuse symptoms. Although headache and mood disorders are the most frequent neuro-
psychiatric complaints in patients with SLE, seizure disorder, cerebrovascular disease, acute 
confusional state, and neuropathy are the most common neuropsychiatric syndromes attri-
buted to SLE.  A major difficulty in the diagnosis of NP-SLE is the lack of clear diagnostic 
definitions, which is caused by a lack of pathognomonic features, inadequacy of diagnostic 
tools, and a vast heterogeneity of clinical disorders. In contrast to LN, where knowledge 
about pathogenic mechanisms is central in establishing a tissue diagnosis and conjoint 
prognosis, little is known about the pathogenesis of NP-SLE. Due to the impracticability 
of performing a brain biopsy, histopathologic studies elucidating pathogenic mechanisms 
are limited and a tissue diagnosis is generally not possible. Therefore, the clinical diagnosis 
of NP-SLE is founded on clinical and neuropsychological assessment, aided by laboratory 
analyses of blood and cerebrospinal fluid (to exclude central nervous system infection), 
electroencephalographic analysis (to diagnose a seizure disorder), nerve conduction studies 
(to diagnose peripheral neuropathy) and magnetic resonance imaging (MRI).122 MRI is a 
central tool in the diagnosis of NP-SLE-related injury, since this modality has the capacity to 
identify brain infarctions as well as confounding disorders such as space-occupying lesions, 
infectious meningitis or brain abscesses. Unfortunately, there is not one MRI finding or 
pattern that is diagnostic or specific for NP-SLE. In the presence of clinical symptoms, MRI 
often shows no abnormalities or unspecific abnormalities such as small white matter hype-
rintensities,123 known as the clinicoradiological paradox. Furthermore, MRI alone cannot 
distinguish between thromboembolic and inflammatory insults in many patients.124
In 1999 “The ACR Nomenclature and Case Definitions for Neuropsychiatric Lupus Syn-
dromes” was published, serving as a guide for clinicians and researchers to identify individual 
NP-SLE disorders (Table 4).125 Because NP-SLE remains a condition that is diagnosed per 
exclusionem, the ACR nomenclature also defines several conditions that must be excluded 
before it can be established that a neuropsychiatric manifestation is the result of the disease 
itself (primary NP-SLE). Possibly 40% of all neuropsychiatric disorders in SLE patients are 
the consequence of secondary conditions related to SLE, such as metabolic disturbances 
attributed to LN, hypertension, and side effects of medications (secondary NP-SLE). 
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Table 4 Neuropsychiatric syndromes that may occur in SLE as defined by the ACR.125
Central nervous system Peripheral nervous system
1. Aseptic meningitis 13. Guillain-Barré syndrome
2. Cerebrovascular disease 14. Autonomic disorder
3. Demyelinating syndrome 15. Mononeuropathy single/multiplex
4. Headache 16. Myasthenia gravis
5. Movement disorder (chorea) 17. Cranial neuropathy
6. Myelopathy 18. Plexopathy
7. Seizure disorders 19. Polyneuropathy





The brain as a site of injury in SLE
The brain represents a unique environment in the study of immune complex-mediated 
injury in SLE.126 Since the brain has limited capacity for repair and regeneration of neurons, 
the immunologic barrier in the brain helps to minimise damage. This immunologic barrier is 
referred to as the blood-brain barrier, and consists of polarised endothelial cells connected 
by tight junctions, further supported by foot processes of astrocytes (Figure 3). This barrier 
prevents entry of cells and macromolecules including immunoglobulins into the central 
nervous system. Under normal circumstances, there is little T cell trafficking into the central 
nervous system and negligible production of antibodies by B cells in the brain. The attenua-
ted cellular response in the brain limits harmless bystander injury of neurologic tissue that 
would occur during a regular immune response. Studies on the pathogenic mechanisms 
contributing to tissue injury in NP-SLE in this unique immunologic environment are limited.
Figure 3 The blood-brain barrier.
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On the basis of neuropathological findings in a subset of patients with NP-SLE, neuropsy-
chiatric involvement in SLE seems to be characterised by a vascular, thrombo-ischemic 
pathogenic mechanism. Microvascular occlusions with hyaline or platelet microthrombi, 
microinfarctions and small vessel vasculopathy are the most common findings in all neuro-
pathological studies that have been performed to date.127, 128 Particularly vasculopathy 
appears to be a very common finding in NP-SLE, defined as endothelial proliferation, 
hyalinisation, and thickening of the vessel wall. The alterations in the blood vessel wall 
recognised as vasculopathy are not accompanied by inflammatory cells in the vessel wall, 
and therefore cannot be classified as vasculitis. Less commonly, macroscopic infarction or 
haemorrhage may be observed, the former occasionally due to an embolism from Lib-
man-Sacks endocarditis, or due to the consequences of antiphospholipid antibodies. Unlike 
these destructive macrovascular changes, the microvascular changes are poorly correlated 
with central nervous system disease, and these changes may be very prominent in cases 
with minimal or no neurologic symptoms.127 Intriguingly, true vasculitis appeared to be a 
rare finding in NP-SLE in various studies.129, 130 The pathophysiology of the widespread 
microvascular injury in NP-SLE is unknown. Clinical syndromes thought to be related to 
thromboischemic pathology include stroke and cognitive dysfunction.131 
In apparent contrast with the thromboischemic pathogenic mechanism just described, a 
mechanism involving inflammation and neurotoxic autoantibodies has also been implicated 
in NP-SLE.  A number of reports have noted immunologic abnormalities including elevated 
levels of anti-dsDNA antibodies, oligoclonal banding, immune complexes, interleukin-6, 
and markers of B-cell activation in the cerebrospinal fluid of patients with NP-SLE.132-
134 Moreover, a number of autoantibodies have been associated with different aspects 
of NP-SLE. To date, 11 autoantibodies directed to intrinsic brain components and nine 
autoantibodies that are also found in general SLE populations have been described in 
NP-SLE.135 However, none of these autoantibodies appear to be specific for any NP-SLE 
manifestation. Clinical syndromes that are presumed to relate to inflammatory autoim-
mune pathology are diffuse neuropsychiatric manifestations including psychosis and acute 
confusional state.131 
Immune complex deposition in the small cerebral vessels of SLE patients has never been 
demonstrated. Since complement-mediated injury is a key event in many of the other 
organ manifestations of SLE, this mechanism could play a similar role in NP-SLE. In the 
setting of NP-SLE, one hypothesis is that circulating immune complexes may activate 
complement via binding of C1q and activation of the classical pathway. Studies have 
identified a number of possible mechanisms that may contribute to subsequent tissue 
injury in the brain. For instance, C5a can induce heparin-sulphate release from endothelial 
cell membranes, promoting endothelial proliferation and upregulation of e-selectin and 
vascular cell adhesion molecule (VCAM).136 Also, the complement system, closely related 
to the coagulation cascade, may mediate secretion of von Willebrand factor and Tissue 
Factor expression in response to C5b-9-induced endothelial injury creating a procoagulant 
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state.137, 138 Studies in mice suggest that complement may also amplify thromboischemic 
damage: in neonatal mice, the infarcted area after clipping of a cerebral artery was over 
three times smaller in C1q-deficient mice compared with wild type mice.139 In this thesis, 
the relationship between complement and thromboischemic injury NP-SLE was explored 
further.
Treatment and prognosis
A major difficulty in the treatment of NP-SLE is the unavailability of targeted therapy due 
to the uncertainty about pathogenic mechanisms. Treatment involves the management of 
comorbidities contributing to the neuropsychiatric event, controlling of symptoms, as well 
as more specific interventions including immunosuppressive and anticoagulation therapy. 
Corticosteroids and cytotoxic immunosuppressive therapy are indicated when NP-SLE is 
thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral 
neuropathy, refractory seizures, psychosis, and acute confusional state) and in the presence 
of generalised SLE activity.  Antiplatelet/anticoagulation therapy is indicated when manifes-
tations are related to antiphospholipid antibodies, particularly thrombotic cardiovascular 
disease.122 The differentiation between an inflammatory or underlying thromboischemic 
pathogenic mechanism may not be feasible and in some patients both mechanisms may 
be operant.
The reported prognosis of NP-SLE is highly variable: several studies have documented an 
increased mortality in patients with NP-SLE compared to SLE without neuropsychiatric 
symptoms,98, 140-142 whereas others have not120, 143, 144
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PART 3: THIS THESIS
The interpretation of Hippocrates’ quote in the prologue of this thesis in the setting of 
SLE uncovers a number of challenges faced by the physician when treating SLE patients. 
First, “telling the antecedents” and “knowing the present” in SLE – essentially making a 
diagnosis based on common aetiology, pathogenesis, or symptoms – is challenged by 
the multifactorial aetiology, the multiple routes of pathogenesis, and the vast diversity of 
clinical manifestations of this disease. Second, “foretelling the future” may be challenged by 
the same factors complicating diagnosis.  As became clear in this introduction, knowledge 
about pathogenic mechanisms plays a crucial role in the diagnosis and prognosis of SLE. 
Two contrasting examples with regard to such knowledge – LN and NP-SLE – clearly 
demonstrate this. In LN, the pathogenesis of immune complex deposition is relatively well 
studied and forms the basis of tissue diagnosis, prognosis, and treatment decisions. In con-
trast, the pathogenesis of NP-SLE is poorly studied, and diagnostic tools, prognostic, and 
therapeutic indicators are relatively limited. Also, clinical heterogeneity between patients 
may greatly affect outcomes, and thereby complicate the ability to estimate the prognosis 
for an individual patient. Third, the objectives “to do good or to do no harm” reflect the 
ever-challenging trade-off between therapeutic benefits of intensive immunosuppressive 
therapy for life-threatening manifestations of SLE, and the concurrently harmful and pos-
sibly life-threatening adverse effects of these therapies. In this thesis, a number of these 
challenges were investigated. 
In the first part of this thesis, challenges in diagnosing SLE were investigated in the setting 
of patients with nephritis showing full house glomerular immune deposits. The full house 
pattern by immunofluorescence is regarded as very characteristic of SLE, and it is unknown 
whether this finding in a patient with absent systemic signs or symptoms of SLE warrants 
its clinical distinction from LN and SLE. In chapter 2, the SLICC classification criteria were 
validated in a cohort of patients with full house glomerular immune deposits, aiming to 
resolve whether SLE classification criteria may be applied to patients from the nephrology 
clinic with renal involvement suggestive of LN. Chapter 3 is focused on the distinction 
between patients with lupus-like renal involvement with full house glomerular deposits in 
the setting of clinically confirmed LN (lupus full house nephropathy) and such patients who 
do not have SLE (non-lupus full house nephropathy). In this chapter, a special focus lies on 
the clinical, histopathologic, and prognostic differentiation between lupus and non-lupus full 
house nephropathy, aiming to clarify whether lupus and non-lupus full house nephropathy 
should be regarded as clinically distinct entities. 
In the second part of this thesis, the aforementioned challenges were investigated 
in two of the most life threatening visceral manifestations of SLE: LN and NP-SLE. In 
chapter 4, patients with class III and IV LN were investigated who did not receive cytotoxic 
immunosuppression. In this study, the natural history of classes III and IV LN was assessed, 
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aiming to identify a subgroup of patients with a favourable prognosis eligible for treatment 
without cytotoxic immunosuppression. In chapter 5, the goal was to advance patient-tailo-
red care for patients with LN by means of the evidence-based identification of clinical and 
histopathologic prognostic indicators of renal outcome in classes I–V LN. In the setting of 
NP-SLE, complement activation as a pathogenic mechanism was investigated to provide 
a possible link between thromboischemic injury in NP-SLE and autoantibody-mediated 
injury characteristic of SLE. In chapter 6, the presence of classical complement deposition 
in cerebral tissue of patients with SLE was examined, and the association between com-
plement and thromboischemic cerebral injury was assessed.
In the third part of this thesis, chimerism as a potential aetiologic factor of SLE was studied. 
To substantiate ongoing research relating microchimerism to autoimmune disease, the 
occurrence of tissue microchimerism during human pregnancy was investigated in chapter 7. 
In chapter 8, the origin and amount of microchimerism in peripheral blood of women 
with SLE and controls was studied.
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In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) presented a new 
classification for systemic lupus erythematosus (SLE). In this classification, biopsy-confirmed 
lupus nephritis (LN) with positive antinuclear or anti-double stranded DNA antibodies 
became a stand-alone criterion. Because of the unknown diagnostic performance among 
patients from nephrology clinics, we aimed to test the validity of the SLICC classification, 
compared with the American College of Rheumatology (ACR) classification, in a cohort 
of patients whose renal biopsies would raise the clinicopathologic suspicion of LN. 
Methods
All patients with a renal biopsy showing full house glomerular deposits between 1968−2014 
and clinical follow-up in our centre were included and re-evaluated after which clinicians 
and a pathologist reached a consensus on the reference-standard clinical diagnosis of SLE. 
The diagnostic performance, and net reclassification improvement (NRI) were assessed. 
We included 149 patients, 117 of whom had clinical SLE. 
Results
Compared with the ACR classification, the SLICC classification had better sensitivity (100 
vs. 94%); although, this was at the expense of specificity (91 vs. 100%; NRI −0.03, P=0.56). 
Excluding the stand-alone renal criterion, the specificity of the SLICC classification reached 
100%, with an NRI of 0.06 (P<0.01) compared with the ACR classification. 
Conclusions
The SLICC classification performed well in terms of diagnostic sensitivity among patients 
with full house glomerular deposits; whereas, the stand-alone renal criterion had no addi-
tional value and compromised the specificity. Clearly, putative LN patients in nephrology 




Validity of SLICC Criteria for Renal Lupus
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical 
manifestations and presenting symptoms that have considerable overlap with other disea-
ses.1 SLE classification criteria have been designed to create homogeneous groups of SLE 
patients to conduct collaborative and reproducible research. Although SLE classification 
criteria have been designed for research purposes, they are often used for the purpose 
of diagnosis in clinical practice. The focus of SLE classification criteria has traditionally 
been on patients encountered in rheumatology clinics, although a need for input from 
non-rheumatology specialists who frequently see lupus patients was recognised.2 This 
may be particularly relevant to nephrologists, since patients with renal biopsy findings 
reminiscent of lupus nephritis (LN) would readily be evaluated in light of these criteria to 
confirm the diagnosis. The recent descriptions of entities including “renal-limited lupus-like 
nephritis”,3 and idiopathic4, 5 and secondary “non-lupus full house nephropathy”4-10 stress 
the importance of valid SLE classification criteria in the nephrology clinic: to help distinguish 
LN patients based on clinical and laboratory findings. 
The importance of valid SLE classification criteria in the nephrology clinic recently gained 
attention by the increased weight that was attributed to renal lupus in the Systemic 
Lupus International Collaborating Clinics (SLICC) 2012 classification.11 In the SLICC clas-
sification,11 biopsy-confirmed LN in the presence of antinuclear antibodies (ANA) or 
anti-double stranded DNA (anti-dsDNA) antibodies was introduced as an exception 
to the conventional requirement of four or more criteria employed in the original12 and 
updated13 American College of Rheumatology (ACR) classifications. Remarkably, the defini-
tion of biopsy-confirmed LN was unspecified in both the ACR and the SLICC classification, 
and firm criteria for biopsy-confirmed LN in the histopathologic classification referred to 
are missing.14 
In light of the increased weight of renal lupus in the SLICC classification and the unknown 
diagnostic performance of the classification in patients from nephrology clinics, we aimed 
to test the validity of the SLICC classification in a cohort of patients whose renal biopsies 
would raise the clinicopathologic suspicion of LN. Since the definition of “biopsy-confir-
med” LN is left open to interpretation, we selected our cohort based on a biopsy feature 
characteristic of LN – so as to raise the clinicopathologic suspicion – but concise enough 
to identify a consistent cohort. From a nephropathologic perspective, the finding of a 
so-called “full house” pattern of immunofluorescence, with concurrent positive glomerular 
staining for IgA, IgG, IgM, C3, and C1q, would certainly raise the possibility of SLE as a 
differential diagnostic consideration warranting the evaluation of clinical criteria. Here, we 
tested the validity of the SLICC compared with the ACR classification criteria to distinguish 
SLE patients with full house glomerular deposits. Moreover, we studied additional biopsy 
findings that may distinguish SLE patients in this setting. This is the first validation study of 
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the SLICC classification in a cohort selected on the basis of renal biopsy findings raising 
the clinicopathologic suspicion LN, reflecting a diagnostic problem area encountered in 
the nephrology clinic.
METHODS
The pathology archives of the Leiden University Medical Center were searched to identify 
all native renal biopsies between 1968–2014 showing full house immunofluorescence, 
defined as concurrent positive staining for IgA, IgG, IgM, C3, and C1q with ≥1+ intensity 
on a 0−3+ scale. Only biopsies showing granular fluorescent staining along capillary walls 
and/or in the mesangium were included. Patients from our centre accordingly identified 
entered the study. In accordance with the ethics committee of the Leiden University 
Medical Center, all patient data were coded and kept anonymously throughout the study. 
All biopsies were processed for light and immunofluorescence microscopy according to 
the standard techniques at our centre. Sections for light microscopy were stained with 
haematoxylin and eosin, periodic acid-Schiff, and methenamine-silver. All biopsies were 
(re)classified by an experienced pathologist (IMB) according to the ISN/RPS classification 
of LN,14 regardless of clinicopathologic diagnosis. For immunofluorescence microscopy, 
sections were frozen in liquid nitrogen, and cryostat sections were stained with FITC-la-
belled antisera to human IgA, IgG, IgM, C3, and C1q. Immunofluorescence reports were 
originally prepared by four experienced nephropathologists who routinely scored the 
immunofluorescence intensity on a 0–3+ scale. Not all biopsies were sent in for analysis 
by electron microscopy; but if at hand, tissue was fixed in 1.5% glutaraldehyde and 1% 
paraformaldehyde and embedded in Epon. Electron microscopy was reviewed if available, 
and findings were compared to the original report. 
Following the methodology of previous validation studies, the reference standard for the 
clinical diagnosis of SLE was based on clinician’s and pathologist’s expert opinion.11, 15-17 
Three investigators (ECR, YKOT, TK) independently reviewed medical records in con-
sultation with an experienced nephropathologist (IMB), assessing whether patients had 
a reference-standard clinicopathologic diagnosis of SLE at the time of renal biopsy by 
considering biopsy findings and the constellation of presenting clinical features, supportive 
laboratory studies, and demographics, and by exclusion of alternative diagnoses. Because 
of the evolving manifestations of SLE, we also confirmed the diagnosis of SLE patients at 
the time of renal biopsy by considering follow-up (including follow-up biopsies and the 
post-transplantation course and biopsies) as a separate examination in addition to the 
diagnosis at the time of biopsy. Patients who were not diagnosed with SLE at the time 
of biopsy were also studied during follow-up to see if they could be diagnosed with SLE 
at a later time. Consensus on the clinical diagnosis of SLE at the time of biopsy or during 
follow-up was achieved by conference.
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Furthermore, clinical records were reviewed by the same investigators individually to assess 
the presence of ACR12, 13 and SLICC11 criteria for SLE at any time up to and including the 
moment of renal biopsy. Qualitative ANA testing was performed routinely at our centre 
using incubation of HEp 2000 cells (Biomedical Diagnostics, Belgium) with 1:40 diluted 
serum samples. A positive test result was reported if a clear and distinct immunofluores-
cence pattern was observed that was more intense than the negative control. Similarly, 
qualitative anti-dsDNA testing was performed using C. Luciliae kit (Aesku.Diagnostics, 
Germany) using 1:10 diluted samples. Fulfilment of sufficient criteria according to either 
classification was assessed. Patients who did not fulfil sufficient ACR or SLICC criteria were 
studied for the presentation of any of the criteria during available follow-up by the same 
investigators. Fulfilment of classification criteria was agreed on by conference. 
Statistical analyses 
Normally distributed data were compared using t-tests. Categorical data were compared 
using Fisher’s exact tests, chi-square tests, or linear-by-linear analysis. The number of clas-
sification criteria was compared between patients with and without a reference standard 
diagnosis of SLE by Mann Whitney U test. The sensitivity and specificity of ACR and SLICC 
classifications were assessed and reported including 95% confidence intervals. Information 
retrieved from follow-up was not considered when assessing diagnostic performance. 
Improvement of the SLICC classification compared with the ACR classification was asses-
sed by calculating the net reclassification improvement (NRI) at the time of biopsy.18 The 
NRI is based on reclassification tables constructed separately for cases with and without 
SLE, and quantifies the correct movement in categories, upwards for cases with SLE 
and downwards for cases without SLE. The null hypothesis NRI=0 was tested using the 
Z-statistic following McNemar’s asymptotic test for correlated proportions. All P-values 
are two-sided and P<0.05 was considered significant. All analyses were performed using 
SPSS 23.0 (IBM, Armonk, New York).
RESULTS
A total of 149 patients with renal biopsies fulfilling our inclusion criteria were identified 
from the pathology archives between August 1968 and July 2014. Fourteen patients were 
biopsied before 1980, 32 from 1980–1989, 47 from 1990–1999, 42 from 2000–2009, and 
14 from 2010–2014. 
Reference standard clinical diagnosis of SLE
According to clinicians’ and pathologist’s expert opinion, 117/149 patients fulfilled the diag-
nosis SLE at the time of biopsy. These diagnoses composed the reference standard; these 
patients will be referred to hereafter as patients with “clinical SLE”. Of the patients with 
clinical SLE, renal involvement first appearing at the time of renal biopsy was the decisive 
factor establishing the clinical diagnosis in 40 patients. In addition, 75 patients had a clinical 
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diagnosis of SLE prior to renal biopsy. For two patients, the time since onset of SLE could 
not be retrieved from the records. The median time between SLE diagnosis and renal 
biopsy was 1.4 years (interquartile range 0–5.3). For all patients with clinical SLE at the 
time of renal biopsy, the diagnosis was confirmed by the clinical course during follow-up 
(median 10.6 years [interquartile range 4.9–18.4]). None of the 32/149 patients without 
clinical SLE at the time of renal biopsy were clinically diagnosed with SLE during median 
follow-up of 20.0 years (interquartile range 8.3–33.8). The consensus clinicopathologic 
diagnoses of these 32 patients were: membranous nephropathy (anti-PLA2R-positive, 
n=1; cancer-associated, n=3), IgA nephropathy (n=4), infection-related glomerulonephritis 
(n=2), ANCA-associated glomerulonephritis (n=2), and idiopathic non-lupus full house 
nephropathy (n=20).5 Details on the clinical presentation, biopsy findings, and clinical 
follow-up of these patients are provided elsewhere.5 
General characteristics of patients with and without clinical SLE
General characteristics of patients in our cohort and the prevalence of individual ACR and 
SLICC classification criteria are shown in Table 1. Patients with clinical SLE were significantly 
younger and more often female than patients without clinical SLE. For some patients, the 
absence or presence of cutaneous and/or immunologic criteria was unconvincing, in which 
cases these criteria were excluded from the comparisons. The 32 patients without clinical 
SLE less frequently fulfilled individual ACR and SLICC classification criteria than the 117 
patients with clinical SLE, except for the criteria oral/nasal ulcers, discoid rash, anti-Sm, and 
antiphospholipid antibodies.
Biopsy findings in patients with and without clinical SLE
Comparisons of biopsy findings between patients with and without clinical SLE are shown 
in Table 2 (see also Rijnink et al.5 for a comparison excluding patients without SLE due to 
secondary causes). Briefly, the pattern of histopathologic injury by light microscopy was 
different between patients with and without clinical SLE (P=0.003); with absent lesions 
or a purely mesangial pattern of injury and a membranous pattern being more prevalent 
in patients without clinical SLE, and with endocapillary and/or extracapillary lesions being 
more prevalent in patients with clinical SLE. C1q and IgM immunofluorescence staining was 
significantly more intense in patients with clinical SLE compared to patients without (both 
P<0.01). By electron microscopy, patients with clinical SLE more often had subendothelial 
deposits (P=0.008).
Fulfilment of ACR and SLICC classification criteria
At the time of renal biopsy, 110 patients in our cohort with clinical SLE fulfilled ≥4 ACR 
and SLICC criteria for the classification of SLE and seven patients fulfilled ≥4 SLICC criteria 
only (Figure 1). Of the 32 patients without clinical SLE, three fulfilled the stand-alone renal 
criterion of the SLICC classification because of their renal biopsy findings in combination with 
ANA but had <4 ACR and SLICC criteria at the time of renal biopsy. Twenty-nine patients 
without clinical SLE did not meet the classification requirements at the time of renal biopsy. 
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Table 1 General characteristics and prevalence of individual 1997 ACRa and 2012 SLICCb criteria in patients with and 
without clinical SLE in the full house cohort. 
Characteristic Clinical SLE (n=117) No clinical SLE (n=32) P
Age, y ± SD 32.6 ± 14.6 38.7 ± 16.2 0.041
Sex, male:female 30:87 21:11 <0.001
ACR criteria, median (range) 5 (3−9) 1 (1−3) <0.001
SLICC criteria, median (range) 7 (4−14) 1 (1−3) <0.001
Clinical criteria n/total (%) n/total (%)
Acute/subacute cutaneous lupusb 66/117 (56.4) 0/32 (0) <0.001
Malar rasha 48/112 (42.9) 0/32 (0) <0.001
Photosensitivitya 25/112 (22.3) 0/32 (0) 0.001
Chronic cutaneous lupusb 14/117 (12.0) 0/32 (0) 0.041
Discoid rasha 11/106 (9.4) 0/32 (0) 0.122
Non-scarring alopeciab 21/117 (17.9) 0/32 (0) 0.008
Oral/nasal ulcersa,b 25/117 (21.4) 3/32 (9.4) 0.200
Arthritisa,b 86/117 (73.5) 1/32 (3.1) <0.001
Serositisa,b 44/117 (37.6) 1/32 (3.1) <0.001
Neurologic disordera,b 18/117 (15.4) 0/32 (0) 0.013
Haemolytic anaemiaa,b 20/117 (17.1) 0/32 (0) 0.008
Lympho-/leukopeniaa,b 36/117 (30.8) 0/32 (0) <0.001
Thrombocytopeniaa,b 28/117 (23.9) 0/32 (0) 0.001
Immunologic criteria 
Antinuclear antibodya,b 116/117 (99.1) 3/26 (11.5) <0.001
Anti-dsDNAa,b 80/109 (73.4) 0/28 (0) <0.001
Anti-Sma,b 18/56 (32.1) 0/8 (0) 0.093
Antiphospholipid antibodya,b 41/81 (50.6) 0/5 (0) 0.057
Hypocomplementaemiab 94/109 (86.2) 2/23 (8.7) <0.001
Direct Coombs’ testb 25/75 (33.3) 0/13 (0) 0.016
Classification criteria were registered up to and including the time of renal biopsy. Fractions indicate the number of patients 
with a particular criterion divided by the total number of patients for whom the presence or absence of a criterion could 
be retrieved. The total number of SLE classification criteria was compared using Mann Whitney U test. The prevalence 




Table 2 Histopathologic findings in patients with and without clinical SLE.
Clinical SLE (n=117) No clinical SLE (n=32) P
Light microscopy  
ISN/RPS 2003 class, n (%)  
I 1 (1) 3 (9)
II 2 (2) 1 (3)
III 24 (21) 11 (34)
IV 79 (68) 8 (25)
III/IV + V 2 (2) 3 (9)
V 9 (8) 6 (19) <0.001
III/IV (+V) A 45 (43) 8 (35)
III/IV (+V) A/C 59 (56) 11 (48)
III/IV (+V) C 1 (1) 4 (17) 0.058*
No lesions/ purely mesangial lesions, n (%) 3 (3) 4 (13)
Endo- and/or extracapillary lesions, n (%) 105 (90) 23 (72)
Membranous lesions, n (%) 11 (9) 9 (28) 0.003
Immunofluorescence microscopy  
IgA, n (%)  
+ 26 (22) 11 (34)
++ 60 (51) 15 (47)
+++ 31 (26) 6 (19) 0.158*
IgM, n (%)  
+ 27 (23) 16 (50)
++ 64 (55) 13 (41)
+++ 26 (22) 3 (9) 0.004*
IgG, n (%)  
+ 21 (18) 9 (28)
++ 67 (57) 10 (31)
+++ 29 (25) 13 (41) 0.682*
C3, n (%)  
+ 8 (7) 7 (22)
++ 64 (55) 14 (44)
+++ 45 (39) 11 (34) 0.131*
C1q, n (%)  
+ 9 (8) 11 (34)
++ 67 (57) 14 (44)
+++ 41 (35) 7 (22) 0.002*
Electron microscopy (n=29) (n=14)
Mesangial deposits, n (%) 10 (35) 5 (36) 1.000
Subendothelial deposits, n (%) 23 (80) 5 (36) 0.008
Subepithelial deposits, n (%) 24 (83) 11 (79) 1.000
Food process effacement, n (%) 24 (83) 11 (79) 1.000
Tubuloreticular inclusions, n (%) 5 (17) 2 (14) 1.000










* Linear-by-linear analysis. † Locations include: mesangial, subendothelial and subepithelial.
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Figure 1 Venn diagram illustrating the distribution of patients with and without clinical SLE identified by the ACR and SLICC 
classifications at the time of renal biopsy. 
Patients with a reference standard clinical diagnosis of SLE (n=117) are indicated in white, and those without (n=32) in grey. 
ACR classification: false negatives
Classification according to the ACR criteria resulted in seven false-negative classifications. 
These patients had, in addition to renal involvement, hypocomplementaemia and two 
other criteria (synovitis, neuropsychiatric lupus, lupus anticoagulant, leukopenia, positive 
ANA, and/or anti-dsDNA). Thus, they were classified according to exactly 4 SLICC criteria. 
Classification of SLE according to the ACR criteria was not possible, as hypocomplemen-
taemia is not included. During median follow-up of 9.0 years (interquartile range 3.2−19.0), 
2 of these 7 patients could also be classified as SLE according to ≥4 ACR criteria after 5 
and 6 years. Thus, the sensitivity of the ACR classification increased from 94 to 96% after 
6 years of follow-up.
SLICC classification: false positives
Classification according to the SLICC criteria resulted in three false positive classifications. 
These patients had a renal biopsy with a full house immunofluorescence pattern in combi-
nation with lesions by light and electron microscopy consistent with LN as detailed below. 
Because of a positive ANA, they were classified as SLE based on the stand-alone renal 
SLICC criterion assuming they had “biopsy-confirmed” LN, but had <4 ACR and SLICC 
criteria at the time of biopsy and during follow-up (median 7.7 [range 2.9–9.0] years). One 
patient had crescentic and endocapillary glomerulonephritis with 2+ intensity for IgG, IgA, 
IgM, C3, and C1q by immunofluorescence, and no material for electron microscopy availa-
ble. This patient was clinically diagnosed with PR3-ANCA-associated glomerulonephritis 
and had a positive ANA 4 years prior to renal biopsy, but negative ANA during follow-up. 
Two other patients had cancer-associated membranous nephropathy; one of them with 
membranous nephropathy with glomerular sclerosis by light microscopy, IgG 3+, IgA 1+, 
IgM 1+, C3 1+ and C1q 3+ by immunofluorescence, and subepithelial deposits by electron 
microscopy; the other with focal endocapillary glomerulonephritis with spikes, IgG 1+, IgA 
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1+, IgM 1+, C3 3+ and C1q 2+ by immunofluorescence, and subepithelial deposits and 
tubuloreticular inclusions by electron microscopy. Both had a positive ANA at the time of 
renal biopsy, and the first also after 4 years of follow-up. A fourth patient without clinical 
SLE at the time of biopsy and during follow-up fulfilled no additional SLE classification 
criteria at the time of renal biopsy, but had a persistently positive ANA after 12 years of 
follow-up. The renal biopsy at baseline showed focal endocapillary glomerulonephritis, IgG 
3+, IgA 1+, IgM 1+, C3 3+, C1q 3+ by immunofluorescence, and subepithelial deposits by 
electron microscopy. Therefore, the specificity of the SLICC classification decreased from 
91 to 88% after 12 years follow-up. 
Comparing the diagnostic performance of the 
ACR and SLICC classifications 
The performance of the ACR and SLICC classifications in our cohort is shown in Table 3. 
Compared with the ACR classification, the SLICC classification was more sensitive (100 vs. 
94%) but less specific (91 vs. 100%). The sensitivity and specificity of the SLICC classifica-
tion were 100% when excluding the stand-alone renal criterion, based on the finding that 
three patients were incorrectly classified as SLE based on the stand-alone renal criterion. 
Compared with the ACR classification, there was no reclassification improvement of the 
SLICC classification (NRI −0.034, P=0.563). Exclusion of the stand-alone renal criterion 
resulted in 6% of SLE patients being appropriately reclassified in this cohort as compared 
with the ACR classification, resulting in significant reclassification improvement (NRI 0.060; 
P=0.014). Reclassification tables are shown in Appendix 2.1.













































6.0 0 0.060 0.008
NRI (net reclassification improvement) was calculated relative to the ACR 1997 classification (reference) and was computed 
separately for clinical SLE cases (SLE(+)) and non-SLE cases (SLE(-)). P-values were calculated for the null hypothesis NRI 
= 0. CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value. * Stand-alone renal criterion is 
defined as a full house renal biopsy in combination with antinuclear or anti-double stranded DNA antibodies.
Comparing our cohort with the SLICC derivation cohort
The prevalence of individual SLICC classification criteria in our cohort was compared to 
the reported prevalence of these criteria in the SLICC derivation cohort (Appendix 2.2). 
Compared with SLE patients from the SLICC derivation cohort, SLE patients in our cohort 
had a lower frequency of non-scarring alopecia, oral/nasal ulcers, and leukopenia. Conver-
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sely, they had a significantly higher frequency of renal disorder (by selection), neurologic 
disorder, haemolytic anaemia, thrombocytopenia, anti-dsDNA, and hypocomplementaemia. 
Compared with control patients without SLE from the SLICC derivation cohort, control 
patients without SLE in our cohort had significantly less frequent acute/subacute cutaneous 
lupus and arthritis, while the occurrences of other SLICC classification criteria were similar.
DISCUSSION
We performed the first study to test the validity of the SLICC classification criteria for SLE 
in a cohort of patients with a clinicopathologic suspicion of SLE based on the finding of full 
house glomerular deposits in their renal biopsies, a group reflecting a diagnostic problem 
area in the nephrology clinic. Our findings show that, overall, the SLICC criteria were more 
sensitive (100 vs. 94%) and enabled earlier classification than the ACR criteria. However, this 
was at the expense of specificity (91 vs. 100%). We identified three patients with biopsy 
findings consistent with LN and a positive ANA, who were classified as SLE according to 
the stand-alone renal SLICC criterion, but who had no further signs or symptoms of SLE. 
Conversely, no patients with clinical SLE were found who only fulfilled the stand-alone 
renal criterion. Exclusion of the stand-alone renal criterion from the SLICC classification 
resulted in significant reclassification improvement compared with the ACR classification 
in this cohort. We conclude that overall the SLICC classification performed well in our 
cohort, but the stand-alone renal criterion compromised the specificity. False-positive 
diagnoses emanating from the adaptation of the stand-alone renal SLICC criterion in 
clinical practice may have major consequences for patients, given the implications of the 
diagnoses LN and SLE.
Bayes’ theorem states that the odds of disease equal the disease frequency (pretest odds 
in Bayesian terms) multiplied by the likelihood ratio. In this equation, the likelihood ratio 
stems from the sensitivity and specificity of the classification criteria set. Both sensitivity 
and specificity are dependent on the population that is studied. First, the sensitivity of a 
criterion may vary when studying a different disease spectrum. Patients with SLE in our 
cohort seemed to represent a different phenotype of SLE than the SLE patients in the 
SLICC derivation cohort who were selected from rheumatology clinics. Compared with 
patients in the SLICC derivation cohort, SLE patients with renal involvement in our cohort 
had a significantly lower frequency of alopecia, oral/nasal ulcers, and leukopenia, and a 
higher frequency of neurologic disorders, haemolytic anaemia, thrombocytopenia, anti-ds-
DNA antibodies, and hypocomplementaemia. These results are in agreement with those 
from a recently published large inception cohort comparing SLE patients with and without 
nephritis19 and support the notion that SLE is a disease with heterogeneous phenotypes.20 
Second, the specificity of a criterion is fully dependent on the control population studied. 
In designing a classification criteria set, the control population is chosen to represent the 
diagnostic problem area.2 By design, renal involvement was less specific in our cohort than 
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in the SLICC derivation cohort, as the latter did not select patients with renal diseases that 
would appear in the differential diagnosis of LN. Moreover, the control population used for 
derivation of the SLICC criteria had more cutaneous and joint manifestations, reflecting 
typical findings in patients from rheumatology clinics.  Thus, the sensitivities, specificities, and 
emanating likelihood ratios of criteria used in the development of the SLICC classification 
cannot be unequivocally applied to potential SLE patients in the nephrology clinic. 
From our results, the combination of ANA and biopsy-confirmed LN as stand-alone criterion 
is questionable, as both had suboptimal specificity.  Three patients were false-positively classi-
fied as SLE according to the stand-alone renal criterion by the SLICC.  Although the specificity 
of ANA in our cohort was 88.5%, ANAs are associated with various other rheumatic and 
non-rheumatic diseases and can be detected in up to 27% of the general population.21 Most 
telling, two patients in our cohort had membranous nephropathy and concurrent malig-
nancy, the latter known for its association with ANA-positivity.22 A positive ANA itself is very 
sensitive for SLE, but clearly ANAs are more accurate in ruling out SLE than confirming the 
diagnosis. Since ANA testing was performed qualitatively using 1:40 diluted serum and titres 
were unavailable for the patients in our study, it is unknown whether higher cut-offs would 
have resulted in more patients being appropriately classified using the stand-alone renal 
criterion. The classification of SLE according to the combination of a renal biopsy consistent 
with LN and positive anti-dsDNA antibodies in the absence of other criteria for SLE was 
not observed in our cohort. Possibly, anti-dsDNA antibodies would be more suitable than 
ANA as part of the stand-alone criterion given their higher specificity for SLE. 
In addition to the problems emanating from the autoantibodies included in the stand-al-
one criterion, there is no consensus among pathologists and clinicians of what defines 
biopsy-confirmed LN. In our opinion, the finding of a full house pattern of immunoflu-
orescence would certainly raise SLE as a differential diagnostic consideration. However, 
32 patients in our cohort without SLE had full house immunofluorescence, affirming 
that full house immunofluorescence per se is a far from optimal indicator for LN and 
must be interpreted in light of clinical and additional biopsy findings. Clearly, the SLICC 
criteria excluding the stand-alone renal criterion appeared to be useful to identify SLE 
cases clinically. Concerning the additional biopsy findings, we found endocapillary and/or 
extracapillary hypercellularity, relative intensity of IgM and C1q, and subendothelial deposits 
by electron microscopy to support the diagnosis of SLE. Other biopsy findings, inclu-
ding tubuloreticular inclusions and coexistent mesangial, subendothelial and subepithelial 
deposits, that have previously been found to be suggestive of LN3 were not significantly 
different between patients with and without clinical SLE in our cohort. It may be anticipated 
that in some cases, these other renal biopsy findings characteristic of LN would lead to 
the designation of biopsy-confirmed LN.3 This emphasises that the extent to which the 
stand-alone criterion by the SLICC may result in false-positive classifications of SLE may 
be underestimated by this study. 
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Conversely, the number of false positives may also be overestimated by our study. In the 
literature, anecdotal reports of patients with “non-lupus full house nephropathy” – similar 
to the 32 patients without clinical SLE in our study – have shown that the minority of these 
patients become seropositive and/or develop extrarenal symptoms of SLE during up to 10 
years follow-up.23-27 However, during a median follow-up of 20.0 years (interquartile range 
8.3–33.8), none of the 32 patients without clinical SLE in our study were clinically diagnosed 
with SLE.  It cannot be excluded that some patients had latent SLE that would be diagnosed 
if more long-term follow-up data would be available. However, other studies have shown 
that non-lupus full house nephropathy can also be associated with atypical presentations 
of other well-established renal diseases or may occur idiopathically.3, 5, 7-10, 24, 28-31 
We have shown that the SLICC classification proved to have great sensitivity among 
patients with a renal biopsy with full house glomerular deposits. This superior sensitivity 
of the SLICC relative to the ACR classification in our cohort was entirely attributed to 
the criterion hypocomplementaemia, which is absent in the ACR classification. Indeed, our 
results underline that complement consumption in the classical pathway is an essential 
finding in active severe SLE with renal involvement.32, 33 In our cohort, the specificity of the 
SLICC classification was lower than the ACR classification, and this was attributed to the 
introduction of the stand-alone renal criterion to the SLICC classification. Other validation 
studies similarly showed a higher sensitivity and lower specificity of the SLICC compared 
with the ACR classification, although none of them elaborated on the stand-alone renal 
criterion.11, 15-17, 34, 35 Only Ungprasert et al. identified three patients with SLE among 55 
who met SLICC criteria who were classified based upon the stand-alone criterion without 
commenting on their biopsy findings.35 We conclude that the SLICC classification may 
perform well as classification and conceivably also as diagnostic criteria for patients with 
renal biopsy findings consistent with LN, but we suggest re-evaluation of the stand-alone 
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Full house immunofluorescence in combination with various histopathologic lesions in 
the renal biopsies of patients without overt systemic lupus erythematosus (SLE) poses a 
diagnostic challenge. In this setting, the biopsy findings are sometimes termed non-lupus 
“full house nephropathy” (FHN). It is presently unknown whether idiopathic non-lupus 
FHN is clinicopathologically and prognostically distinct from lupus FHN. 
Methods
We included non-lupus FHN patients and lupus FHN controls (four or more ACR or 
SLICC criteria) who were biopsied between 1968–2014 at the Leiden University Medical 
Center. Non-lupus FHN patients were studied for progression to SLE and/or the presence 
of other conditions with FHN. The clinicopathologic characteristics and prognosis of idio-
pathic non-lupus FHN patients were compared to those of lupus FHN patients. 
Results
Of 149 included patients, 32 had non-lupus FHN. During the median follow-up of 20 
years, no non-lupus FHN patients developed SLE. Twenty non-lupus FHN patients had 
idiopathic non-lupus FHN, and in 12 patients secondary non-lupus FHN was considered 
due to membranous nephropathy (anti-PLA2R-positive, n=1; cancer-associated, n=3), IgA 
nephropathy (n=4), infection-related glomerulonephritis (n=2), or anti-neutrophil cytop-
lasmic antibody-associated glomerulonephritis (n=2). Idiopathic non-lupus FHN patients 
were more often male (P<0.001) than lupus FHN patients, and their renal biopsies more 
often showed a mesangial (P=0.04) or membranous pattern of injury (P=0.02), and less 
intense C1q staining (P=0.002). Clinically, they presented with lower-range erythrocyturia 
(P=0.04), more proteinuria (P<0.01), and less complement consumption in the classical 
pathway (P<0.001) than lupus FHN patients. By multivariable Cox regression analysis 
of patients with a lupus nephritis class III/IV pattern of injury, idiopathic non-lupus FHN 
compared to lupus FHN was an independent risk factor for end-stage renal disease (HR 
5.31; 95% CI 1.47 to 19.24). 
Conclusion




Clinicopathologic Distinction of Non-Lupus Full House Nephropathy
INTRODUCTION
A typical finding in renal biopsies of patients with lupus nephritis (LN) is a full house 
pattern by immunofluorescence, which is defined as concurrent positive staining for IgA, 
IgG, IgM, C3, and C1q.1 In a patient with extrarenal signs and symptoms of systemic lupus 
erythematosus (SLE), identification of nephritis with a full house immunofluorescence 
pattern on renal biopsy is consistent with LN. However, a diagnostic challenge ensues 
when patients present with various histopathologic lesions – either or not resembling 
LN – in combination with a full house pattern by immunofluorescence in the absence of 
autoantibodies and other classifying signs or symptoms of SLE. In this setting, the biopsy 
findings are sometimes termed non-lupus “full house nephropathy” (FHN).2 Non-lupus 
FHN was first systematically described in a group of 24 patients by Wen and Chen, who 
defined the clinicopathologic spectrum of this entity and indicated that in future studies, 
the emergence of overt SLE remained to be elucidated.2 Anecdotal reports have shown 
that only a minority of these patients eventually develop the autoantibodies characteristic 
of SLE and/or extrarenal symptoms of SLE during follow-up,2-7 whereas other reports 
have shown that non-lupus FHN can be associated with atypical manifestations of other 
well-established pathologies.2, 8-15 It remains unclear how to classify and treat non-lupus 
FHN patients for whom the origin of FHN is idiopathic.
In the present study, patients with idiopathic non-lupus FHN and non-lupus FHN due to 
other disease processes were identified from the largest cohort of patients with renal bio-
psies showing full house immunofluorescence to date. The clinicopathologic characteristics 
and prognosis of idiopathic non-lupus FHN patients were compared to those of lupus 
FHN patients according to four or more American College of Rheumatology (ACR)16 or 
Systemic Lupus International Collaborating Clinics (SLICC)17 criteria.
METHODS
The pathology archives of the Leiden University Medical Center were searched from 1968 
to 2014 to identify all patients with native renal biopsies showing full house immunofluo-
rescence, which was defined as concurrent positive staining for IgA, IgG, IgM, C3, and C1q 
with ≥1+ intensity on a 0–3+ scale. Only biopsies showing granular fluorescent staining 
along the capillary walls, in the mesangium, or both were included. Patients meeting these 
criteria and who were followed in our centre entered the study. In accordance with the 
ethics committee of the Leiden University Medical Center, all patient data were coded 
and kept anonymous throughout the study. Renal biopsies were re-evaluated by an expe-
rienced nephropathologist (IMB). In cases where renal biopsies were unavailable, the 
histopathologic diagnosis was deduced from the original biopsy report if possible; but they 
were excluded from analyses involving categorical pathology scoring.  All biopsies were (re)
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classified according to the ISN/RPS classification of LN,18 regardless of the clinicopatholo-
gic diagnosis. Global glomerulosclerosis, fibrous crescents, tubular atrophy, and interstitial 
fibrosis were scored semi-quantitatively as (0) <5%; (1) 5–25%; (2) 26–50%; (3)>50% of 
glomeruli, tubules, or cortical area. The scores were summed to generate a total chroni-
city score. Finally, the pathologist made a differential diagnosis based on light microscopy 
findings knowing that the patients had a full house pattern by immunofluorescence. 
All biopsies were processed for light and immunofluorescence microscopy according to 
the standard techniques at our centre. For immunofluorescence microscopy, sections were 
frozen in liquid nitrogen, and cryostat sections were stained with FITC-labelled antisera to 
human IgA, IgG, IgM, C3, and C1q. Immunofluorescence reports were originally prepared 
by four experienced nephropathologists who consistently scored the immunofluorescence 
intensity on a 0–3+ scale. Not all biopsies were sent in for analysis by electron microscopy; 
but if at hand, tissue was fixed in 1.5% glutaraldehyde and 1% paraformaldehyde and 
embedded in Epon. 
The medical records of the patients were reviewed independently by investigators (ECR, 
YKOT, and TK) for the presence of four or more cumulative ACR16 and/or SLICC17 criteria 
for SLE at the time of renal biopsy. After independent review, a consensus was reached 
for fulfilment of the classification criteria. Cases that did not fulfil four or more ACR16 or 
SLICC17 criteria at the time of biopsy were considered representative of non-lupus FHN 
and were evaluated in a clinicopathologic conference by investigators (ECR, YKOT,  TK, and 
IMB) reaching consensus on the clinicopathologic differential diagnosis at the time of biopsy. 
Additional serologic parameters were recorded for non-lupus FHN patients if available. Fol-
low-up data of non-lupus FHN patients were meticulously studied to investigate whether 
they fulfilled ACR16 or SLICC17 classification criteria at any time after renal biopsy. 
For lupus FHN and non-lupus FHN patients, serum creatinine, estimated glomerular fil-
tration rate (eGFR),19, 20 24h proteinuria, erythrocyturia, and grade of hypertension21 were 
recorded at the time of renal biopsy. Induction immunosuppression was recorded for all 
patients, as was immunosuppression initiated after renal transplantation in non-lupus FHN. 
End-stage renal disease (ESRD) was defined as dialysis-dependence for >3 months or 
renal transplantation. Patients lost to follow-up were checked in the population register 
to see if they were alive at the end of this study (5 October 2015); if not, the date of 
death was recorded. 
Statistical analyses
Normally distributed data were compared with t-tests, and non-normally distributed data 
with Mann-Whitney U tests. Categorical data were compared with Fisher’s exact tests, 
chi-square tests, or linear-by-linear analysis. 
The outcomes time to ESRD, death, and ESRD/death were analysed using Kaplan-Meier 
 67
3
Clinicopathologic Distinction of Non-Lupus Full House Nephropathy
curves and log-rank tests. The observation period considered for the outcome analyses 
started at the time of renal biopsy demonstrating FHN. Multivariable analyses included 
idiopathic non-lupus FHN and lupus FHN patients. The following subgroups classified 
according to the ISN/RPS classification were analysed separately: (i) class I/II; (ii) class III/
IV (±V); and (iii) class V. The following candidate predictors of ESRD and/or death were 
entered in multivariable proportional hazards models: idiopathic non-lupus FHN; sex; age, 
eGFR, and proteinuria at the time of biopsy; and induction immunosuppression (model 1). 
A second model was designed including non-lupus FHN, induction immunosuppression 
and histologic chronicity score (model 2).  All P-values are two-sided and were considered 
significant at P<0.05.  Analyses were performed using SPSS 23.0 (IBM, Armonk, New York).
RESULTS
Of the 149 patients included, 117 patients had lupus FHN, while 32 patients had non-lupus 
FHN. A total of 26 non-lupus FHN and 99 lupus FHN patients had a renal biopsy availa-
ble for re-evaluation. The median number of scorable glomeruli was 15 (range 6–65) in 
non-lupus FHN patients, and 14 (range 6–56) in lupus FHN patients.
Clinicopathologic diagnoses of non-lupus FHN patients
The clinicopathologic characteristics of individual non-lupus FHN patients are shown in 
Table 1 (see Appendix 3.1 for detailed descriptions). The 32 non-lupus FHN patients were 
neither originally diagnosed with SLE at the time of biopsy, nor after revision of the medical 
files and evaluation of SLE classification criteria. The following cumulative SLE criteria were 
registered at the time of biopsy in non-lupus FHN patients: oral/nasal ulcers (cases 5, 27, 
and 28), synovitis (case 6), serositis (case 6), hypocomplementaemia (cases 5 and 27), and 
anti-nuclear antibody (ANA) (cases 28, 31, and 32). During median follow-up of 20 years 
(interquartile range [IQR] 8.3–33.8), two cases developed additional ACR/SLICC criteria: 
case 12 developed arthritis 9 years after renal biopsy (likely attributable to rheumatoid 
arthritis), and case 19 developed serositis and arthritis 2 years after renal biopsy. However, 
none of the 32 patients were clinically diagnosed with SLE during follow-up or met four 
or more ACR or SLICC criteria. 
In view of the presence of FHN in the absence of SLE in these 32 patients, we re-evaluated 
their clinical presentation including serologic and histopathologic findings, and long-term clini-
cal follow-up (including follow-up biopsies) to investigate whether other differential diagnostic 
considerations than SLE would apply to some of them. In 12 patients, we considered atypical 
variants of the following entities (Table 1 and Appendix 3.1): membranous nephropathy 
(anti-PLA2R-positive, n=1; cancer-associated, n=3), IgA nephropathy (n=4), infection-related 
glomerulonephritis (n=2), and anti-neutrophil cytoplasmic antibody (ANCA)-associated glo-
merulonephritis (AAGN, n=2). We will henceforth refer to these 12 patients as “secondary 
non-lupus FHN”. Importantly, 20 non-lupus FHN patients had idiopathic FHN. 
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Table 1 Clinical presentation and histopathologic findings in patients with non-lupus full house nephropathy (FHN). 
Patient 
number
Sex Age, y Presentation Clinicopathologic differential diagnosis Light microscopy pattern Immunofluorescence Classification 
as in SLE†IgA, + IgG, + IgM, + C3, + C1q, +
Idiopathic non-lupus FHN
1 F 16 NS Idiopathic Minimal lesions 1 1 2 2 2 I
2 M 58 NS Idiopathic Minimal lesions 2 2 2 2 2 I
3 M 27 Hematuria, subnephrotic proteinuria Idiopathic Mesangioproliferative 2 2 1 2 1 II
4 F 16 Acute renal insufficiency Idiopathic Diffuse proliferative, crescents 2 2 3 3 3 IV-G (A/C)
5 M 58 RPGN Idiopathic Diffuse proliferative 2 3 3 2 2 IV-G (A/C)
6 M 56 NS Idiopathic Segmental chronic lesions, spikes 3 2 2 3 3 III (C) + V
7 M 31 NS Idiopathic Focal proliferative 2 3 2 2 2 III (A/C)
8 M 29 Haematuria Idiopathic Focal proliferative 1 1 1 1 1 III (A/C)
9 M 58 NS, haematuria Idiopathic Focal proliferative 1 3  2 1 1 III (A)
10 M 45 NS Idiopathic Focal proliferative 1 3 1 3 3 III (A/C)
11 F 28 NS, renal insufficiency, malignant 
hypertension
Idiopathic Diffuse proliferative 2 2 1 1 1 IV-G (A)
12 M 52 RPGN Idiopathic Diffuse proliferative, crescents, fibrinoid necrosis 2 1 2 3 2 IV-G (A/C)
13* F 29 NS Idiopathic MPGN, spikes 2 2 2 2 2 IV-G (A/C) + V
14 M 31 NS Idiopathic Focal proliferative 1 3 2 2 2 III (A/C)
15 M 31 NS Idiopathic Membranous 2 2 1 2 1 V
16* M 67 Acute renal insufficiency Idiopathic Membranous 3 3 1 1 1 V
17* F 22 NS Idiopathic Membranous 1 3 2 2 3 V
18 M 21 RPGN Idiopathic Membranous, interstitial nephritis, minimal vasculopathy 3 3 1 3 1 V
19 M 52 NS Idiopathic Segmental chronic lesions, occasional spikes 1 3 2 2 2 III (C)
20 F 19 Hypertension Idiopathic FSGS, segmental chronic lesions, TMA 1 1 1 2 1 III (A/C)
Secondary non-lupus FHN
21* M 34 Macroscopic haematuria, 
subnephrotic proteinuria
IgA-like nephropathy Segmental chronic lesions 2 1 1 2 2 III (C)
22 M 31 Haematuria, subnephrotic proteinuria Crescentic IgA-like nephropathy Focal proliferative, crescents 2 1 1 1 2 III (A/C)
23 F 32 Malignant hypertension, acute renal 
insufficiency
Crescentic IgA-like nephropathy Diffuse proliferative, crescents 3 2 2 3 2 IV-G (A/C)
24 F 18 Haematuria, subnephrotic proteinuria Crescentic IgA-like nephropathy Focal proliferative, crescents, fibrinoid necrosis 2 1 1 3 1 III (A/C)
25 M 55 Haematuria, microalbuminuria Infection-related glomerulonephritis Minimal lesions 2 2 1 2 2 I
26* M 50 RPGN Infection-related glomerulonephritis Diffuse proliferative 2 3 2 3 3 IV-G (A)
27 F 21 RPGN ANCA-associated glomerulonephritis Diffuse proliferative, crescents 1 1 1 1 1 IV-G (A/C)
28 F 47 Haematuria, subnephrotic proteinuria ANCA-associated glomerulonephritis Diffuse proliferative, crescents 2 2 2 2 2 IV-S (A) 
29 M 30 NS MN (anti-PLA2R) Membranous 3 3 3 3 3 V
30 M 55 Haematuria, subnephrotic proteinuria MN (cancer-associated) + FSGS Focal proliferative, FSGS, spikes 3 3 1 3 1 III (A/C) + V
31 M 71 NS MN (cancer-associated) + secondary glomerular 
sclerosis
Membranous 1 3 1 1 3 V
32 F 50 NS MN (cancer-associated) + minimal endocapillary 
proliferation
Focal proliferative, occasional spikes 1 1 1 3 2 III (A)
ANCA, anti-neutrophil cytoplasmic antibody; F, female; FSGS, focal segmental glomerulosclerosis; M, male; MN, membranous nephropa-
thy; MPGN, membranoproliferative glomerulonephritis; NS, nephrotic syndrome; RPGN, rapidly progressive glomerulonephritis; 
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10 M 45 NS Idiopathic Focal proliferative 1 3 1 3 3 III (A/C)
11 F 28 NS, renal insufficiency, malignant 
hypertension
Idiopathic Diffuse proliferative 2 2 1 1 1 IV-G (A)
12 M 52 RPGN Idiopathic Diffuse proliferative, crescents, fibrinoid necrosis 2 1 2 3 2 IV-G (A/C)
13* F 29 NS Idiopathic MPGN, spikes 2 2 2 2 2 IV-G (A/C) + V
14 M 31 NS Idiopathic Focal proliferative 1 3 2 2 2 III (A/C)
15 M 31 NS Idiopathic Membranous 2 2 1 2 1 V
16* M 67 Acute renal insufficiency Idiopathic Membranous 3 3 1 1 1 V
17* F 22 NS Idiopathic Membranous 1 3 2 2 3 V
18 M 21 RPGN Idiopathic Membranous, interstitial nephritis, minimal vasculopathy 3 3 1 3 1 V
19 M 52 NS Idiopathic Segmental chronic lesions, occasional spikes 1 3 2 2 2 III (C)
20 F 19 Hypertension Idiopathic FSGS, segmental chronic lesions, TMA 1 1 1 2 1 III (A/C)
Secondary non-lupus FHN
21* M 34 Macroscopic haematuria, 
subnephrotic proteinuria
IgA-like nephropathy Segmental chronic lesions 2 1 1 2 2 III (C)
22 M 31 Haematuria, subnephrotic proteinuria Crescentic IgA-like nephropathy Focal proliferative, crescents 2 1 1 1 2 III (A/C)
23 F 32 Malignant hypertension, acute renal 
insufficiency
Crescentic IgA-like nephropathy Diffuse proliferative, crescents 3 2 2 3 2 IV-G (A/C)
24 F 18 Haematuria, subnephrotic proteinuria Crescentic IgA-like nephropathy Focal proliferative, crescents, fibrinoid necrosis 2 1 1 3 1 III (A/C)
25 M 55 Haematuria, microalbuminuria Infection-related glomerulonephritis Minimal lesions 2 2 1 2 2 I
26* M 50 RPGN Infection-related glomerulonephritis Diffuse proliferative 2 3 2 3 3 IV-G (A)
27 F 21 RPGN ANCA-associated glomerulonephritis Diffuse proliferative, crescents 1 1 1 1 1 IV-G (A/C)
28 F 47 Haematuria, subnephrotic proteinuria ANCA-associated glomerulonephritis Diffuse proliferative, crescents 2 2 2 2 2 IV-S (A) 
29 M 30 NS MN (anti-PLA2R) Membranous 3 3 3 3 3 V
30 M 55 Haematuria, subnephrotic proteinuria MN (cancer-associated) + FSGS Focal proliferative, FSGS, spikes 3 3 1 3 1 III (A/C) + V
31 M 71 NS MN (cancer-associated) + secondary glomerular 
sclerosis
Membranous 1 3 1 1 3 V
32 F 50 NS MN (cancer-associated) + minimal endocapillary 
proliferation
Focal proliferative, occasional spikes 1 1 1 3 2 III (A)
ANCA, anti-neutrophil cytoplasmic antibody; F, female; FSGS, focal segmental glomerulosclerosis; M, male; MN, membranous nephropa-
thy; MPGN, membranoproliferative glomerulonephritis; NS, nephrotic syndrome; RPGN, rapidly progressive glomerulonephritis; 




Clinical presentation of idiopathic non-lupus FHN compared to lupus 
FHN patients
Of the 20 idiopathic non-lupus FHN patients, 12 (60%) presented with a nephrotic syn-
drome, 2 (10%) with abnormal urinary sediment, 2 (10%) with acute renal insufficiency, 
3 (15%) with rapidly progressive glomerulonephritis, and 1 (5%) with hypertension and 
raised serum creatinine in the absence of erythrocyturia/proteinuria (Table 1).
The clinical characteristics of idiopathic non-lupus FHN compared to lupus FHN patients at 
the time of biopsy are shown in Table 2. Briefly, compared to lupus FHN patients, idiopathic 
non-lupus FHN patients were more often male (P<0.001); they had significantly more 
proteinuria (P<0.01), less erythrocyturia (P=0.04), and less complement consumption in 
the classical pathway (P<0.001 for C3, C4, and CH50). Up to and including the time of renal 
biopsy, oral/nasal ulcers (n=1), synovitis (n=1), serositis (n=1), and hypocomplementaemia 
(n=1) were observed in idiopathic non-lupus FHN patients. 
Table 2 Clinical characteristics of patients with lupus full house nephropathy (FHN) compared to idiopathic non-lupus 
FHN at the time of renal biopsy. 
Characteristic Lupus FHN 
(n=117)
Idiopathic non-lupus FHN 
(n=20)
P
Sex, male/female 30/87 14/6 <0.001#
Age, y 32.6 ± 14.6 37.3 ± 16.6 0.195§
Hypertension stage, no hypertension/stage 1/
stage 2/stage 3
74/29/11/3 15/4/1/0 0.702†
Serum creatinine, µmol/L 97 (76–150) 114 (94–222) 0.074¶
eGFR, mL/min 75 ± 36 78 ± 51 0.760§
ESR, mm/h 68 ± 33 83 ± 47 0.296§
Leukocytes, *109/L 6.6 ± 3.3 6.2 ± 1.0 0.783§
Thrombocytes, *103/mm3 250 ± 103 225 ± 40 0.629§
Proteinuria, g/24h 3.9 ± 4.1 6.9 ± 5.5 0.006§
Erythrocyturia, missing/-/+/++ 28/16/28/45 13/4/2/1 0.037†
CH50, u/mL (ref. 207–467) 152 ± 118 433 ± 87 <0.001§
C3, mg% (ref. 47–80) 39 ± 20 81 ± 23 <0.001§
C4, mg% (ref. 13–39) 13 ± 11 40 ± 11 <0.001§
C1q, mg% (ref. 9–14) 11 ± 14 17 ± 2 0.463§
Acute cutaneous lupus, n/total (%) 66/117 (56) 0/20 (0) <0.001‡
Malar rash, n/total (%) 48/112 (43) 0/20 (0) <0.001‡
Photosensitivity, n/total (%) 25/112 (22) 0/20 (0) 0.014‡
Chronic cutaneous lupus, n/total (%) 14/117 (12) 0/20 (0) 0.222‡
Discoid rash, n/total (%) 11/106 (9) 0/20 (0) 0.367‡
Oral/nasal ulcers, n/total (%) 25/117 (21) 1/20 (5) 0.122‡
Non-scarring alopecia, n/total (%) 21/117 (18) 0/20 (0) 0.043‡
Synovitis, n/total (%) 86/117 (74) 1/20 (5) <0.001‡
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Table 2 Continued. 
Characteristic Lupus FHN 
(n=117)
Idiopathic non-lupus FHN 
(n=20)
P
Serositis, n/total (%) 44/117 (38) 1/20 (5) 0.004‡
Neurologic disorder, n/total (%) 18/117 (15) 0/20 (0) 0.074‡
Haemolytic anaemia, n/total (%) 20/117 (17) 0/20 (0) 0.044‡
Lympho-/leukopenia, n/total (%) 36/117 (31) 0/20 (0) 0.002‡
Thrombocytopenia, n/total (%) 28/117 (24) 0/20 (0) 0.013‡
Hypocomplementaemia, n/total (%) 94/109 (86) 1/13 (8) <0.001‡
ANA, n/total (%) 116/117 (99) 0/16 (0) <0.001‡
Anti-DNA, n/total (%) 80/109 (73) 0/19 (0) <0.001‡
Anti-ENA, n/total (%) 50/66 (76) 0/3 (0) 1.000‡
Anti-SS-A, n/total (%) 26/57 (46) 0/3 (0) 1.000‡
Anti-SS-B, n/total (%) 14/57 (25) 0/3 (0) 1.000‡
Anti-RNP, n/total (%) 24/53 (45) 0/3 (0) 1.000‡
Anti-Sm, n/total (%) 18/56 (32) 0/3 (0) 0.546‡
Anti-Scl70, n/total (%) 8/53 (15) 0/3 (0) 1.000‡
Anti-Jo1, n/total (%) 12/53 (23) 0/3 (0) 1.000‡
Antiphospholipid antibody, n/total (%) 41/81 (51) 0/1 (0) 1.000‡
Direct Coombs’, n/total (%) 25/75 (33) 0/7 (0) 0.095‡
PR3-ANCA, n/total (%) 2/39 (5) 0/4 (0) 1.000‡
MPO-ANCA, n/total (%) 30/39 (77) 0/4 (0) 0.006‡
Anti-C1q, n/total (%) 15/22 (68) 0/2 (0) 0.130‡
Normally distributed data are as expressed mean ± standard deviation. Non-normally distributed data are expressed 
as median (interquartile range). Cumulative SLE classification criteria were registered at the time of renal biopsy. 
Erythrocyturia was scored as: (−) 0–18 erythrocytes/µL; (+) 19–25 erythrocytes/µL; (++) >26 erythrocytes/µL. † 
Linear-by-linear analysis. ‡ Fisher’s exact test. # Pearson chi-Square. § t-test. ¶ Mann-Whitney U test. ANA, anti-nuclear 
antibody; ANCA, anti-neutrophil cytoplasmic antibody; anti-ENA, anti-extractable nuclear antigen antibody; eGFR, 
estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate.
Histopathologic features of idiopathic non-lupus FHN compared to 
lupus FHN patients
The biopsies of idiopathic non-lupus FHN patients were histopathologically described as: 
no lesions (10%), focal segmental glomerulosclerosis (5%), mesangioproliferative (5%), 
focal proliferative (25%), segmental chronic lesions (10%), diffuse proliferative (10%), active 
crescentic (10%), membranoproliferative (5%), and membranous lesions (20%; see Table 1). 
By electron microscopy, immune deposits were consistent with findings in LN; showing 
the combination of mesangial, subendothelial and subepithelial deposits. Furthermore, in 
case 6 tubuloreticular inclusions were identified by electron microscopy (Appendix 3.2).
The histopathologic findings in lupus FHN compared to idiopathic non-lupus FHN patients 
are shown in Table 3. After classification of non-lupus FHN according to the ISN/RPS 
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classification, the distribution across LN classes was significantly different between lupus 
FHN and idiopathic non-lupus FHN (P<0.001). Absence of glomerular lesions or a purely 
mesangial pattern of injury by light microscopy (akin class I/II) was significantly more preva-
lent in idiopathic non-lupus FHN compared to lupus FHN (P=0.04), as was a membranous 
pattern (akin class V, P=0.02). Proliferative lesions (akin class III/IV) were significantly less 
prevalent in non-lupus FHN (P<0.01). Idiopathic non-lupus FHN patients had a different 
distribution across activity/chronicity subclasses (A, A/C, and C) associated with a class III/
IV pattern of injury than lupus FHN patients – with chronic subclasses being present more 
frequently. However, individual chronic lesions were similar between lupus and idiopathic 
non-lupus FHN patients (global glomerulosclerosis, fibrous crescents, interstitial fibrosis 
and tubular atrophy, see Table 3). C1q immunofluorescence staining was significantly more 
intense in lupus FHN compared to idiopathic non-lupus FHN (P<0.01). 
Table 3 Histopathologic findings in patients with lupus full house nephropathy (FHN) compared to idiopathic non-
lupus FHN. 
Histopathologic finding Lupus FHN (n=117) Idiopathic non-lupus FHN (n=20) P
Light microscopy  
ISN/RPS 2003 class, n (%)  
I 1 (1) 2 (10)
II 2 (2) 1 (5)
III 24 (21) 7 (35)
IV 79 (68) 4 (20)
III/IV + V 2 (2) 2 (10)
V 9 (8) 4 (20) 0.001#
III/IV (+V) A 45 (43) 2 (15)
III/IV (+V) A/C 59 (56) 9 (69)
III/IV (+V) C 1 (1) 2 (15) 0.001#
No lesions/ purely mesangial lesions, 
n (%)
3 (3) 3 (15) 0.040‡
Proliferative lesions, n (%) 105 (90) 13 (65) 0.008‡
Membranous lesions, n (%) 11 (9) 6 (30) 0.020‡
Glomeruli with global glomerulosclerosis, 
n (%)
 
0% 70 (71) 9 (56)
1–25% 22 (22) 5 (31)
26 – 50% 4 (4) 1 (6)
≥50% 3 (3) 1 (6) 0.245†
Glomeruli with fibrous crescents, n (%)  
0% 75 (76) 12 (75)
1–25% 23 (23) 4 (25)
26 – 50% 1 (1) 0 0.984†
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Table 3 Continued. 
Histopathologic finding Lupus FHN (n=117) Idiopathic non-lupus FHN (n=20) P
Interstitial fibrosis, n (%)  
Absent 57 (58) 6 (38)
Mild 33 (33) 7 (44)
Moderate 6 (6) 3 (19)
Severe 3 (3) 0 (0) 0.186†
Tubular atrophy, n (%)  
Absent 60 (61) 6 (38)
Mild 29 (29) 8 (50)
Moderate 7 (7) 1 (6)
Severe 3 (3) 1 (6) 0.168†
Immunofluorescence microscopy  
IgA, n (%)  
+ 26 (22) 8 (40)
++ 60 (51) 9 (45)
+++ 31 (26) 3 (15) 0.087†
IgM, n (%)  
+ 27 (23) 8 (40)
++ 64 (55) 10 (50)
+++ 26 (22) 2 (10) 0.076†
IgG, n (%)  
+ 21 (18) 4 (20)
++ 67 (57) 7 (35)
+++ 29 (25) 9 (45) 0.265†
C3, n (%)  
+ 8 (7) 4 (20)
++ 64 (55) 11 (55)
+++ 45 (39) 5 (25) 0.074†
C1q, n (%)  
+ 9 (8) 8 (40)
++ 67 (57) 8 (40)
+++ 41 (35) 4 (20) 0.002†
All biopsies were rescored according to the ISN/RPS 2003 classification of LN regardless of clinicopathologic diagnosis. 
† Linear-by-linear analysis. ‡ Fisher’s exact test. # Pearson chi-Square.
Treatment and outcomes of non-lupus FHN patients
Half of the non-lupus FHN patients received immunosuppressive therapy after renal biopsy 
(Table 4). Four patients presented with acute renal insufficiency and required dialysis by 
the time of renal biopsy. Overall, ESRD developed in 8 of 15 non-lupus FHN patients 
who received immunosuppression (including corticosteroids), and in 9 of 16 who did 
not (P=0.39). In the idiopathic group, renal survival similarly was not different between 
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patients who did (n=9) and did not (n=11) receive immunosuppression (P=0.42). ESRD 
developed in 12 (60%) idiopathic and 6 (50%) secondary non-lupus FHN patients and 
death occurred in in 8 (40%) idiopathic and 5 (42%) secondary non-lupus FHN patients 
(see Appendix 3.1). By Kaplan-Meier analysis, progression to ESRD and/or death did not 
differ between idiopathic non-lupus FHN patients and non-lupus FHN patients with other 
differential diagnoses (P=0.55). Considering both patients with idiopathic and secondary 
non-lupus FHN, the overall group of non-lupus FHN patients progressed significantly more 
rapidly to ESRD and ESRD/death than lupus FHN patients (both P<0.01). 
Table 4 Induction and maintenance immunosuppressive therapy for patients with lupus and idiopathic non-lupus full 




Idiopathic non-lupus FHN 
(n=20)
Induction
No immunosuppression, n (%) 2 (2) 11 (55)
Corticosteroids, n (%) 4 (3) 5 (25)
Cyclophosphamide ± corticosteroids, n (%) 44 (38) 0 (0)
Azathioprine ± corticosteroids, n (%) 45 (38) 3 (15)
Mycophenolate mofetil ± corticosteroids, n (%) 10 (9) 0 (0)
Other, n (%) 1 (1) 1 (5)
Unknown, n (%) 11 (9) 0 (0)
Maintenance
No specific maintenance immunosuppression *, n (%) 11 (9) 17 (85)
Azathioprine ± corticosteroids, n (%) 48 (41) 3 (15)
Mycophenolate mofetil ± corticosteroids, n (%) 37 (32) 0 (0)
Other, n (%) 3 (3) 0 (0)
Unknown, n (%) 18 (15) 0 (0)
* “No specific maintenance immunosuppression” may include corticosteroids.
Outcomes of idiopathic non-lupus FHN compared 
to lupus FHN patients
Considering idiopathic non-lupus FHN patients only (excluding patients with secondary 
non-lupus FHN), outcomes were not significantly different between idiopathic non-lupus 
and lupus FHN patients (Figure 1a-c). No differences in outcome were noted between 
idiopathic non-lupus FHN and lupus FHN patients in the subgroups with classes I/II and 
class V (data not shown). In contrast, in the class III/IV (±V) subgroup, idiopathic non-lupus 
FHN patients (n=13) progressed significantly more rapidly to ESRD (P=0.01) and ESRD/
death (P=0.01) than lupus FHN patients (n=105; Figure 1d,f). 
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In the class III/IV (±V) subgroup, idiopathic non-lupus FHN was an independent risk factor 
for ESRD adjusted for possible clinical confounders in models 1 (see overview of con-
founders in Table 5, HR 5.31; 95% CI 1.47 to 19.24) and 2 (HR 3.64; 95% CI 1.04 to 3.64).
Figure 1 Renal and overall survival of patient with lupus and idiopathic non-lupus full house nephropathy (FHN). 
a-c: Kaplan-Meier analyses comparing lupus FHN (n=117) and idiopathic non-lupus FHN (n=20). a: Survival without end-
stage renal disease (ESRD, median follow-up idiopathic non-lupus FHN: 10.2 years (interquartile range [IQR] 2.2–23.1); 
lupus FHN: 9.3 years [IQR 3.8–16.0]). b: Overall survival (median follow-up idiopathic non-lupus FHN: 24.4 years (IQR 
11.8–35.1); lupus FHN: 14.1 years [IQR 7.2–20.8]). c: Survival without the combined outcome of death or ESRD (median 
follow-up idiopathic non-lupus FHN: 10.2 years (IQR 2.2–23.1); lupus FHN: 9.5 years [IQR 4.4–16.5]). d-f: Kaplan-Meier 
analyses of the subset of patients with a class III/IV (±V) pattern of injury comparing patients with lupus FHN (n=105) and 
idiopathic non-lupus FHN (n=13). d: Survival without ESRD. e: Overall survival. f: Survival without the combined outcome 
of death or ESRD. Vertical bars represent censored data.
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Table 5 Predicting renal and/or patient survival in patients with a lupus (n=105) and idiopathic non-lupus (n=13) full house 
nephropathy (FHN) and a lupus nephritis class III/IV (±V) pattern of injury. 
Model Outcome: ESRD Outcome: ESRD/death
Hazard ratio 95% CI Hazard ratio 95% CI
Model 1
Idiopathic non-lupus FHN  
vs. lupus FHN
5.31 1.47; 19.24 3.23 1.01; 10.32
eGFR (mL/min) 0.99 0.98; 1.01 0.99 0.98; 1.00
Proteinuria (g/24h) 1.05 0.98; 1.12 1.02 0.96; 1.09
Female vs. male 1.05 0.40; 2.72 0.89 0.39; 2.02
Age (years) 1.00 0.97; 1.03 1.02 0.99; 1.04
Immunosuppressive therapy*  
vs. no immunosuppressive therapy
2.72 0.63; 11.84 1.93 0.51; 7.28
Model 2
Idiopathic non-lupus FHN  
vs. lupus FHN
3.64 1.04; 3.64 1.32 0.76; 1.32
Immunosuppressive therapy*  
vs. no immunosuppressive therapy
1.96 0.43; 8.95 2.06 0.54; 7.79
Chronicity score 1.36 1.14; 1.63 1.41 1.22; 1.64
* Immunosuppressive therapy with at least corticosteroids. CI, confidence interval.
DISCUSSION
In this study, we investigated non-lupus FHN in the largest cohort of FHN patients to 
date. Of the 149 FHN patients, 32 (21%) patients had non-lupus FHN. None of these 
non-lupus FHN patients developed SLE during median follow-up of 20 years. Patients with 
non-lupus FHN represented a heterogeneous group with an overall poor outcome with 
some patients showing atypical presentations of other well-established renal diseases and 
63% having idiopathic non-lupus FHN. Importantly, idiopathic non-lupus FHN was clinically 
and histopathologically distinct from lupus FHN, and idiopathic non-lupus FHN patients 
with a proliferative pattern of injury progressed significantly more rapidly to ESRD than 
lupus FHN patients with class III/IV (±V) LN. Our results indicate that FHN is pattern of 
renal injury most often encountered in SLE, but also rarely occurring in a number of other 
diseases, as well as being representative of an idiopathic variant urging careful consideration 
by the nephrologist. 
To confine the group of patients with idiopathic non-lupus FHN, we considered a number 
of atypical presentations of other diagnoses in non-lupus FHN patients: membranous 
nephropathy, IgA nephropathy, infection-related glomerulonephritis, and anti-neutrophil 
cytoplasmic antibody-associated glomerulonephritis (AAGN). The combination of severe 
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clinicopathologic features at presentation and poor renal survival of more than half of these 
patients raises the possibility that in some instances, non-lupus FHN may represent severe 
forms of other renal diseases that are accompanied by strong activation of the immune 
system, as has also been suggested in previous case series.2, 8-15, 22, 23 Notably, three patients 
had recurrent IgA nephropathy with crescentic glomerulonephritis in their renal allograft, 
similar to patients reported by Kowalewska et al. showing an uncommon and aggressive 
form of IgA nephropathy.24 Furthermore, we identified two patients with FHN and AAGN, 
one of whom required dialysis at the time of biopsy. Previous reports have demonstrated 
convincingly that glomerular immune complexes may be present in AAGN.25 It has been 
suggested that immune complexes may act synergistically with ANCA to produce more 
severe glomerulonephritis than seen with either immune complexes or ANCA alone.26 
The possibility that secondary causes for which we could not test may underlie FHN in 
the remaining 20 idiopathic non-lupus FHN patients cannot be fully excluded, which is a 
limitation inherent to our retrospective study design. Nevertheless, it is crucial to realise 
that ESRD was associated with non-lupus FHN, irrespective of its cause. Importantly, 
although we did not observe such patients, patients have been reported in the literature 
with non-lupus FHN who developed SLE during follow-up,2-5 adding the possibility that 
some non-lupus FHN patients may have latent SLE. Taken these considerations together, 
we compiled a diagnostic scheme for FHN (Figure 2).
Idiopathic non-lupus FHN patients show similarities with an entity previously described 
as “renal-limited lupus-like nephritis”.27 However, this entity was originally defined by a 
lupus-like constellation of immunofluorescence and electron microscopic evaluations, and 
not by a full house pattern per se.27 In the study by Huerta and colleagues,27 two of four 
“renal-limited lupus-like nephritis” patients had FHN, and both progressed to ESRD despite 
aggressive therapy. Importantly, our study indicates that idiopathic non-lupus FHN, as 
defined by the absence of sufficient SLE criteria and exclusion of other diagnoses, should 
be recognised as a category with poor outcome by itself, without the requirement of 
additional lupus-like pathologic features. Therefore, the term “lupus-like nephritis” should 
not be used for idiopathic non-lupus FHN – emphasising the clinical distinction from lupus.
The prevalence of non-lupus FHN in our cohort is in accordance with a previous study, 
in which non-lupus FHN was described in 28/94 (30%) cases with FHN identified over a 
9-year period.2 In our study, idiopathic non-lupus compared to lupus FHN patients were 
more often male. Moreover, laboratory results revealed lower-range erythrocyturia, pre-
dominantly nephrotic-range proteinuria, and less complement consumption in the classical 
pathway.  We identified a number of immunohistochemical and histopathologic features 
that predominated in idiopathic non-lupus FHN compared to lupus FHN: weaker C1q 
staining by immunofluorescence; less frequent proliferative lesions and more frequent 
mesangial and membranous lesions by light microscopy; and an increased frequency of 
a chronic subclass associated with proliferative nephritis. Thus, in a patient with a renal 
biopsy showing FHN in the absence of sufficient SLE classification criteria, the features 
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above would support a diagnosis of idiopathic non-lupus FHN. Further study is warranted 
to identify additional indicators that could help to distinguish idiopathic non-lupus FHN 
from lupus FHN. Tubuloreticular inclusions would appear promising based on the study 
by Wen and Chen,2 although we did find them in one patient with idiopathic non-lupus 
FHN. Other promising indicators, such as IgG subclass staining,28 remain to be investigated. 
Figure 2 Diagnostic scheme of full house nephropathy (FHN).
Dotted lines represent considerations that were not supported by our study, but remain to be investigated. ACR,  American 
College of Rheumatology; SLICC, Systemic Lupus International Collaborating Clinics.
Since we performed the first study of idiopathic non-lupus FHN in which control cases 
with lupus FHN were included, we were able to compare outcomes between these 
groups to substantiate their clinical distinction. Given the heterogeneity of histopathologic 
lesions, we analysed renal and patient survival in subsets with relatively homogeneous 
injury patterns, and found that idiopathic non-lupus compared to lupus FHN was a strong 
independent risk factor for ESRD in the subset of patients with proliferative lesions (akin 
class III/IV [±V] LN). Possibly because the number of patients with others histopathologic 
patterns of injury was small, we could not demonstrate a survival difference in these 
subgroups. Our results are in agreement with previous reports that hinted that the clini-
cal course and outcome of idiopathic non-lupus FHN patients are worse than those of 
patients with similar patterns of glomerulonephritis with SLE.4, 6, 15, 27
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It is reasonable to speculate that a number of factors relating to idiopathic-non-lupus 
FHN patients contributed to their poor outcome. The higher levels of proteinuria and 
the tendency towards a higher chronicity score in idiopathic non-lupus FHN patients 
are remarkable in this aspect, although these factors did not explain the renal survival 
difference between idiopathic non-lupus and lupus FHN in our statistical models. A major 
conundrum of this study is that 11 of 20 idiopathic non-lupus FHN patients did not receive 
any type of immunosuppression; and of the 9 patients who did, 5 received corticosteroids 
alone and none received cyclophosphamide. This contrasts to the 38% of lupus FHN 
patients who did receive cyclophosphamide. Whereas we did not find that immunosup-
pression including corticosteroids affected renal survival within the group of idiopathic 
non-lupus FHN patients, the poor outcome of idiopathic non-lupus FHN patients may 
well be related to their lack of cytotoxic therapy. In a recent study of paediatric non-lupus 
patients with complement (C1q, C3) and immunoglobulin (IgG, IgM and/or IgA) glomerular 
staining, patients who received intensive cytotoxic immunosuppression had a favourable 
renal outcome.7 Although FHN was defined differently, this study raises the possibility that 
idiopathic non-lupus FHN patients may also benefit from cytotoxic immunosuppression. 
On the other hand, the relative lack of immunosuppression in idiopathic non-lupus FHN 
patients in our study eliminates the possibility that treatment induced sustained remission 
and prevented latent lupus from becoming active systemically for the majority of these 
patients. This accentuates the clinical distinction from lupus, as none of the (idiopathic) 
non-lupus FHN patients developed SLE during long-term follow-up. It remains speculative 
as to whether the uncertainty of a definite diagnosis of SLE due to the lack of systemic 
signs and symptoms and/or the imminent progression to ESRD discouraged physicians 
from initiating intensive immunosuppression after risk-benefit assessment. 
The aetiology and pathogenesis of idiopathic non-lupus FHN remain to be elucidated. 
Given its strong similarity to LN, it may be considered that the two entities share similar 
pathogenic mechanisms. In LN, it has been suggested that immune complexes may occur 
in the glomerulus both due to the deposition of preformed immune complexes and in situ 
formation. The formation of autoantibodies and the resulting immune complexes in LN 
may therefore originate from a combination of pathogenic mechanisms: (i) an increased 
antigenic load due to dysregulated apoptosis and defective clearance of apoptotic debris; 
(ii) a subsequent aberrant immune response directed to these endogenic antigens; and 
(iii) a defective clearance of immune complexes. Quantity, size, and type of the immune 
complexes determine the microscopic pattern of injury in LN related to the site of depo-
sition.29 The occurrence of full house glomerular deposits in LN may then be seen as the 
result of a pronounced immune response with polyclonal B cell activation in the setting of 
these mechanisms. The occurrence of full house glomerular deposits in the absence of a 
clinical diagnosis of SLE may similarly be seen as the expression of a more pronounced type 
of defective immune complex clearance following abnormal immune complex overload 
or immune complex handling.30 The previously mentioned secondary forms of non-lupus 
FHN2, 8-15, 22, 23 are likely associated with these mechanisms. Unidentified endogenous and/
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or exogenous antigens involved in immune complex formation may underlie idiopathic 
non-lupus FHN. Moreover, genetic factors resulting in defective clearance of immune com-
plexes that have been implicated in LN, such as Fcγ‐receptor deficiency31 and deficiency 
of the erythrocyte C3b‐receptor,32 may also be involved in idiopathic non-lupus FHN. 
In conclusion, our study indicates that idiopathic non-lupus FHN is associated with poor 
renal survival and therefore, deserves careful consideration by the nephrologist. We poin-
ted out what should prompt the recognition of idiopathic non-lupus FHN, and hopefully 
initiated efforts to determine possible underlying cause(s) and potential treatment.
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Present guidelines for lupus nephritis (LN) recommend that all patients with class III or IV 
LN receive cytotoxic immunosuppression. Scarce data from the past suggest that some 
patients with class III or IV LN maintained renal function without such therapy in clinical 
trials. In this study, we aimed to study the natural history of class III or IV LN and explore 
a subgroup of patients for whom treatment without cytotoxic drugs could suffice. 
Methods
All patients were included with a renal biopsy showing class III or IV LN between 1983–2011 
and with clinical follow-up at the Leiden University Medical Center. Evolution of eGFR 
during 10 years follow-up was compared between all consecutive patients who did and 
did not receive guideline-recommended cytotoxic immunosuppression. 
Results
Three patients were identified with class III or IV LN presenting with relatively preserved 
renal function who did not receive cytotoxic immunosuppression, in defiance of current 
guidelines. Follow-up of 9–24 years revealed that these patients achieved remission with 
stable renal function and without LN flares, despite mild non-nephrotic proteinuria in the 
absence of erythrocyturia. Their eGFR evolution over 10 years did not differ from that 
observed in 98 patients from the same cohort who received cytotoxic immunosuppres-
sion (P=0.56). 
Conclusions
The three cases undertreated according to guidelines represent a subgroup of patients 
with class III or IV LN for whom milder therapy regimens without cytotoxic immunosup-




Class III/IV LN Undertreated According to Guidelines
INTRODUCTION
For patients with class III or IV lupus nephritis (LN), standard care includes intravenous cyclo- 
phosphamide or mycophenolate mofetil (MMF) in combination with corticosteroids.1-5 
However, such treatment is associated with severe side effects, including sepsis, avascular 
bone necrosis, gonadal dysfunction, and malignancy.6 Even with these therapies, LN carries 
considerable risks of end-stage renal disease (ESRD) and death.7-13 Randomised control-
led trials (RCTs) have focused on treatment strategies to improve prognosis focusing on 
patients at high risk of these adverse outcomes. As a consequence, a subgroup of patients 
with class III or IV LN who might have a lower risk of adverse outcomes has been over-
looked in these trials. Yet, it has always been clear from the landmark trials performed 
at the National Institute of Health (NIH), that about 10–40% of patients who received 
prednisolone therapy alone did not reach ESRD during 10 years follow-up.8 Unfortunately, 
the clinical course of these patients has never been detailed; thus, little is known about the 
natural history of class III or IV LN. Treating patients with prednisolone therapy alone is no 
longer recommended.1-5 Therefore, it is presently unknown whether a conceivably lower-
risk subgroup of patients with class III or IV LN could be treated with milder regimens 
omitting cytotoxic immunosuppression.
In this study, we aimed to explore the existence of a subgroup of patients with class III or IV 
LN for whom milder immunosuppressive regimens could suffice. We report the results of a 
retrospective study in which we identified patients with class III or IV LN as registered in the 
pathology archives of the Leiden University Medical Center between 1983–2011 who did 
and did not receive guideline-recommended cytotoxic immunosuppression. We present 
the clinical characteristics, therapeutic strategies, and clinical outcomes in all consecutive 
patients with class III or IV LN who did not receive guideline-recommended cytotoxic 
immunosuppression in this cohort. The evolution of eGFR during 10 years follow-up was 
compared between these patients and patients from the same cohort who did receive 





The pathology archives at the Leiden University Medical Center were searched for all 
patients biopsied between 1983−2011 with class III or IV LN. Patients were included if 
they had a renal biopsy available for re-evaluation, fulfilled ≥4 American College of Rheu-
matology (ACR) or ≥4 Systemic Lupus International Collaborating Clinics (SLICC) criteria 
for systemic lupus erythematosus (SLE),14 and had clinical follow-up at our centre. 
Biopsies were reclassified according to the ISN/RPS 2003 classification.15 Medical records 
were evaluated for history of immunosuppressive medication prior to biopsy and during 
follow-up. The glomerular filtration rate was estimated using the Cockcroft-Gault formula 
(eGFR). eGFR was recorded at the time of renal biopsy, as well as at 1, 2, 3, 4, 5, and 10 
years of follow-up. In accordance with the ethics committee of Leiden University Medical 
Center, all patient data were coded and kept anonymously throughout the study.
Statistical analysis
Normally distributed data are expressed as means ± standard deviation and non-normally 
distributed data are presented as median values and interquartile range. Normally distributed 
data were compared with t-tests and categorical data with Fisher’s exact tests or chi-square 
tests. To compare non-normally distributed data, Mann-Whitney U tests were used. 
A random intercept/random slope mixed model was used to compare the course of eGFR 
between patients. In the mixed model, “treatment according to guidelines” was analysed as 
fixed effect. Visual inspection of residuals was performed to assess normality assumptions. 
All analyses were performed using SPSS Statistics 23.0 (IBM, Armonk, New York). 
RESULTS
We included 101 patients who had biopsy-confirmed class III or IV LN between 1983−2011. 
Of these, 98 received cytotoxic immunosuppression according to guidelines: corticos-
teroids in combination with intravenous cyclophosphamide (NIH protocol12 [n=26]; 
Euro-Lupus protocol13 [n=30]), azathioprine (n=33), or MMF (n=9). We identified three 
consecutive patients who – in defiance of treatment guidelines – did not receive any of 
the aforementioned regimens prior to biopsy and during follow-up for LN. Clinical and 
histopathologic characteristics at the time of diagnostic renal biopsy of the latter three 
patients, as well as of the other 98 patients in the cohort, are shown in Table 1. No diffe-
rences in biopsy findings and clinical presentation were noted between the two groups. 
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Table 1 Clinical and histopathologic characteristics of patients at time of diagnostic renal biopsy.





Age, y 23 33 32 30 ± 13 0.2
Sex Female Female Male 20 Male 
78 Female
0.6
ISN/RPS class of LN III (A/C) IV-G (A) III (A/C) 23 III
24 IV S
45 IV G
6 III/IV + V
0.7
Time since diagnosis of SLE, y 0.3 0 0 3.7 ± 5.0 0.1
Glomeruli without abnormalities 14% (5/36) 0% (0/20) 30% (3/10) 10% 0.9
Glomeruli with proliferative lesions 33% (12/36) 95% (19/20) 10% (1/10) 55% 0.8
Glomeruli with global sclerosis 0% (0/36) 0% (0/20) 10% (1/10) 7% 0.4
NIH Activity Index16 7 6 4 10 (6–12) 0.1
NIH Chronicity Index16 1 0 4 1 (0–3) 0.8
Serum creatinine, µmol/L 88 74 90 144 ± 135 0.3
eGFR, mL/min 72 86 92 73 ± 35 0.1
Proteinuria, g/24h 3.9 3.1 1.6 4.4 ± 3.8 0.7
ANA + + + 97% (n=98) 1.00
Anti-dsDNA + not tested - 80% (n=96) 0.5
Data are expressed as mean ± standard deviation or median (interquartile range).  ANA, antinuclear antibody; anti-ds-




In 1993, a 22-year-old Caucasian woman was diagnosed with SLE based on a malar 
rash, pleuropericarditis, Libman-Sacks endocarditis, photosensitivity, pancytopenia, hypo-
complementaemia, positive antinuclear, anti-dsDNA anti-(double stranded DNA), and 
antiphospholipid antibodies. Shortly after diagnosis, she experienced an epileptic insult 
and MRI showed multiple white matter lesions consistent with cerebral SLE involvement. 
Simultaneously, proteinuria increased (Figure 1A) and renal biopsy indicated LN class III 
(A/C) with endocapillary hypercellularity, fibrinoid necrosis, and cellular crescents. Virtually 
no chronic damage was present, except for one fibrous crescent. 
The patient was started on 40 mg prednisolone and anti-proteinuric treatment with 
5 mg enalapril. Due to the patient’s stable renal function with class III LN (Figure 1A), 
conservative therapy was maintained and no additional immunosuppressive therapy was 
initiated.  Two years later, the patient experienced two exacerbations of cutaneous SLE with 
secondary impetiginisation, for which she received 200 mg hydroxychloroquine. Four years 
after renal biopsy, SLE was in remission, and prednisolone treatment was discontinued. 
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The patient was followed in our centre for nine years, with her last follow-up showing 
no symptoms of active LN, despite persisting mild proteinuria of 1–2 g/24h (Figure 1A).
Case 2
In 1994, a 33-year-old Caucasian woman with a history of HLA-B27-positive oligoarthritis 
and preeclampsia presented with fluid retention in her fingers and macroscopic hae-
maturia, anaemia, leukocytopenia, and proteinuria. One year later, she was diagnosed 
with post-streptococcal glomerulonephritis based on hypocomplementaemia, elevated 
anti-streptolysin O, erythrocyturia, nephrotic-range proteinuria (4–5 g/24h), hypertension 
(RR 150/90 mmHg), and a history of pharyngitis. Her renal function was normal (eGFR 
± 90 mL/min). She was started on 20 mg enalapril with close follow-up, during which 
hypocomplementaemia, proteinuria (3–4 g/24h), and erythrocyturia persisted. 
In 1996, renal biopsy revealed a membranoproliferative pattern with full house immunoflu- 
orescence, which was retrospectively classified as LN class IV-G (A). She had no other 
systemic symptoms of SLE, but additional testing showed a positive antinuclear antibody 
(ANA). At the time, the patient fulfilled 4 SLICC criteria: leukocytopenia, hypocomple-
mentaemia, nephritis, and ANA. Due to the patient’s wish for pregnancy, she declined 
immunosuppression and enalapril was switched to methyldopa. Her subsequent pregnancy 
3 months later was complicated by preeclampsia (i.e. hypertension with proteinuria of 
10 g/24h) in the first trimester, and was therefore terminated. Enalapril treatment was 
restarted, with the addition of 12.5 mg hydrochlorothiazide. In the following years, she 
showed stable normal renal function, but persisting proteinuria and erythrocyturia. Four 
years after renal biopsy, the patient was formally diagnosed with SLE based on the serial 
occurrence of haematologic disturbances, hypocomplementaemia, positive ANA, and LN. 
Eleven years after renal biopsy, while LN was in remission, the patient presented with 
psychosis, which was diagnosed as cerebral SLE based on cerebellar atrophy on MRI. She 
was started on 60 mg prednisolone, antipsychotics, and intravenous cyclophosphamide 
following the NIH scheme. Her condition quickly improved. Within eight months, cerebral 
SLE was in remission and prednisolone treatment was discontinued. At her last follow-up 
in our centre, 19 years after renal biopsy, SLE was in complete remission with minimal 
proteinuria, absent erythrocyturia, and normal eGFR (Figure 1B).
Case 3
In 1990, a 31-year-old Caucasian man presented with erythema and arthralgia of his 
lower legs, for which he received a non-steroidal anti-inflammatory drug. Two months 
later, laboratory analyses revealed a strongly positive ANA, together with proteinuria and 
erythrocyturia, with a normal eGFR (Figure 1C). Renal biopsy revealed LN class III (A/C) 
with concomitant thrombotic microangiopathy. The diagnosis of SLE was confirmed based 
on LN, arthritis, positive ANA, and antiphospholipid antibodies. Therapy was initiated with 
hydroxychloroquine. For unknown reasons, no additional immunosuppressive therapy was 
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started. Over the following years, SLE was in remission, although mild sediment disturban-
ces and proteinuria persisted (Figure 1C). 
Fifteen years after renal biopsy, SLE activity increased, with myalgias, arthralgias, and macu-
lous skin lesions of the buttocks and legs. These symptoms resolved after increasing the 
hydroxychloroquine dosage. Over the following years, eGFR was 55–75 mL/min, protei-
nuria 2–3.5 g/24h, and erythrocyturia was absent. In 2011, the patient was started on 10 
mg enalapril due to persisting proteinuria. In 2013, a second renal biopsy was performed 
because of a temporarily raised serum creatinine (eGFR ±45 mL/min) together with 
longstanding proteinuria without erythrocyturia. The biopsy showed one glomerulus with 
perihilar focal segmental glomerulosclerosis, but no active lesions. There were no chronic 
lesions, apart from one glomerulus showing global sclerosis. Immunofluorescence was 
negative, but electron microscopy revealed a limited number of transmembrane and 
subepithelial deposits. At the last follow-up in our centre, 24 years after initial renal biopsy, 
the patient showed a stable renal function (Figure 1C) without erythrocyturia and with 
adequate blood pressure (RR 130/80 mmHg).
Renal function in patients with and without guideline-recommended 
immunosuppression compared
The evolution of eGFR was compared between the 98 patients who did and the three 
patients who did not receive guideline-recommended cytotoxic immunosuppression 
during 10 years follow-up.  A random intercept/random slope mixed model revealed that 
the evolution of the eGFR did not significantly differ between the two groups (P=0.56). 
Figure 1D shows the course of eGFR among the patients treated with and without cyto-
toxic immunosuppression, demonstrating the lack of notable differences in trend for the 




Figure 1 Clinical course of patients undertreated according to current guidelines.
A: case 1. B: case 2. C: case 3. D: course of eGFR during 10 years follow-up of patients who were undertreated according to 
current guidelines (cases 1−3; highlighted) in relation to patients from the same cohort who received cyclophosphamide, 
MMF, or azathioprine (n=98; in grey).
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DISCUSSION
We studied consecutive patients from the Leiden University Medical Center with class 
III or IV LN diagnosed between 1983 and 2011 who did not receive guideline-recom-
mended cytotoxic immunosuppression. We found three patients with class III or IV LN who 
were undertreated according to current guidelines, having received prednisolone alone 
or no immunosuppressive therapy. During long-term follow-up, these patients maintained 
a relatively preserved renal function without LN flares. Their eGFR evolution over 10 
years follow-up did not differ from that observed in patients from the same cohort who 
received guideline-recommended cytotoxic immunosuppression. To our knowledge, this 
is the first detailed analysis of patients belonging to the understudied subgroup of class 
III or IV LN who could benefit from a therapeutic approach omitting cytotoxic drugs for 
their renal manifestations, in disagreement with current treatment guidelines. The three 
patients described herein may signal a need to more closely investigate similar patients in 
future prospective studies.
Large RCTs have clearly demonstrated the benefits of various cytotoxic regimens for the 
pooled group of patients with class III or IV LN, upon which the current LN treatment 
guidelines are based. Attempts to identify prognostic subgroups of patients with class III or 
IV LN have focused on patients in high-risk groups. In the trial by Austin et al. performed 
at the NIH,8 high-risk patients identified by the presence of a chronicity index ≥1 had 
a significantly increased risk of ESRD as compared to the patients who had no chronic 
lesions. In the high-risk group, little over 10% of patients in the prednisolone arm did not 
reach the end-point ESRD after 10 years follow-up, whereas this percentage increased to 
nearly 40% in the total group of patients receiving prednisolone including low-risk patients 
with absent chronic lesions.  Although there were only 28 patients in the prednisolone arm, 
these data suggest that improvement in the qualification of the subgroup of patients for 
whom milder therapy could suffice is attainable. Focusing on high-risk subgroups in RCTs 
is profitable, since a treatment effect – if present – is anticipated to be greater among 
these patients. However, separate analyses of lower-risk patients may reveal under which 
conditions milder therapies with less harmful side effects may suffice. 
Interestingly, the same focus on high-risk patients is observed in the way eligibility criteria 
for RCTs are defined. Inspection of the inclusion criteria of landmark RCTs, upon which 
treatment guidelines are based, reveals that patients with a mildly disturbed eGFR and/or 
mild proteinuria were frequently excluded, as their smaller deviation from normal renal 
function is reasonably anticipated to be accompanied by a smaller treatment effect.7-
12 Consequently, results of these RCTs cannot be unequivocally applied to all patients 
with LN in a clinical setting, creating a gap in the guidelines for patients with relatively 
preserved renal function and a possibly favourable prognosis. Currently, more and more 
patients with class III or IV LN with preserved renal function and mild proteinuria are 
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encountered, since current guidelines recommend a renal biopsy for patients with SLE 
and any sign of renal involvement, particularly reproducible proteinuria of >0.5 g/24h.1-5 
Without supporting evidence, the EULAR/ERA-EDTA guideline2 attempts to close this gap, 
proposing that patients with preserved renal function and without adverse histopathologic 
findings could be considered candidates for milder therapy regimens (e.g. azathioprine). 
The three patients described here showed relatively preserved renal function at the 
time of renal biopsy, notwithstanding that they are not typically mild cases unfulfilling the 
eligibility criteria of some large RCTs. Moreover, these patients’ histopathologic findings 
would probably not be designated as “non-adverse,” although this is uncertain since there 
is no specific definition for this entity. There remains a need for a clear definition of the 
specific histopathologic lesions and clinical parameters that characterise patients eligible 
for milder therapy regimens. 
Further specification of this subgroup will be challenging. Previous studies showed that 
neither histopathologic nor clinical parameters are optimal prognosticators in LN. Patients 
with the same LN class may experience heterogeneous clinical courses, and clinical features 
alone are poor predictors of histopathologic findings. Most telling, in a recent study by 
Wakasugi et al., protocolised biopsies of SLE patients without clinical renal involvement 
revealed class III or IV LN in 13 of 86 cases.17  Those 13 patients were followed for a median 
duration of 30 months, and only two patients with class III LN experienced exacerbated 
LN associated with pregnancy and malignancy. Remarkably, the remaining 11 patients 
showed no LN flares and had a good prognosis with prednisolone therapy alone. These 
findings underline three important points: the lack of coherence between clinical findings 
and histology, the difficulty of determining treatment purely based on LN class, and the 
challenge of predicting clinical course. 
In the present guidelines, no prognostic subgroups of patients with class III or IV LN are 
recognised: treatment decisions are based solely on the histopathologic classification with 
no regard of clinical parameters. Here we have shown that these guidelines are at risk of 
overtreatment, as we demonstrate the existence of a subgroup of patients with class III or 
IV LN for whom therapy without cytotoxic drugs could suffice. Since we found only three 
consecutive patients who retrospectively appeared to have been unexposed to cytotoxic 
immunosuppression, a limitation of our study is that we were hampered by a lack of power 
to identify features characterising these patients. We speculate that the three patients had 
(combinations of) the following features in common which may give clues as to why they 
had a favourable prognosis in the absence of cytotoxic immunosuppression: newly or 
very recently diagnosed SLE at the time of renal biopsy, a relatively preserved and stable 
renal function at presentation (only gradual decline in eGFR during the month preceding 
the renal biopsy of 0–3 mL/min), and a relatively low percentage of proliferative lesions 
(cases 1 and 3).  Awaiting the results of further studies investigating the specific subgroup 
of patients with yet undefined combinations of clinical and histopathologic manifestations, 
the following could be deliberated. For selected patients with class III or IV LN, it may be 
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advisable to institute a window of “watchful waiting” following renal biopsy during which 
patients are closely monitored, paralleling the strategy in other renal diseases like idiopathic 
membranous nephropathy.3  Tailored treatment may be optimal, with a tentative approach 
involving watchful waiting, and possible introduction of anti-inflammatory treatment with 
corticosteroids followed by suppression of autoimmunity using cytotoxic immunosup-
pressive drugs only if deemed necessary. Indeed, older studies have demonstrated that 
anti-inflammatory doses of corticosteroids alone were as effective as corticosteroids plus 
cyclophosphamide in the early phase of LN treatment.8, 18 Obviously, appropriate cases 
must be selected with extreme caution, as patients with class III or IV LN who are under-
treated due to non-adherence to treatment may show a detrimental disease course.19 Also, 
SLE is a systemic disease and successful conservative treatment for LN does not imply that 
this approach can be extrapolated to all extrarenal SLE manifestations. Nevertheless, an 
approach involving watchful waiting was successful in the three presently described cases 
and could possibly decrease the burden of cytotoxic regimens in more patients.
ACKNOWLEDGEMENTS
The authors are most grateful to Dr. David Jayne (Vasculitis and Lupus Clinic, Adden-
brooke’s Hospital, Cambridge) for stimulating discussions and critical reading of the 




1. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al. American College of Rheumatology 
guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012; 64(6): 797-808.
2. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism 
and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations 
for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71(11): 1771-82.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice 
Guideline for Glomerulonephritis. Kidney Int Suppl. 2012; 2: 139-274.
4. van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sevaux RG, Berger SP, et al. Dutch guidelines for diagnosis and therapy 
of proliferative lupus nephritis. Neth J Med. 2012; 70(4): 199-207.
5. Ruiz Irastorza G, Espinosa G, Frutos MA, Jimenez Alonso J, Praga M, Pallares L, et al. Diagnosis and treatment of lupus 
nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal 
Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012; 32 Suppl 1: 1-35.
6. Hogan J, Avasare R, Radhakrishnan J. Is newer safer? Adverse events associated with first-line therapies for ANCA-as-
sociated vasculitis and lupus nephritis. Clin J Am Soc Nephrol. 2014; 9(9): 1657-67.
7. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate Mofetil versus Cyclophos-
phamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol. 2009; 20(5): 1103-12.
8. Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled 
trial of prednisone and cytotoxic drugs. N Engl J Med. 1986; 314(10): 614-9.
9. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophos-
phamide for lupus nephritis. N Engl J Med. 2005; 353(21): 2219-28.
10. Gourley MF, Austin HA, 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, 
alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996; 125(7): 
549-57.
11. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methyl-
prednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006; 
70(4): 732-42.
12. Boumpas DT, Austin HA, Balow JE, Vaughan EM, Yarboro CH, Klippel JH, et al. Controlled trial of pulse methylprednisolone 
versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The Lancet. 1992; 340(8822): 741-5.
13. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy 
in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclo-
phosphamide. Arthritis Rheum. 2002; 46(8): 2121-31.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus 
erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
15. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in 
systemic lupus erythematosus revisited. Kidney Int. 2004; 65(2): 521-30.
16. Austin HA, 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions 
of clinical and histologic data. Kidney Int. 1994; 45(2): 544-50.
 97
4
Class III/IV LN Undertreated According to Guidelines
17. Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, Katsumata Y, et al. Frequency of class III and IV nephritis in systemic 
lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol. 2012; 39(1): 
79-85.
18. Donadio JV, Jr., Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone 
and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299(21):1151-5.
19. Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. 
Rheumatology (Oxford). 2007; 46(6): 895-8.

Chapter 5
Clinical and Histopathologic Characteristics 
Associated with Renal Outcomes in Lupus Nephritis 
Emilie C. Rijnink, Y.K. Onno Teng, Suzanne Wilhelmus, Mathilde Almekinders,  
Ron Wolterbeek, Karlien Cransberg, Jan A. Bruijn, Ingeborg M. Bajema





The prognostic significance of histopathologic (sub)classes in the current classification of 
lupus nephritis (LN) is controversial. We analysed clinical and histopathologic predictors 
of renal outcomes in LN outside the framework of the classification.
Methods
Variables (50 histopathologic and 10 clinical) were tested in mixed, linear, and Cox regres-
sion models for their association with renal flare, end-stage renal disease (ESRD), and 
estimated glomerular filtration rate (eGFR) during follow-up (1, 5, and 10 years) in 105 
LN patients biopsied from 1987–2011.
Results
During median follow-up of 9.9 years (25th–75th percentile, 5.9−13.8), 47 patients expe-
rienced a renal flare and 21 progressed to ESRD. Renal flare was predicted by fibrinoid 
necrosis (hazard ratio [HR] 1.04 per % [95% confidence interval [CI], 1.00 to 1.07]) and 
non-Caucasian race (HR 2.23 [95% CI, 1.23 to 4.04]). ESRD was predicted by fibrinoid 
necrosis (HR 1.08 per % [95% CI, 1.02 to 1.13]), fibrous crescents (HR 1.09 per % [95% 
CI, 1.02 to 1.17]), interstitial fibrosis/tubular atrophy (IF/TA) ≥25% (HR 3.89 [95% CI, 
1.25 to 12.14]), eGFR at baseline (HR 0.98 per mL/min/1.73 m2 [95% CI, 0.97 to 1.00]), 
and non-Caucasian race (HR 7.16 [95% CI, 2.34 to 21.91]). A higher mean eGFR during 
follow-up was associated with normal glomeruli (+0.2 mL/min/1.73 m2/% [95% CI, 0.1 to 
0.4]). Like ESRD, a lower eGFR during follow-up was associated with fibrous crescents, 
IF/TA ≥25%, and non-Caucasian race, as well as with cellular/fibrocellular crescents (−0.4 
mL/min/1.73 m2/% [95% CI, −0.6 to −0.2]) and age (−0.8 mL/min/1.73 m2/year [95% CI, 
−1.2 to −0.4]).
Conclusions
The LN classification should include an index of evidence-based prognosticators.  Awaiting 
validation of a formal index, we suggest that at least fibrinoid necrosis, fibrous crescents, 
and IF/TA warrant explicit independent scoring to assess the risk of progressive renal 
dysfunction in conjunction with clinical findings.
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INTRODUCTION
The disease manifestations and outcomes in lupus nephritis (LN) are heterogeneous, but 
10−30% of patients progress to end-stage renal disease (ESRD) within 15 years.1, 2 The 
prognosis can usually be improved by immunosuppression; although, there are severe and 
sometimes lethal adverse effects.3 There is a constant need for refined and novel indicators 
to help clinicians predict outcomes and determine when intensive immunosuppression 
should be initiated for individual LN patients.
Currently, clinical guidelines for LN4-6 reserve intensive immunosuppression primarily for 
patients with class III or IV (±V) LN according to the International Society of Nephrology/
Renal Pathology Society (ISN/RPS) classification.7 Although the ISN/RPS classification is 
useful in terms of standardisation and reproducibility of diagnosis,8-10 studies concerning the 
power of this classification in predicting disease outcome reported conflicting results.9, 11-18 
Conflicting results may be due to the grouping of a wide variety of prognostically, patho-
genically, and chronically different glomerular lesions in broad classes, thereby assuming 
that the prognosis of individuals within classes is equal regardless of the type of lesions. 
A revision of the ISN/RPS classification is called for.19, 20 An evidence-based approach, 
similar to the Oxford classification of IgA nephropathy would be the resolution for a 
future classification.21, 22 In the current study, we aimed to identify evidence-based clinical 
and histopathologic predictors of renal outcome in LN outside the framework of the ISN/
RPS classification. 
METHODS
We collected a cohort of patients, biopsied from 1987–2011, with biopsy-confirmed LN 
from the pathology archives at the Leiden University Medical Center (LUMC). Inclusion 
criteria were: patients with a first renal biopsy available for re-evaluation with ≥5 scorable 
glomeruli, fulfilling ≥4 of the revised American College of Rheumatology23, 24 or Systemic 
Lupus International Collaborating Clinics25 classification criteria for SLE, and with clinical 
follow-up at the LUMC, Bronovo hospital (The Hague, the Netherlands), or Erasmus 
Medical Center (Rotterdam, The Netherlands). In accordance with the ethics committee 
guidelines at the LUMC, all patient data were coded and kept anonymous. Biopsies were 
processed for light and immunofluorescence microscopy according to standard techniques 
in our centre, including haematoxylin and eosin, periodic acid-Schiff, and methenamine-sil-
ver staining. Immunofluorescence reports were originally prepared by four experienced 




Histopathology definitions and scoring
Definitions of histopathologic lesions are shown in Appendix 5.1. Slides were scored 
by an experienced nephropathologist (IMB). All glomerular variables were determined 
for each scorable glomerulus separately and tubulointerstitial parameters were scored 
categorically (Appendix 5.1). We treated glomerular parameters as continuous variables 
and expressed them as the percentage involved of all scorable glomeruli. We considered 
50 histopathologic variables (Figure 1). To reduce the number of candidate variables, we 
excluded lesions with a low prevalence (occurring in ≤5 patients) and included only one 
of two strongly correlated variables (r/ρ >0.8). The decision on which of the correlated 
variables to be included was based on relevance and ease of scoring.
Figure 1 Histopathologic variables that were assessed.
Glomerular variables
Global sclerosis % glomeruli with global sclerosis 
Normal glomeruli % glomeruli noted as normal
Normal glomeruli/minimal leukocyte influx % glomeruli noted as normal/containing 1−3 leukocytes
Minimal leukocyte influx % glomeruli with 1−3 leukocytes 
Ischemic glomeruli % glomeruli noted as ischemic
Mesangial 1† Mean score for mesangial hypercellularity
Mesangial 2 % glomeruli with mesangial hypercellularity
Mesangial 3 % glomeruli with mesangial matrix expansion
Segmental sclerosis % glomeruli with segmental sclerosis
Endocapillary 1 % glomeruli with segmental endocapillary hypercellularity
Endocapillary 2 % glomeruli with segmental/global endocapillary hypercellularity
Endocapillary 3† % glomeruli with segmental/global endocapillary hypercellularity/minimal 
leukocyte influx
Endocapillary 4 % glomeruli with global endocapillary hypercellularity
Endocapillary inflammatory infiltrate† % glomeruli with influx of ≥4 inflammatory cells
Endocapillary granulocytes % glomeruli with ≥4 endocapillary granulocytes
Endocapillary lymphocytes % glomeruli with ≥4 endocapillary lymphocytes
Endocapillary monocytes† % glomeruli with ≥4 endocapillary monocytes
Endothelial swelling† % glomeruli with endothelial cell swelling
Wire loops % glomeruli with wire loops
Adhesions % glomeruli with adhesions
Fibrinoid necrosis % glomeruli showing fibrinoid necrosis
Extracapillary 1† % glomeruli with cellular crescents
Extracapillary 2 % glomeruli with cellular/fibrocellular crescents
Extracapillary 3† Mean cellular + fibrocellular crescent score
Extracapillary 4 % glomeruli showing fibrous crescents
Extracapillary 5† Mean fibrous crescent score
Extracapillary 6 % glomeruli with fibrocellular + fibrous crescents
Karyorrhexis % glomeruli with karyorrhexis
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Figure 1 Continued.
Glomerular variables
Microthrombi* % glomeruli with microthrombi
Pseudothrombi* % glomeruli with pseudothrombi
Double contours % glomeruli with double contours
Spikes/vacuoles % glomeruli with spikes/vacuoles
Tubulointerstitial variables
Tubular atrophy‡ Tubular atrophy score
Acute tubular injury* Acute tubular injury (+/-)
Tubular casts Tubular casts (+/-)
Tubular luminal macrophages Tubular luminal macrophages (+/-)
Tubular reabsorption droplets Tubular reabsorption droplets (+/-)
Tubular regeneration* Tubular regeneration (mitoses) (+/-)
Tubulitis* Tubulitis (+/-)
Interstitial infiltration Interstitial infiltration score
Interstitial lymphocytes† Interstitial lymphocyte-dominant infiltrate (+/-)
Interstitial granulocytes Interstitial granulocyte-dominant infiltrate (+/-)
Interstitial fibrosis‡ Interstitial fibrosis score (+/-)
Focal cortical atrophy* Focal cortical atrophy (+/-)
Vascular variables
Vasculitis* Vasculitis (+/-)
Fibrinoid necrosis in large vessels* Fibrinoid necrosis in large vessels (+/-)
Thrombosis* Thrombosis (+/-)
Hyaline arteriolosclerosis* Hyaline arteriolosclerosis (+/-)
Fibrous intimal hyperplasia* Fibrous intimal hyperplasia (+/-)
Arterial intimal fibrosis Arterial intimal fibrosis (+/-)
For definitions of histopathologic lesions, see Appendix 5.1. Percentages represent the proportion of involved scorable 
glomeruli. Crescent score: a multiplication factor of 1 was used for segmental crescents, and 2 for circumferential crescents. 
* Excluded from analyses because of low prevalence (≤5 patients). † Excluded from analyses because the variable was 
strongly correlated with another variable (r/ρ>0.8). ‡ Interstitial fibrosis and tubular atrophy were combined to form the 
composite variable “IF/TA” (interstitial fibrosis/tubular atrophy; whichever was the higher value).
Clinical dataset
The following clinical parameters were recorded for each patient at the time of biopsy0: 
age, sex, race, mean arterial pressure ([MAP] diastolic blood pressure + ⅓ pulse pressure), 
antihypertensive medication, previous immunosuppression, induction immunosuppression, 
time since SLE diagnosis, estimated glomerular filtration rate (eGFR), 24h proteinuria, 
erythrocyturia, and the presence of antinuclear, anti-double stranded DNA, and antipho- 
spholipid antibodies. The Cockcroft-Gault26 (normalised to a body surface area of 1.73 m2 
and Schwartz 27-29 formulas were used to calculate eGFR for adults and children, respectively. 
The eGFR and 24h proteinuria were registered at 1, 5, and 10 years (±0.5 year) and at 
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the last follow-up. Clinical data were studied throughout follow-up for the occurrence of 
renal flare and/or ESRD.
Brief study outcomes and statistical methods
A complete outline of this section is given in Appendix 5.2. Outcomes were studied in two 
settings: (i) the complete cohort of patients with all observed LN classes who received 
various therapies and (ii) a subset of patients with class III or IV (±V) LN who received 
induction immunosuppression including cyclophosphamide (CYC), mycophenolate mofetil 
(MMF), or azathioprine (AZA). Prespecified variables for multivariable analyses were: varia-
bles from the reduced histopathology dataset; interaction terms of these with race, age, and 
induction immunosuppression; and the clinical variables sex, race, time since SLE diagnosis, 
age0, proteinuria0, erythrocyturia0, MAP0, induction immunosuppression, and decade during 
which the patient was biopsied. 
Renal flare and ESRD
Time to first LN flare was calculated for patients who achieved (partial) remission from 
the date of biopsy until the date of flare for patients who reached this endpoint; the remai-
ning patients were censored at the last follow-up or at the time of ESRD. Time to ESRD 
was calculated analogously. Patients who reached ESRD before 10 years follow-up were 
regarded as having eGFR=0 mL/min/1.73 m2 at the remaining time points. Multivariable 
Cox proportional-hazards models included the prespecified variables and were simplified 
by stepwise removal of the least significant variables. 
eGFR during follow-up
The extent by which variables were associated with irreversible nephron loss was inves-
tigated by modelling eGFR during follow-up.  The prespecified variables were tested for 
their potential to predict a change in the intercept of the adjusted average level of decline 
in multivariable random intercept/slope linear mixed-effects models, which were simplified 
by removing the least significant variables (Wald test) and comparing the goodness of fit 
of nested models (maximum likelihood ratio test). 
Progressive eGFR decline
To investigate progressive eGFR decline that did not necessarily result in ESRD and/or 
renal flare, variables were analysed in association with progressive eGFR decline over 1, 5, 
and 10 years relative to its linear prediction based upon eGFR0. 
Normally distributed data were expressed as mean ± standard deviation (SD). Non-nor-
mally distributed data were expressed as median (25th–75th percentile). Correlations 
between clinical and histopathologic variables were assessed using Pearson and Spear-
man tests, as appropriate. Given the chance of false-positives by multiple correlations of 
histopathologic variables, Bonferroni correction was performed (Appendix 5.3).  All other 
P-values were two-tailed and considered significant at P<0.05.  All analyses were performed 
using SPSS 23.0 (IBM, Armonk, New York).
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RESULTS
We retrieved 293 reports of LN patients from the pathology archives at the LUMC. Of 
these, 134 patients were not followed at any of the specified centres, and 54 did not have 
a retrievable renal biopsy or their biopsy was of insufficient quality. Thus, 105 patients 
were included. Baseline clinical and laboratory findings are summarised in Table 1 and 
histopathologic findings in Table 2. A complete overview of histopathologic findings and 
assessment of scorable glomeruli are found in Appendix 5.4. The histopathology dataset 
(Figure 1) was reduced from 32 to 27 glomerular and 18 to 9 tubulointerstitial variables 
by excluding lesions occurring in ≤5 patients, excluding one of two strongly correlated 
variables, and combining interstitial fibrosis and tubular atrophy (IF/TA, see Appendix 5.3). 
Correlations between histopathologic variables and MAP0, eGFR0, and proteinuria0 are 
shown in Appendix 5.5.
Treatment and outcome
The median follow-up was 9.9 years (25th–75th percentile, 5.9−13.8). Induction immunosup-
pression was given to 102 patients (Table 1). Patients biopsied before 2000 received 
significantly more frequently AZA and less often CYC or MMF than patients biopsied 
after 2000 (all P<0.001). Five patients required dialysis at the time of renal biopsy and did 
not regain renal function during follow-up. Of 100 patients without ESRD at the time of 
biopsy, 99 achieved (partial) remission; of these, 47 experienced a renal flare during fol-
low-up. Fifteen of the patients who experienced a renal flare eventually developed ESRD. 
In addition to the five patients with ESRD at the time of biopsy, 16 patients progressed to 
ESRD and did not regain renal function (Figure 2). Five patients died during follow-up due 
to renal failure (n=1), infection (n=2), cardiovascular disease (n=1), and trauma (n=1). A 
comparison between patients biopsied before and after 2000 revealed no difference in 
renal survival (P=0.34) and renal flare rate (P=0.66).
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Characteristic All patients (n=105)










Mean ± SD 
<18 years, n (%)
29.8 ± 13.2
22 (21)








Previous diagnosis of SLE, n (%)
Years since SLE diagnosis, median (25th–75th percentile) 





Mean ± SD 22.4 ± 4.4
Diastolic BP ≥90 mm Hg, n (%) [total=101] 31 (31) 
MAP (mm Hg)
Mean ± SD 97 ± 17
Taking antihypertensive medication, n (%) [total=103] 34 (33)
Treated with RAS blockade, n (%) [total=103] 19 (18)
Induction immunosuppression, n (%)
No immunosuppression 3 (3)*
CS alone 4 (4)†
CS + CYC NIH 26 (25)
CS + CYC EuroLupus 27 (26)
CS + MMF 14 (13)
CS + AZA 31 (30)
eGFR0, mL/min/1.73 m2
Mean ± SD 76.5 ± 36.2












Median (25th–75th percentile) 2.48 (1.25–5.00)
Erythrocyturia, n
−/+/++/+++ 5/22/22/56
Previous immunosuppression, n (%) 19 (18)
ANA, n (%) 104 (99) 
Anti-dsDNA, n (%) [total=101] 77 (76)
Antiphospholipid antibodies, n (%) [total=57] 29 (51)
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Table 2 Distribution of selected histopathologic lesions in 105 patients with LN. 
Scorable glomeruli, n
Median (25th–75th percentile) 13 (10–19)












































































IF/TA, interstitial fibrosis or tubular atrophy.
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Figure 2 Probabilities of renal survival (A, n=105) and renal flare (B, n=99) among patients in the cohort.
Time to end-stage renal disease (ESRD) and time to first renal flare are depicted according to the Kaplan-Meier method. 
A: during follow-up, 21 patients progressed to ESRD. The probability of renal survival was 93% at 1 year, 90% at 5 years, 
85% at 10 years, and 71% at 20 years of follow-up. B: only patients were considered who achieved (partial) remission 
after renal biopsy and were not censored because they already reached ESRD. During follow-up, 47 patients experienced 
a renal flare. The probability of renal flare was 8% at 1 year, 35% at 5 years, and 48% at 10 years.
Predictors of renal outcome
Predictors of renal outcome were similar for the complete cohort and the subset (Tables 
3, 4, and Appendix 5.6). Below, parameter estimates refer to the complete cohort. 
Renal flare and ESRD
Non-Caucasian race (HR 2.23 [95% confidence interval (95% CI), 1.23 to 4.04]) and fibri-
noid necrosis (HR 1.04 for each percent of glomeruli [95% CI, 1.00 to 1.07]) independently 
predicted renal flare (Table 3). The following variables independently predicted ESRD 
(Table 3): non-Caucasian race (HR 7.16 [95% CI, 2.34 to 21.91]), eGFR0 (HR 0.98 for each 
mL/min/1.73 m2 [95% CI, 0.97 to 1.00]), fibrous crescents (HR 1.09 for each percent of 
glomeruli [95% CI, 1.02 to 1.17]), fibrinoid necrosis (HR 1.08 for each percent of glomeruli 
[95% CI, 1.02 to 1.13]), and the presence of IF/TA ≥25% (HR 3.89 [95% CI, 1.25 to 12.14]). 
eGFR during follow-up
The adjusted mean eGFR at the time of renal biopsy was 116.5 mL/min/1.73 m2, with an 
average change of −0.7 mL/min/1.73 m2 per year (Table 4). Cellular/fibrocellular crescents 
independently predicted an overall lower eGFR (i.e. lower adjusted mean eGFR at base-
line and during follow-up) of −0.4 mL/min/1.73 m2/%glomeruli (95% CI, −0.6 to −0.2), as 
did fibrous crescents (−1.4 mL/min/1.73 m2/%glomeruli [95% CI −2.4 to −0.5]) and the 
presence of IF/TA ≥25% (−40.5 mL/min/1.73 m2 [95% CI, −56.2 to −24.8]). Conversely, 
each percent of normal glomeruli, including glomeruli with 1−3 leukocytes, independently 
predicted an overall higher eGFR (+0.27 mL/min/1.73 m2/%glomeruli [95% CI, 0.1 to 0.4]). 
Clinically, non-Caucasian race and age0 independently predicted an overall lower eGFR 
(−11.4 mL/min/1.73 m2 [95% CI, −21.9 to −0.8] and −0.7 mL/min/1.73 m2/year [95% CI, 
−1.2 to −0.4], respectively).
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Table 3 Multivariable prediction models for renal flare and end-stage renal disease (ESRD). 
Model ISN/RPS Class I−V (n=105) ISN/RPS Class III/IV (±V)* (n=91)
HR (95% CI) P HR (95% CI) P
Renal flare (n=99)
Non-Caucasian 2.23 (1.23; 4.04) 0.008 2.08 (1.09; 3.98) 0.03
% Fibrinoid necrosis (glomerular) 1.04 (1.00; 1.07) 0.04 1.04 (1.00; 1.08) 0.04
HR (95% CI) P HR (95% CI) P
ESRD (n=105)
Non-Caucasian 7.16 (2.34; 21.91) 0.001 9.12 (2.85; 29.22) <0.001
Age0, y 1.02 (0.99; 1.06) 0.18 1.02 (0.99; 1.06) 0.23
eGFR0, mL/min/1.73 m2 0.98 (0.97; 1.00) <0.05 0.99 (0.97; 1.00) 0.12
% Fibrinoid necrosis (glomerular) 1.08 (1.02; 1.13) 0.004 1.07 (1.02; 1.13) 0.01
% Fibrous crescents 1.09 (1.02; 1.17) 0.02 1.10 (1.02; 1.19) 0.01
IF/TA ≥25% 3.89 (1.25; 12.14) 0.02 4.53 (1.40; 14.73) 0.01
* Patients with class III/IV (±V) LN who received induction immunosuppressive treatment with cytotoxic drugs were 
analysed separately from the complete cohort. CI, confidence interval; eGFR0, eGFR at the time of renal biopsy; HR, hazard 
ratio; IF/TA, interstitial fibrosis/tubular atrophy.
Table 4 Multivariable prediction model for the course of eGFR during follow-up†.
Model ISN/RPS Class I−V (n=105) ISN/RPS Class III/IV (±V)‡ (n=91) 
β (95% CI) P β (95% CI) P 
(Intercept) 116.5 (100.1; 132.8) <0.001 116.4 (98.9; 133.9) <0.001
(Time, y) −0.7 (−1.5; 0.0) 0.06 −0.6 (−1.4; 0.2) 0.13
Baseline predictors
  Non-Caucasian −11.4 (−21.9; −0.8) 0.04 −13.5 (−25.2; −1.7) 0.03
  Age0, y −0.8 (−1.2; −0.4) <0.001 −0.8 (−1.2; −0.4) <0.001
  % Normal glomeruli/minimal leukocyte influx 0.2 (0.1; 0.4) 0.01 0.2 (0.0; 0.5) 0.03
  % Cellular/fibrocellular crescents −0.4 (−0.6; −0.2) 0.001 −0.4 (−0.6; −0.1) 0.003
  % Fibrous crescents −1.4 (−2.4; −0.5) 0.004 −1.6 (−2.6; −0.5) 0.004
  IF/TA ≥25% −40.5 (−56.2; −24.8) <0.001 −41.4 (−58.3; −24.4) <0.001
β indicates eGFR in mL/min/1.73 m2. eGFR at time t is given by: eGFR(t) = intercept + βTime*t + Z, where Z is the value 
given by the baseline predictors of the patient: Z = βAge0*Age0 + β%Normal glomeruli/minimal leukocyte influx*%Normal glomeruli/minimal 
leukocyte influx + β%cellular/fibrocellular crescents*%cellular/fibrocellular crescents + β%fibrous crescents*%fibrous crescents + βnon-Caucasian 
(if Non-Caucasian) + βIF/TA ≥25% (if IF/TA ≥25%). † Mixed model analysis. ‡ Patients with class III/IV (±V) LN who received 
induction immunosuppression with cytotoxic drugs were analysed separately from the complete cohort. CI, confidence 




Briefly, a decline of eGFR over 1 and 5 years was independently predicted by non-Cau-
casian race, age0, fibrinoid necrosis, fibrous crescents, and IF/TA ≥25%. Contrastingly, wire 
loops and endocapillary lymphocytes were associated with eGFR recovery over 10 years 
follow-up (Appendix 5.6). 
Influence of therapy, race, and age on the predictive values of histopa-
thologic variables 
In the complete cohort, cytotoxic immunosuppression and/or ACE inhibition were not 
associated with any of the renal outcomes (Appendix 5.2). Of the histopathologic varia-
bles, only segmental/global endocapillary hypercellularity (P=0.03) and cellular crescents 
(P=0.05) were associated with cytotoxic immunosuppression (CYC, MMF, or AZA). The-
rapy showed no interactions with histopathologic variables for the different outcomes, 
with the exception of global glomerulosclerosis with ESRD (HR 1.03 for each percent 
glomeruli [95% CI, 1.00 to 1.06]) only in patients treated with AZA within the class III/IV 
subset (Appendix 5.7). Spikes/vacuoles and tubular reabsorption droplets were associated 
with a lower eGFR during follow-up in patients with Afro-Caribbean race compared with 
other races (Appendix 5.7). None of the prespecified clinical variables were correlated 
both with spikes/vacuoles or tubular reabsorption droplets and race. Age0 showed no 
interactions with histopathologic variables for the different outcomes (Appendix 5.7). 
Immunofluorescence in relation to outcome
The intensities of the individual immunoglobulins (IgA, IgG, and IgM) and complement fac-
tors (C3 and C1q) were not associated with ESRD, renal flare, or eGFR during follow-up 
(data not shown); neither were different immunofluorescence patterns, including <1+ IgG 
and C1q or the full house pattern.
ISN/RPS classes in relation to outcome
ISN/RPS classes were not significantly associated with overall renal survival (P=0.72) and 
renal flare (P=0.29). LN classes were significantly associated with eGFR during follow-up 
(P<0.05), with the lowest eGFR in class IV-S LN. For detailed results, see Appendix 5.8.
DISCUSSION
Controversies surrounding the prognostic significance of histopathologic (sub)classes in 
the classification of LN indicate that the prognosticators should be restructured from 
scratch.19, 20 Without preconceptions, we analysed clinical and histopathologic predictors 
of renal outcomes in 105 patients with class I–V LN, including a subset of 91 patients with 
class III or IV (±V) LN treated relatively uniformly with cytotoxic immunosuppression. 
Essentially, our analysis of the different outcomes in the complete cohort and its subset 
revealed two categories of clinical and histopathologic predictors: (i) variables predictive 
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of the level of eGFR during follow-up and (ii) variables predictive of renal flare, progressive 
eGFR decline, and ultimately ESRD.  The variables that emerged as independent predictors 
in the complete cohort were consistent with the predictors in the class III or IV (±V) LN 
subset. Here, we discuss the clinicopathologic predictors of renal outcome as identified 
among patients with class I–V LN.
In our study, the percentage of normal glomeruli with <4 leukocytes, in the absence of 
other abnormalities, was the only independent histopathologic predictor associated with 
a higher eGFR during follow-up. The prognostic significance of glomeruli that are normal 
by light microscopy most likely indicates that the relatively unaffected part of the kidney is 
vital in determining renal function. This notion is well known in the setting of anti-neutrophil 
cytoplasmic autoantibody-associated glomerulonephritis, where biopsies in which ≥50% of 
glomeruli are normal using identical definitions have been incorporated in a well-validated 
“focal class” in the classification.30-35 Based on our results, glomeruli that are normal by 
light microscopy may similarly transcend the LN classes and warrant incorporation into 
a separate index.
Only a limited number of active glomerular lesions had adverse prognostic value. Of the 
endocapillary lesions, wire loops and endocapillary lymphocytes were associated with 
eGFR recovery rather than decline over 10 years follow-up (Appendix 5.6), suggesting 
that the treatment of active endocapillary lesions was successful and damage was largely 
reversible for most patients. This result reflects the suggestion of the Oxford study on IgA 
nephropathy that endocapillary hypercellularity is a lesion more responsive to immunosup-
pression given the lack of its association with renal function decline among patients who 
received immunosuppression.22 In contrast with active endocapillary lesions, the associa-
tion of cellular/fibrocellular crescents with a lower eGFR during follow-up suggests active 
extracapillary lesions may result in irreversible damage. Yet, like active endocapillary lesi-
ons, active extracapillary lesions were not associated with progressive eGFR decline. The 
prognostic significance of extracapillary lesions also implies a treatment effect, but more 
in terms of halting the progression. In the current classification of LN, active endocapillary 
and extracapillary lesions contribute equally to the assignment of class III or IV LN. Our 
findings indicate that more weight should be given to extracapillary lesions.
In contrast with other active glomerular lesions, fibrinoid necrosis was not associated 
with eGFR0, but rather with renal flare, progressive eGFR decline, and ESRD. Interestingly, 
fibrinoid necrosis was correlated with segmental, but not global endocapillary hypercellu-
larity. This finding is consistent with the notion that global and segmental lesions represent 
distinct entities in class IV LN,13, 14, 36 and that segmental lesions, with emphasis on fibrinoid 
necrosis, may have a different immunopathogenesis than global lesions.13 
Apart from fibrinoid necrosis, chronic glomerular lesions were generally better predictors 
of eGFR and progressive eGFR decline than active lesions. Fibrous crescents were inde-
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pendently associated with lower eGFR during follow-up, progressive eGFR decline, and 
ESRD. Correspondingly, it has been demonstrated that the composite chronicity index 
devised by Austin et al.37 as well as its components individually, are excellent predictors of 
ESRD; whereas, the activity index and its components are weaker predictors.37-42 
Currently, primarily the histopathologic class based on glomerular pathology determines 
the recommended clinical management of LN.4-6 Our results confirm that, in addition to 
glomerular variables, tubulointerstitial variables including IF/TA, interstitial infiltrates, tubular 
casts, and arterial intimal fibrosis;38, 39, 41-44 as well as clinical variables including non-Caucasian 
race, age, MAP0, and eGFR0, are also valuable predictors of renal outcome in LN.39, 40, 45, 46 
Our study has some limitations. First, the predictors we identified apply to patients with 
the spectrum of clinical and histopathologic features observed in our cohort, in which the 
biopsies were scored by an experienced nephropathologist using our definitions. Indeed, a 
number of lesions, including microthrombi and vasculitis, were excluded from our analyses 
due to a low prevalence.  These lesions may well have prognostic significance and should be 
evaluated in other cohorts. Second, we did not analyse electron microscopy (EM); which, 
if at hand, is the usual complement to light and immunofluorescence microscopy to com-
prehensively study LN pathology.  Whereas in our study immunofluorescence microscopy 
did not confer prognostic significance, EM studies may reveal additional prognosticators. 
Third, our study is retrospective, whereas an ideal prognostic study would be prospective 
and standardise diagnostic and therapeutic procedures for all patients. However, our design 
allowed us to identify a cohort that could be followed to determine long-term outcomes. 
Inherent to any histopathologic study investigating active LN, our results must be inter-
preted in the light of immunosuppression. Most patients (68%) in the class III or IV (±V) 
subset were treated relatively uniformly with regimens including CYC or MMF according 
to guidelines. Importantly, 29 (31%) patients were treated with AZA. Within the subset, no 
interactions between pathology variables and treatment were found, with one exception: 
global glomerulosclerosis was significantly associated with ESRD for patients treated with 
AZA, whereas in patients who received CYC or MMF, it was not. AZA has been associ-
ated with increased risk of renal flare and inferior efficacy compared with CYC in terms 
of delaying the progression of chronic lesions.47, 48 The adverse prognostic significance of 
global glomerulosclerosis among patients treated with AZA and of chronic lesions in gene-
ral provides circumstantial evidence that AZA should not be recommended as induction 
therapy in case of chronic lesions.
In conclusion, our results show that while ISN/RPS classes were poorly associated with 
the clinically relevant outcomes, prognostication in LN may benefit from the specific 
assessment of clinical variables and lesions currently obscured in the classification. Normal 
glomeruli, cellular/fibrocellular crescents, fibrous crescents, and IF/TA were potent predic-
tors of eGFR during follow-up. Importantly, particularly active endocapillary lesions were 
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likely responsive to immunosuppression since they were not associated with renal function 
deterioration. Contrastingly, fibrinoid necrosis, fibrous crescents, and IF/TA predicted pro-
gressive renal dysfunction even in the uniformly treated subset, implying that these lesions 
are unlikely to benefit from immunosuppression and thereby correspond to the clinically 
most relevant category of predictors. An evidence-based era of classifying LN is on the 
horizon, with an international effort to refine the histopathologic classification already on 
its way. Our results suggest that LN classes should be expanded with an evidence-based 
index, analogous to the MEST score in the Oxford classification, with special attention 
to defining clinically important categories of predictors. Awaiting further validation of 
a formal index, we suggest that at least fibrinoid necrosis, fibrous crescents, and IF/TA 
warrant explicit independent scoring to assess the risk of progressive renal dysfunction in 
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Neuropsychiatric (NP) involvement is a poorly understood manifestation of systemic 
lupus erythematosus (SLE). We studied post-mortem histopathology in relation to clinical 
NP-SLE syndromes and complement deposition in brains of NP-SLE and SLE patients, and 
control cases. Furthermore, we investigated the correlation between cerebral post-mor-
tem histopathology and ex vivo 7-Tesla MRI findings in SLE and NP-SLE patients.
Methods
A nationwide search for autopsy material yielded brain tissue from 16 NP-SLE and 18 SLE 
patients. Brains obtained from 24 patients who died from acute cardiac events served as 
controls. Apart from a histopathologic evaluation, paraffin-embedded tissue from the cer-
ebral cortex was stained for components of the classical and lectin complement pathways, 
as well as for the terminal complement complex. 
Results
Diffuse vasculopathy, microinfarction, macroinfarction, vasculitis, and microthrombi occurred 
significantly more often in NP-SLE than SLE, and were absent in controls. Focal vasculopa-
thy was found both in SLE patients and controls. Complement deposition was strongly 
associated with both SLE and NP-SLE, but not with controls (P<0.001). Microthrombi were 
found uniquely in NP-SLE, and were associated with C4d and C5b-9 deposits (P<0.05). 
7-Tesla MRI was unable to detect most small vessel injury that was visible histopatholo-
gically. 
Conclusions 
Our study demonstrates that histopathologic lesions in NP-SLE represent a continuum, 
ranging from nonspecific lesions such as focal vasculopathy, to more specific lesions such 
as C4d- and C5b-9-associated microthrombi and diffuse vasculopathy related to clinical 
syndromes defining NP-SLE. Complement deposition may be a key factor in the interaction 
between circulating autoantibodies and thromboischemic lesions observed in NP-SLE. In 
conclusion, complement inhibition may have novel therapeutic potential in NP-SLE. 
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterised by 
circulating autoantibodies and immune complexes. SLE can manifest in virtually any organ 
system.1 Nervous system involvement in SLE is commonly referred to as neuropsychiatric 
SLE (NP-SLE),2 and occurs in 10–80% of SLE patients.3-7 NP-SLE can present with a variety 
of symptoms, including stroke and psychosis, which are frequently under-recognised despite 
being associated with increased morbidity and mortality.8, 9 Because NP-SLE is clinically 
heterogeneous, and because we lack aetiologic insight and evidence-based therapeutic 
interventions, the clinical management is complex.
As part of the clinical workup of a potential NP-SLE patient, magnetic resonance imaging 
(MRI) of the brain plays a prominent role,10 although interpretation of scans is often ham-
pered by the so-called “clinicoradiological paradox”, by which some patients with SLE and 
severe neurologic symptoms exhibit no or nonspecific abnormalities on MRI. In an analysis 
of MRI findings from 74 NP-SLE patients, 42% had no MRI abnormalities, despite having 
signs and symptoms of active cerebral disease. Otherwise, white matter hyperintensities 
were the most common MRI finding, which has been suggested to represent cerebral 
hypoperfusion and infarction.11
The few studies performed to date regarding histopathology of NP-SLE revealed that most 
lesions are related to ischemic injury in the vicinity of small-diameter vessels.12-16 Specifically, 
microthrombosis, microinfarction, and microbleeds were generally found. Whereas SLE is 
characterised by autoantibody-mediated inflammation, the findings in the brain suggest a 
thromboischemic pathogenesis.  Thus far, studies in patients have failed to provide clues for 
the interaction between the autoantibody-mediated inflammation and thromboischemic 
lesions in NP-SLE. Given the recent evidence that classical complement activation cor-
responds with the presence of glomerular microthrombi in lupus nephritis17 and other 
thrombotic microangiopathies,18-22 we hypothesised that complement activation may also 
underlie thromboischemic injury typically observed in brains of NP-SLE patients. 
In a nationwide study using cerebral autopsy material from NP-SLE, SLE, and control cases, 
we examined post-mortem histopathology in relation to clinical NP-SLE syndromes and 
complement deposition. Furthermore, in order to evaluate whether histopathologic lesions 
could be detected clinically, we investigated the correlation between cerebral post-mortem 




Nationwide search for cerebral tissues from SLE patients 
We conducted a nationwide search for cerebral autopsy tissue obtained from SLE patients 
with and without clinical signs of neuropsychiatric involvement. Samples were searched 
using the Dutch PALGA database, a histo- and cytopathology network and archive founded 
in 1971 to which all pathology laboratories within the Netherlands contribute.23 Hence, 
our search included patients autopsied between 1971–2010. We excluded samples from 
patients who had cutaneous or discoid lupus only, and included all patients with SLE 
according to the 1982 American College of Rheumatology (ACR) revised criteria24, 25 with 
cerebral autopsy tissue available. 
Clinical data were collected by contacting the rheumatologists at the different locations 
where the patients had been hospitalised. Because banking of sera and cerebrospinal 
fluid was not routinely performed as part of the clinical workup for the patients in this 
study, analysis of these materials was not feasible. Patients were divided into the following 
groups by two rheumatologists with extensive experience in diagnosing NP-SLE (GMSB 
and TWJH): patients with neuropsychiatric syndromes attributable to SLE (NP-SLE group) 
and SLE patients without neuropsychiatric syndromes attributed to SLE (SLE group). The 
presence of neuropsychiatric syndromes in each patient was evaluated according to the 
ACR definitions,2 and the existence of secondary factors causing these manifestations 
was assessed. 
Controls were identified from the archives of the Leiden University Medical Center and 
the Reinier de Graaf Hospital (Delft, the Netherlands) and included previously healthy 
patients who died of an acute cardiac event (confirmed at autopsy) between 2006–2009. 
Histopathology and immunohistochemistry 
Sections were stained with haematoxylin and eosin using standard protocols. The following 
cerebral complement components were stained: C1q (classical pathway), Mannose Binding 
Lectin (MBL, lectin pathway), C4d, and C5b-9 (membrane attack complex). Deparaffinised 
sections were subjected to antigen retrieval using EDTA-TRIS (pH 9.0), 10 mM citrate 
buffer (pH 6.0), or proteinase (bacterial, type XXIV; Sigma-Aldrich, St. Louis, Missouri). The 
sections were then stained with antibodies against C1q (Dako Cytomation, Denmark, 
1:800), C4d (Biomedica Gruppe, Austria, 1:50), and MBL (Sigma-Aldrich Biotechnology, 
1:500), and C5b-9 (A239; Quidel, San Diego, California; 1:500). Staining was visualised using 
the appropriate secondary antibodies with diaminobenzidine as chromagen. Finally, sections 
were counterstained with haematoxylin. Optimal antibody dilutions and incubation times 
were predetermined empirically by titration experiments using positive controls. 
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Histopathologic and immunohistochemical evaluation 
All sections were evaluated by a neuropathologist (SGvD) who was blinded with respect 
to clinical data. Each case was scored for the presence of microinfarction, macroinfarction, 
large haemorrhage, microbleeds, cerebral infection, vasculitis, and vasculopathy. Infarction 
was defined as sharply delimited regions of cellular death or tissue necrosis, sometimes with 
cavitation; the distinction between microinfarction and macroinfarction was made based 
upon the ability to detect these lesions by light microscopy or by gross inspection, respec-
tively.26 Infarction could be observed in the absence of (micro)thrombi. Microthrombi were 
defined as microscopic clumps of fibrin, platelets, and erythrocytes.27 Microbleeds were 
defined as small (<5 mm) perivascular haemosiderin-deposits (usually within macropha-
ges), generally associated with local vessel wall damage. Large haemorrhage was defined as 
rupture of the blood vessel wall and extravasation of erythrocytes without inflammation in 
acute stages and oedema, ischemia, infiltration of neutrophils, haemosiderin-laden macrop-
hages, and necrosis in later stages.27 Vasculitis was defined as an inflammatory infiltrate 
and destructive change in the blood vessel wall.27 In contrast, vasculopathy was defined as 
endothelial cell proliferation, thickening of the vessel wall, and narrowing of the capillary 
lumen without an inflammatory infiltrate.15 Vasculopathy was scored semi-quantitatively as 
“absent” (<10% of vessels with vasculopathy per low-power field [LPF]), “focal” (10–50% 
of vessels with vasculopathy per LPF), or “diffuse” (>50% of vessels with vasculopathy in 
every LPF). 
The immunohistochemically stained sections were scored by two independent observers 
who were blinded with respect to the clinical data. C1q and C4d primarily stained endot-
helial cells of small vessels in the white and grey matter, and were scored as “absent” (<10% 
of small vessels with C1q or C4d per LPF), “focal” (10–50% of small vessels with C1q or 
C4d per LPF), or “diffuse” (>50% of small vessels with C1q or C4d in every LPF). C5b-9 
similarly stained vessels, as well as cells with the morphology of glial cells; thus, scoring 
for vessels was performed similar to C1q and C4d. Because MBL did not stain vessels, 
MBL-positive cells were scored as being either present or absent. 
Whole formalin-fixed brains: Clinical case histories
From three patients, whole formalin-fixed brains were available, enabling a direct com-
parison between post-mortem ex vivo MRI and cerebral histopathology. Patient 1 was a 
57-year-old female with NP-SLE, antiphospholipid syndrome, and severe cerebrovascular 
disease. Patient 2 was a 38-year-old male with NP-SLE, acute neurologic deterioration, and 
vasculitis. Patient 3 was a 63-year-old-female with SLE without neuropsychiatric symptoms 
during the course of her disease who suffered from acute myocardial infarction. Detailed 
case histories are provided in Appendix 6.1.
Post-mortem neuroimaging and evaluation of the acquired images
The procedure of post-mortem 7-Tesla MRI scanning is detailed in Appendix 6.2. MRI 
scans were reviewed by two neuroradiologists with extensive experience in the field of 
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NP-SLE (MAvB and BJE), who then identified areas of interest. 
Histopathologic analysis of post-mortem MRI-scanned brains
After radiological analysis, tissue blocks of areas of interest were sampled, embedded in 
paraffin, and stained with haematoxylin and eosin. The neuropathologist reported the 
histopathologic changes in each sample.
Ethical considerations
The ethics committee of the Leiden University Medical Center approved this study 
(P02.028). In accordance with the Dutch National Ethics guideline (Code for Proper 
Secondary Use of Human Tissue, Dutch Federation of Medical Scientific Societies), all 
tissue samples and patient data were coded and kept anonymous throughout the study. 
Statistical analyses
Categorical variables were compared using chi-square test and its trend version for ordered 
categories (linear-by-linear analysis). Correlations between histopathologic variables were 
assessed by calculation of Pearson or Spearman correlation coefficients, as appropriate. 
All analyses were performed using SPSS Statistics 23.0 (IBM, Armonk, New York). P-values 
<0.05 were considered significant.
RESULTS
Our nationwide search for cerebral autopsy tissue of SLE patients yielded 296 hits. Of 
these, 48 fulfilled our inclusion criteria. From 14 of these patients, paraffin blocks were 
no longer available, or tissue quality was unsuitable for analysis. Thus, formalin-fixed tissue 
samples from 34 SLE patients (27 females, 7 males) autopsied between 1981−2009 were 
retrieved from 12 Dutch pathology laboratories and used for analysis.  Twenty-four patients 
who died of an acute cardiac event were included as controls. Table 1 provides an overview 
of clinical characteristics of NP-SLE, SLE, and control cases.
Three patients in the SLE group had neuropsychiatric syndromes that could be attributed 
to factors other than SLE. Specifically, one patient suffered intracerebral haemorrhage 
associated with anticoagulant therapy, one patient had a severe cerebral mycotic infection 
associated with high-dose immunosuppressive therapy for lupus nephritis, and one patient 
died in a uraemic coma following acute renal failure secondary to lupus nephritis. 
Histopathology
The majority of histopathologic lesions were located in the cerebral cortex, distributed 
equally across the white and grey matter.  The patient groups (NP-SLE and SLE) differed 
significantly from the controls with respect to all histopathologic parameters. Microinfarc-
tion (P=0.016), macroinfarction (P=0.002), and vasculitis (P<0.050) were more frequent 
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in NP-SLE patients than SLE patients. Microthrombi were found exclusively in NP-SLE 
patients (P=0.002, versus the other groups). Histopathologic findings in the three groups 
are shown in Figure 1. 
Table 1 Patient characteristics.
Characteristic NP-SLE (n=16) SLE (n=18) Controls (n=24)
Females, n (%) 15 (94) 12 (67) 10 (42)
Age at death in years, mean (SD) 44 (14) 46 (19) 47 (17)
Neuropsychiatric syndromes (ACR 99 definitions)*
  Cerebrovascular disease, n (%) 11 (69) 2 (11) 0 (0)
  Movement disorder, n (%) 2 (13) 0 (0) 0 (0)
  Seizures and seizure disorders, n (%) 1 (6) 0 (0) 0 (0)
  Acute confusional state, n (%) 2 (13) 1 (6) 0 (0)
  Cognitive dysfunction, n (%) 1 (6) 0 (0) 0 (0)
  Psychosis, n (%) 1 (6) 0 (0) 0 (0)
  No neuropsychiatric symptoms, n (%) 0 (0) 15 (83) 24 (100)
Primary versus secondary NP-SLE
  Primary NP-SLE, n (%) 16 (100) 0 (0) 0 (0)
  Secondary NP-SLE, n (%) 0 (0) 3 (17) 0 (0)
  Neurologic infection, n (%) 3 (19) 5 (28) 0 (0)
Brain mass in grams, mean (SD) 1308 (177) 1290 (137) 1437 (171)
* Eleven NP-SLE patients had one syndrome, four patients had two syndromes, and one patient had three syndromes.
Figure 1 Histopathologic lesions in NP-SLE, SLE, and controls.
Frequency of the indicated lesions in brain tissue of SLE patients (n=18), NP-SLE patients (n=16), and control subjects 
(n=24). Microthrombi, microinfarctions, macroinfarctions, and vasculitis were present more often in the brains of patients in 
the NP-SLE group compared to those of patients in the SLE group (*, P<0.05 versus SLE). None of the seven parameters 
were present in the brains of control patients. 
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The presence of vasculopathy – and its distribution in either a focal or diffuse pattern – 
differed between the three groups based on linear-by-linear association (P<0.001; Figure 2). 
Figure 2 Vasculopathy in NP-SLE, SLE, and controls.
Results of semi-quantitative scoring of vasculopathy in brain tissues of SLE patients (n=18), NP-SLE patients (n=16), and 
control subjects (n=24). Diffuse vasculopathy was present more often in the NP-SLE brains than in SLE and control 
brains. * P<0.05. 
Vasculitis was found in six patients (five NP-SLE, one SLE; P<0.050). Each NP-SLE patient 
with vasculitis also had vasculopathy (four diffuse, one focal). Vasculitis was associated 
with cerebrovascular disease in four NP-SLE patients and with acute confusional state in 
one NP-SLE patient. The patient from the SLE group with vasculitis had a severe mycotic 
infection associated with immunosuppressive therapy. 
Typical examples of vasculopathy and cerebral microthrombi are shown in Figure 3A and 
3B, respectively. 
Correlations between neuropathological findings in patients 
with SLE and NP-SLE
In patients with SLE (NP-SLE and SLE), vasculopathy was correlated with macroinfarction 
(ρ=0.43, P=0.012) and microthrombi (ρ=0.57, P<0.001). Furthermore, microthrombi were 
correlated with microinfarction (r=0.54, P=0.001) and microbleeds (r=0.40, P=0.018). 
Large haemorrhage was correlated with macroinfarction (r=0.35, P=0.042) and vasculitis 
(r=0.38, P=0.027), and microinfarction was correlated with microbleeds (r=0.46, P=0.006). 
Immunohistochemistry
Figure 3C-J shows typical examples of immunohistochemical staining with C1q, C4d, MBL, 
and C5b-9 in patients and controls. C1q, C4d, and C5b-9 were observed on endothelial 
cells of small vessels (Figure 3D, F, J). Table 2 shows C1q, C4d, and C5b-9 staining patterns 
in patients and controls. Additionally, C5b-9 was observed on cells with the morphology 
of glial cells (Figure 3I). Cellular staining of C5b-9 was not different between patients and 
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controls (data not shown). MBL deposits did not stain vessels; thus, co-localisation between 
MBL and C1q or C4d did not occur. Instead, MBL-positive staining was observed on cells 
resembling astrocytes. These MBL-positive cells (Figure 3G−H) were detected both in 
patients and controls (no difference between the groups; data not shown). 
Table 2 Vascular C1q, C4d, and C5b-9 staining in patients and controls.
Staining pattern NP-SLE (n=16) SLE (n=18) Controls (n=24) P*
No C1q staining 0 (0) 1 (6) 15 (63)
Focal C1q staining 11 (69) 10 (55) 9 (37)
Diffuse C1q staining 5 (31) 7 (39) 0 (0) <0.001
No C4d staining 2 (12) 2 (11) 18 (75)
Focal C4d staining 11 (69) 14 (78) 6 (25)
Diffuse C4d staining 3 (19) 2 (11) 0 (0) <0.001
No C5b-9 staining 3 (19) 3 (17) 20 (83)
Focal C5b-9 staining 9 (56) 12 (67) 4 (17)
Diffuse C5b-9 staining 4 (25) 3 (17) 0 (0) <0.001
All values are given as n (%). C1q: NP-SLE vs. controls P<0.001; SLE vs. controls P<0.001; NP-SLE vs. SLE P=0.531.C4d: 
NP-SLE vs. controls P<0.001; SLE vs. controls P<0.001; NP-SLE vs. SLE P=0.801. C5b-9: NP-SLE vs. controls P<0.001; 
SLE vs. controls P<0.001; NP-SLE vs. SLE P=0.796. *Chi-square test.
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Figure 3 Examples of histopathologic lesions and immunohistochemical staining patterns.
A, B, D, F, H, I, J: staining patterns in an NP-SLE case. C, E, G: staining patterns in a control case. Stainings: haematoxylin 
and eosin (H&E, A−B), C1q (C−D), C4d (E−F), mannose-binding lectin (MBL, G−H), and C5b-9 (I−J). Magnification: 40X. 
A: vasculopathy (thickening of the vessel wall, no inflammatory infiltrate). B: cerebral microthrombus. C−D: negative and 
positive C1q staining, respectively. E−F: negative and positive C4d staining, respectively. C1q showed a linear pattern of 
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Complement deposition in relation to neuropathological 
findings in patients with SLE and NP-SLE
We investigated the relationship between C1q, C4d, C5b-9, and the presence of micro-
thrombi, microinfarctions, macroinfarctions, vasculitis, and vasculopathy. Only the presence 
of microthrombi was associated with C4d and C5b-9 staining (P=0.047 and P=0.020, 
respectively). Every patient with microthrombi also had either focal or diffuse C4d and 
C5b-9 staining. C4d and C5b-9 were strongly associated with microthrombi within the 
NP-SLE group (linear-by-linear association: P=0.024 and P=0.008, respectively).
Relationship between C4d, C1q, and C5b-9 in SLE and NP-SLE
To gain additional insight into the cascade of events in classical complement activation, 
the staining patterns of C1q, C4d, and C5b-9 were related to one another in the SLE and 
NP-SLE patient groups. In general, diffuse C1q staining was present more often than diffuse 
C5b-9 and C4d staining (35%, 21%, and 15%, respectively). Twenty-five of 34 (74%) patients 
with SLE and/or NP-SLE had concurrent positive (either focal or diffuse) vascular staining 
of C1q, C4d, and C5b-9. Twenty-nine of the 30 patients with positive C4d staining (either 
focal or diffuse) had concurrent C1q deposits and 25 had concurrent C5b-9 deposits 
(an overlap of 97% and 83%, respectively). Conversely, 29 of the 33 patients with positive 
C1q staining (either focal or diffuse) had concurrent C4d, and 28 had concurrent C5b-9 
staining (an overlap of 89% and 85%, respectively). Of the 28 patients with positive C5b-9 
staining, 25 (89%) had concurrent C1q and C4d staining. Appendix 6.3 shows that the 
distributions of C1q, C4d, and C5b-9 were quite similar in both the SLE and NP-SLE group. 
Post-mortem ex vivo MRI and correlations with 
histopathology and immunohistochemistry
The results of post-mortem ex vivo MRI scans and histopathology sections of two NP-SLE 
patients and one SLE patient are shown in Figure 4. 
Patient 1: Post-mortem ex vivo MRI
MRI revealed extensive confluent periventricular and deep white matter lesions with 
notable sparing of U-fibres (Figure 4A−B). Furthermore, central lacunae in the deep 
white matter suggested tissue loss consistent with lacunar infarction. White matter lesions 
around confluent white matter lesions and adjacent to deep white matter lesions were 
perivascular in distribution.
Patient 1: Histopathology
Sections taken from both the deep and periventricular white matter lesions revealed areas 
of recent and less recent microinfarctions and macroinfarctions. In one deep white matter 
lesion, multiple microthrombi (Figure 4C−D) were identified. In all sections, prominent vas-
culopathy in both grey and white matter was found (Figure 4E). Vasculopathy was present 
within white matter hyperintensities and infarcted areas, as well as in normal-appearing 
white and grey matter. Furthermore, vast areas of atrophied cortex – particularly in the 
proximity of infarctions – had laminar necrosis (Figure 4F).
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Patient 2: Post-mortem ex vivo MRI
MRI revealed normal grey and white matter differentiation (Figure 4G−H). Several linear 
hyperintensities were characteristic of normal Virchow-Robin spaces (Figure 4G). Unlike 
Patient 1, the white matter in Patient 2 was homogeneous, and cortical thickness was 
normal. 
Patient 2: Histopathology
Because no abnormalities were identified on MRI, sections were obtained from several 
cortical areas. Each of these revealed diffuse vasculopathy (Figure 4I−J). Furthermore, lympho- 
cytes had invaded vascular walls of several veins and venules, reflected by the presence 
of fragmented nuclei and fibrinoid material (Figure 4K). No intravascular microthrombi, 
infarctions, or gliosis were identified. 
Patient 3: Post-mortem ex vivo MRI
MRI revealed a prominent Virchow-Robin space (Figure 4L). In addition, a linear perivascu-
lar white matter hyperintensity was present in the internal capsule. Another white matter 
lesion was identified in the frontal white matter (Figure 4M). 
Patient 3: Histopathology 
Sections taken from the frontal white matter lesion revealed focal vasculopathy. No other 
abnormalities were identified. Vasculopathy was present in a similar focal distribution pat-
tern throughout all sections (Figure 4N−O).
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Figure 4 Post-mortem 7-Tesla MRI in relation to histopathologic findings in NP-SLE and SLE patients.
Patients 1 and 2 were NP-SLE patients, patient 3 had SLE without neuropsychiatric symptoms. A: confluent periventricular 
and deep white matter lesions*. B: deep white matter lesions with sparing of U-fibres*; perivascular white matter lesions 
(arrow). C−F: sections from deep and periventricular white matter lesions. C: microinfarction*. D: microthrombi* in vicinity 
of white matter lesions. E: vasculopathy*. F: laminar necrosis*. G−H: normal grey/white matter with linear hyperintensities 
(normal Virchow-Robin spaces; G, arrow). I−K: sections from normal-appearing cortex. I−J: vasculopathy. K: venous vasculitis. 
L: prominent Virchow-Robin space and normal grey/white matter. M: frontal white matter lesion*. N: vasculopathy in section 




In this study, we described the injury in brains of patients with NP-SLE as compared to SLE 
and control cases. Furthermore, we studied brain injury in NP-SLE in relation to classical 
complement deposition. We were able to identify a number of histopathologic lesions that 
were specific to NP-SLE, and could thereby be linked to clinical NP-SLE manifestations as 
defined by the ACR.2 Compared to SLE patients, NP-SLE patients had significantly more 
microinfarction, macroinfarction, vasculitis, and microthrombi, though in controls these and 
other neuropathological abnormalities were absent. Also, diffuse vasculopathy occurred 
significantly more often in NP-SLE than in SLE patients, whereas focal vasculopathy was 
found in all groups (NP-SLE, SLE, and controls). The common finding of vasculopathy 
and the absence of a relationship between vasculopathy and acute clinical NP-SLE are in 
accordance with previous findings.15 Our data show that the injury and clinical manifesta-
tions of NP-SLE represent a continuum, ranging from relatively nonspecific lesions found 
in most SLE patients such as focal vasculopathy – to specific and even pathognomonic 
lesions in this setting, including diffuse vasculopathy and microthrombi associated with 
clinical syndromes defining NP-SLE.2
Our study is the first to demonstrate that deposits of C1q and C4d, both components of 
the classical complement pathway, as well as the terminal complement complex (C5b-9), 
are concurrently present in the cerebral vessels of patients with NP-SLE and SLE signi-
ficantly more often than in controls. This constellation of staining patterns indicates that 
activation of the classical complement pathway proceeded to completion, as demonstrated 
by the formation of the terminal complement complex. The role of complement activation 
in the development of thrombosis and ischemia has been studied extensively outside the 
field of SLE, where complement has been linked to microthrombotic injury in antiphospho- 
lipid syndrome19, 22 and thrombotic microangiopathy.18 In these conditions, accumulation 
of antibodies in small vessels most likely leads to activation of the classical complement 
pathway, endothelial injury, and the subsequent formation of microthrombi.18 Given that 
vasculopathy, microinfarction, macroinfarction, vasculitis, and microthrombi may all evoke 
vascular occlusion and could thereby result in clinical abnormalities, the question arises as 
to why some of these lesions were found to be more specific in our study for NP-SLE 
than other lesions. Our findings suggest that thromboischemic injury may occur in all SLE 
patients but that overt NP-SLE ensues only after a certain threshold of complement-me-
diated injury is reached. The finding that, of all vascular lesions, only microthrombi were 
correlated with C4d and C5b-9, suggests that microthrombi represent a more progressed 
stage of complement-mediated injury. Conceivably, microthrombi were also present in 
patients with subclinical NP-SLE – though in smaller quantities and would therefore be 
more readily missed in these cases due to sampling error.
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Although cerebral vasculitis is generally considered to be a rare finding in NP-SLE, we iden-
tified five NP-SLE patients (31%) with vasculitis in our study.  This relatively high incidence 
as compared to previous studies12-15 may be explained by our clear distinction of SLE and 
NP-SLE cases. In four of the NP-SLE cases with vasculitis, vasculitis was associated with 
cerebrovascular disease. Interestingly, our neuropathological analyses revealed that vasculitis 
was correlated with large haemorrhage.  Although according to the recommendations for 
the management of NP-SLE, cerebrovascular disease due to ischemic stroke and/or TIA 
comprises over 80% of cases and therefore does not require immunosuppressive the-
rapy,10 we showed that vasculitis may still be an underlying factor in a substantial number 
of cases. Our findings emphasise that immunosuppressive therapy may occasionally be 
indicated in cases with a component of vasculitis underlying cerebrovascular disease as a 
manifestation of NP-SLE.
Diamond et al. focused on the role of autoantibodies in the development of neuropsychi-
atric symptoms in a murine model and found that anti-double stranded DNA antibodies 
derived from human SLE patients can cross-react with N-methyl-D-aspartate receptors 
on neurons causing neuronal death by excitotoxicity and apoptosis.28-30 However, in subse-
quent studies in which these antibodies were induced in mice, neuronal damage occurred 
solely when a breach in the blood-brain barrier was present.31, 32 Our findings may indicate 
that continuously exposing the cerebral endothelium to autoantibodies can cause comple-
ment activation and endothelial injury in all SLE patients. Possibly, a second hit is required 
to develop overt clinical disease in the form of NP-SLE as defined by the ACR.2 Infection, 
pregnancy, drug toxicity, and defects in complement regulation have all been described as 
triggering factors.20, 21 Possibly, these evoke a breach in the blood-brain barrier together with 
the formation of C4d- and C5b-9-associated microthrombi as well as the other lesions we 
identified to be distinctive of NP-SLE. Since sera and cerebrospinal fluid (CSF) were not 
available from the patients in our study, it was not possible to further analyse the antibody 
profile in CSF in relation to the CSF/albumin ration as a possible indicator of blood-brain 
barrier integrity in concert with the assessment of thromboischemic injury in NP-SLE and 
SLE cases. Whether these or other factors affecting the integrity of the blood-brain barrier 
play a role in NP-SLE will be the subject of future studies.
Apart from the clinicopathologic paradox of impressive histopathologic cerebral lesions 
that are sometimes not accompanied by overt clinical NP-SLE, there is also a clinicoradio-
logical paradox. In contrast to the clinicopathologic paradox, the latter is defined by the 
absence of abnormalities on conventional MRI in patients with over clinical NP-SLE, and 
this hampers assessment of the extent of cerebral injury in NP-SLE patients.11 We investi-
gated whether microvascular and thromboischemic injury could be detected clinically by 
analysing three whole brains of SLE patients using 7-Tesla MRI. High-field MRI can provide 
images at higher spatial resolution, resulting in more detailed information regarding micro-
vascular injury compared to conventional MRI. Interestingly, for these brains (two NP-SLE, 
one SLE), even high-field MRI was unable to detect most small-vessel injury that was visible 
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histopathologically. The microvascular injury that could be detected was most prevalent 
in the vicinity of white matter hyperintensities. On the other hand, high-field MRI would 
detect nonspecific lesions more readily than conventional MRI.33 White matter hyperinten-
sities by conventional MRI may be found in 20 percent of the general population younger 
than age 50, and in 90 percent of people older than age 70.33 Furthermore, white matter 
lesions may be observed in SLE patients who do not have neuropsychiatric symptoms. 
Indeed, white matter lesions were detected by 7-Tesla MRI in one SLE patient without 
NP-SLE in our study, which lesions corresponded to focal vasculopathy. Thus, although 
white matter hyperintensities may indicate an initial phase of vascular damage in some SLE 
patients, they should generally be considered nonspecific. Probably, more sensitive as well 
as more specific imaging tools are required for the diagnosis of NP-SLE. Future studies to 
determine the feasibility of, for instance, quantitative techniques such as volumetric mag-
netisation transfer imaging (MTI)34, 35 to detect specific lesions in SLE and NP-SLE patients 
are called for, as brain biopsies remain unattainable in routine clinical practice.
Concluding, NP-SLE is a poorly understood manifestation of SLE, associated with significant 
morbidity and mortality. NP-SLE is usually treated with aggressive immunosuppression, 
which can be beneficial in some – but certainly not all – NP-SLE patients.10, 36 Our finding 
that complement activation is present in both SLE and NP-SLE suggests that this mecha-
nism may contribute to the development of injury. It remains to be elucidated whether 
the clinical manifestations of NP-SLE following injury are due to a thromboischemic 
pathomechanism, due to a breach in the blood-brain barrier facilitating antibody-media-
ted neuroinflammation, or due to a combination of both. Importantly, our novel finding 
of complement in association with injury in SLE and NP-SLE proposes the complement 
system as a promising new target in the treatment of NP-SLE. The finding that C5b-9 
deposits were present in 82% of patients with SLE and NP-SLE in our study, suggests that 
at least this proportion of patients with NP-SLE – and perhaps also patients with SLE – 
may benefit from treatment with the terminal complement inhibitor eculizumab.37-42 The 
efficacy of such treatment in NP-SLE and SLE remains to be investigated in future studies.
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Tissue Microchimerism is Increased During Human 
Pregnancy: A Human Autopsy Study 
Emilie C. Rijnink, Marlies E. Penning, Ron Wolterbeek, Suzanne Wilhelmus, 
Malu Zandbergen, Sjoerd G. van Duinen, Joke Schutte, Jan A. Bruijn, Ingeborg M. Bajema





Microchimerism is the occurrence of small populations of cells with a different gene-
tic background within an individual. Tissue microchimerism is considered to be primarily 
pregnancy-derived and is often studied relative to female-dominant autoimmune diseases, 
pregnancy complications, malignancies, response to injury, and transplantation outcomes. 
A particular distribution pattern of chimeric cells across various organs was recently des-
cribed in a model of murine pregnancies. Our aim was to determine the frequency and 
distribution of tissue microchimerism across organs during and after pregnancy in humans. 
Methods
We performed in situ hybridization of the Y chromosome on paraffin-embedded autopsy 
samples of kidneys, livers, spleens, lungs, hearts, and brains that were collected from 26 
women who died while pregnant or within one month after delivery of a son. Frequen-
cies of chimeric cells in various tissues were compared to those of a control group of 
non-pregnant women who had delivered sons. 
Results
Tissue microchimerism occurred significantly more frequently in lungs, spleens, livers, kid-
neys, and hearts of pregnant women than non-pregnant women (all P<0.01). We showed 
that some of the chimeric cells were CD3+ or CD34+. Corrected for cell density, the 
lung was most chimeric (470 Y chromosome-positive nuclei per million nuclei scored), 
followed by the spleen (208 Y+/106 nuclei), liver (192 Y+/106 nuclei), kidney (135 Y+/106 
nuclei), brain (85 Y+/106 nuclei), and heart (40 Y+/106 nuclei). 
Conclusions
Data from this unique study group of women who died while pregnant or shortly after 
delivery provide information about the amount and physiologic distribution of chimeric 
cells in organs of pregnant women. We demonstrate that during pregnancy, a boost of 
chimeric cells is observed in women, with a distribution across organs that parallels findings 
in a mouse model. 
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INTRODUCTION
Microchimerism is defined as the occurrence of a small number of cells in an individual 
that originate from another individual.1 One possible source of naturally occurring micro-
chimerism is pregnancy. Knowledge about the source and dynamics of naturally occurring 
tissue microchimerism is relevant for interpreting its contribution to the pathogenesis of 
autoimmune disease, pregnancy complications, and malignancies; and for studying its role 
in response to injury and transplantation outcomes. Because of the association between 
certain autoimmune diseases and pregnancy, as well as their increased incidence in women 
of fertile age, the aim of many studies has been to investigate the role of microchimerism in 
the onset of autoimmune disease.2 An adverse effect of pregnancy-acquired microchime-
rism has also been suggested in kidney transplantation. Here, female recipients of a spousal 
donor kidney who had not been pregnant had better graft survival than those who had 
been pregnant.3 On the other hand, a decreased incidence of malignancy in association 
with increasing parity has been found for various malignancies,4 suggesting a protective role 
for pregnancy-acquired microchimerism. To assess the significance of pregnancy-derived 
tissue microchimerism in autoimmune disease, malignancy, and other pregnancy-related 
conditions, however, its occurrence during pregnancy in humans must be established first. 
During pregnancy fetal cells enter the maternal circulation (fetal microchimerism) and 
maternal cells enter the fetal circulation (maternal microchimerism). Fetal cellular micro-
chimerism in the maternal circulation has been detected as early as seven weeks of 
gestation5 and remains detectable in maternal blood up to 27 years postpartum.6 Male 
cells of presumably fetal origin can differentiate and be incorporated into maternal tissues 
after pregnancy.7 We previously demonstrated that microchimerism, as measured by in situ 
hybridization of the Y chromosome, is present in the thyroid gland, lungs, skin, lymph nodes, 
kidneys, livers, and hearts of healthy non-pregnant women.8, 9 Remarkably, these studies 
showed no significant association between microchimerism and parity, yet pregnancy is 
often assumed to be the main source of tissue microchimerism in women. Most studies 
have focused on microchimerism in relation to pregnancy in blood samples.10-14 Studies on 
microchimerism during pregnancy at the tissue level are limited to the demonstration of 
presumably fetal male microchimerism in affected tissues of pregnant women with poly-
morphic eruptions of pregnancy,15 pregnancy-associated breast cancer,16 melanoma,17 and 
appendicitis.18 However, no studies have systematically investigated human microchimerism 
in relation to pregnancy in healthy tissues. 
Studying murine pregnancies, Fujiki et al. detected fetal cells in tissues of mouse dams after 
mating wild-type females with green fluorescent protein (GFP)-transgenic males.19 Interes-
tingly, these authors found a particular distribution pattern of chimeric cells across various 
organs, identifying the greatest concentrations in the lungs, followed by the spleen, liver, 
and kidney. Remarkably, microchimerism in maternal lungs exceeded that found in other 
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organs 10- to 100 fold. Fujiki et al. suggested that the high rate of blood flow through lung 
tissue might explain this high rate of microchimerism in the lungs, in addition to the fact 
that the lung contains the first capillary bed a fetal cell crosses after entering the maternal 
uterine venous circulation. To further unravel the impact of microchimerism on maternal 
health by studying mouse models, the validity of these models to represent the human 
situation must be confirmed by studying the distribution of tissue microchimerism during 
human pregnancy.
The aim of the present study was to investigate the frequency and distribution of tissue 
microchimerism in lungs, spleens, livers, kidneys, brains, and hearts from women pregnant 
with sons and the influence of the postpartum interval on the amount of microchimerism. 
Our results provide information about the physiologic distribution of chimeric cells across 
the organs of pregnant women, allowing comparisons to animal models, and support a 
role for pregnancy as a source of tissue microchimerism. 
METHODS
Patient selection and ethical approval
Tissue specimens came from autopsies performed on women in the Netherlands between 
1990 and 2006. Samples were searched using the Dutch PALGA database, a histo- and 
cytopathology network and archive to which all pathology laboratories within the Nether-
lands contribute.20  The search strategy included the parameters “autopsy”, “women”, and 
“age between 18 and 45 years”.  All patients were included who died while pregnant with 
male fetuses or who died within one month after delivery of a son.
With this search strategy, we obtained formalin-fixed, paraffin-embedded tissue samples 
from 26 women, including samples from 19 lungs, 15 spleens, 19 livers, 19 kidneys, 17 
hearts, and 5 brains. The number and availability of organ samples varied because of diffe-
rences between laboratories. Also, some samples were excluded because of poor quality 
due to autolysis. A previously described group of non-pregnant women with sons served 
as historic controls.8, 9 Patient characteristics of the pregnant women included in the current 
study and those of the historic control group are shown in Table 1. 
Clinical data were obtained from autopsy reports and from the records of the National 
Maternal Mortality Committee of the Dutch Society of Obstetrics and Gynaecology. All 
samples were coded and handled anonymously in accordance with the Dutch National 
Ethics Guidelines (Code for Proper Secondary Use of Human Tissue, Dutch Federation 
of Medical Scientific Societies). In addition, this study was approved by the ethics commit-
tee of the Leiden University Medical Center (P12.107). Table 2 shows pregnancy-related 
characteristics of the 26 pregnant women included in this study.
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Table 1 Characteristics of pregnant women and controls.
Characteristic This study Koopmans et al. 2005 Koopmans et al. 2008




Number of women 26 45 50
Age in years, mean (range) 32 (20–45) 64 (29–93) 64 (29–93)
Cause of death
Infectious 0 9 11
Malignancy 0 14 13
Cerebral 1 8 10
Vascular/myocardial 14 12 13
Other 11, i.e. pre-eclampsia/
eclampsia (6), amniotic 
fluid embolism (2), liver 
cirrhosis, EUG, sarcoidosis
2, i.e. liver cirrhosis, 
cachexia
3, i.e. liver cirrhosis (2x), 
cachexia
Blood transfusion
Yes 1 29 30
No 25 16 20
Organ samples studied by ISH
Kidney 19 30 -
Liver 19 33 -
Heart 17 42 -
Spleen 15 29 -
Thyroid - - 43
Lung 19 - 37
Skin - - 20
Lymph node - - 6
Brain 5 - -
EUG, extra-uterine gravidity; ISH, in situ hybridization.
In situ hybridization
The same protocol for in situ hybridization of the Y chromosome was used as previously 
described for our historic control group.8, 9 Formalin-fixed, paraffin-embedded samples 
were cut into 4 µm slices, transferred to Superfrost plus glass slides (Menzel-Glaser, Ger-
many), and dried overnight at 37 °C.  A Y chromosome-specific DNA probe21 was labelled 
with digoxigenin (DIG) according to the standard Nick-translation protocol.  After labelling, 
the probe was precipitated, dried, and dissolved in hybridization mixture (50% deionised 
formamide; 0.05 M sodium phosphate buffer, pH 7.0; 0.3 mol/L NaCl; 30 mmol/L Na citrate 
(2×SSC); and 10% dextran sulphate). Salmon sperm DNA, transfer RNA, and Cot-1 DNA 
were added to the hybridization mixture to prevent nonspecific binding of DNA.
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Table 2 Pregnancy-related characteristics of cases.
Characteristic Pregnant women (n=26)
Death postpartum, n 11
 GA at birth, weeks 37.4 (29.9–39.1)
 Death postpartum, hours 36.0 (0.2–432)
Death during pregnancy, n 15
 GA at death, weeks 29.0 (10–40.3)
Death to autopsy time, hours 24.0 (1–48)
Sex of fetus  
 Male, % 100




Data are presented as mean (range), unless indicated otherwise. GA, gestational age.
The slides were deparaffinised in xylene and rehydrated in an ethanol series followed by a 
distilled water rinse. The slides were prepared with 0.05 M citrate buffer (pH 6.0) at 80 °C 
for 80 minutes and rinsed in prewarmed distilled water at 37 °C. Enzyme digestion was 
performed using 0.5% pepsin (Serva Electrophoresis GmbH, Heidelberg, Germany) in 
0.01 M HCl at 37 °C for 20 minutes. The slides were dehydrated in upgraded ethanol and 
air-dried. Tissue sections on each slide were covered with 30 µL of hybridization mixture 
containing 5 ng/µL labelled probe. The slides were denatured for 10 minutes on a metal 
plate at 80 °C and incubated at 37 °C overnight. The following day, the slides were washed 
three times in 2×SSC/0.1% Tween at 37 °C to remove the cover slips and three times in 
0.1×SSC at 60 °C.  To visualise the DIG-labelled probe, the sections were incubated con-
secutively with a mouse anti-DIG monoclonal antibody (Sigma-Aldrich, St. Louis, Missouri, 
USA) and anti-mouse Envision-HRP (Dako, Glostrup, Denmark), followed by development 
with Nova Red Vector for 10 minutes. Haematoxylin staining was used as a background. 
We confirmed by nested PCR and sequencing that the probe was specific for the Y chro-
mosome.8 As a positive control, we used a male tissue sample in which the sensitivity of 
the Y chromosome signal was 58%.  As a negative control, a male tissue sample was used 
on which the complete hybridization protocol was performed using the hybridization 
mixture without the Y chromosome probe.
Double staining
To study the phenotype of the chimeric cells in pregnant women, we performed CD3 
and CD34 immunohistochemical staining in combination with in situ hybridization of the 
Y chromosome as described previously.22
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Scoring
Slides were scanned using a Panoramic Digital Slide Scanner (3DHISTECH Kft., Budapest, 
Hungary) and scored using Panoramic Viewer (3DHISTECH Kft., Budapest, Hungary). A 
predefined random area of 50 mm2 was scored at 400× magnification by two observers. 
The Y chromosome was considered to be present when a red dot was visible within nuclei 
of similar size, colour, and intensity to those in positive controls. The degree of microchime-
rism in positive samples was scored quantitatively by counting the number of positive nuclei 
and expressing them as the number of positive nuclei per mm2. To correct for differences 
in cell density among organs, image analysis using ImageJ (NIH) was performed to estimate 
the number of nuclei scored on each slide individually.
Because of the potential relationship between tissue injury and microchimerism, the degree 
of injury in each organ was scored semi-quantitatively by a pathologist. Haematoxylin and 
eosin-stained sections of the same tissue blocks on which in situ hybridization of the Y 
chromosome was performed were analysed by light microscopy.  A score for active injury 
was composed of the following criteria: (0) no foci of inflammation, haemorrhage, and 
congestion; (1) minor focal inflammatory infiltrates, small foci of haemorrhage, and/or mild 
congestion; (2) more diffuse inflammatory infiltrates, diffuse signs of haemorrhage, and/or 
moderate congestion; (3) extensive inflammatory infiltrates, extensive haemorrhage, and/
or extensive signs of congestion. Moreover, a score for chronic injury was based on the 
following criteria: (0) no calcifications, fibrosis, and steatosis; (1) minor foci of calcifications, 
fibrosis, and/or steatosis; (2) moderate signs of calcifications, fibrosis, and/or steatosis; (3) 
diffuse calcifications, fibrosis, and/or steatosis.
Statistical analyses 
Fisher’s exact tests were used to compare proportions of organs from pregnant women 
and non-pregnant women that were scored as positive.  To correct for correlations among 
organ measurements within a patient, we used a linear mixed model to compare quanti-
ties of  Y chromosomes in different organs. In our mixed model, we performed analyses 
with organ type and gravidity as fixed effects, as well as conducting separate analyses for 
organ type and maternal death either ante- or postpartum, organ type and gestational 
age, and organ type and either vaginal delivery or Caesarean section. Visual inspection of 
the distribution of residuals was performed to assess normality assumptions. We assessed 
correlations between active and chronic injury scores and number of  Y chromosome-pos-
itive nuclei per million nuclei by calculating Spearman correlation coefficients (ρ). P-values 
<0.05 were considered significant. All analyses were done using SPSS Statistics 20.0 (IBM 




Frequency of male cells in maternal organs 
We performed in situ hybridization of the Y chromosome on 19 lungs, 15 spleens, 19 livers, 
19 kidneys, 5 brains, and 17 hearts. Chimeric cells were found in all organs studied. Table 3 
shows that the proportion of women with male cells in their lungs, spleens, livers, kidneys, 
and hearts was significantly higher in this study of pregnant women with sons than in a 
historic control group of non-pregnant women with sons.8, 9 
Table 3 Fractions of chimeric organs in pregnant versus non-pregnant women.
Organ Pregnant women with sons (%) Non-pregnant women with sons (%) P 
Kidney 16/19 (84) 5/30 (17) <0.0001
Liver 18/19 (95) 6/33 (18) <0.0001
Spleen 15/15 (100) 3/29 (10) <0.0001
Heart 5/17 (29) 0/42 (0) <0.01
Lung 19/19 (100) 10/37 (27) <0.0001
Brain 5/5 (100) - -
Organ distribution of male cells 
For the quantitative analyses of tissue microchimerism, the numbers of Y chromoso-
me-positive cells per section were corrected for area and cell density.  The spleen showed 
the most microchimerism per area with, on average, 0.45 positive Y chromosomes per 
mm2, followed by the lung (0.30/mm2), kidney (0.27/mm2), liver (0.23/mm2), brain (0.06/
mm2), and heart (0.02/mm2). However, after correction for cell density, the lung was most 
chimeric, with an average of 470 Y chromosome-positive nuclei per million nuclei scored. 
The lung was followed by the spleen (208 Y+/106 nuclei), liver (192 Y+/106 nuclei), kidney 
(135 Y+/106 nuclei), brain (85 Y+/106 nuclei), and heart (40 Y+/106 nuclei). Figure 1 shows 
the organ distribution of chimeric cells. 
Lungs contained significantly more Y chromosome-positive cells corrected for cell density 
than any of the other organs studied (lung vs. any organ: P<0.001). Furthermore, the 
spleen and liver were significantly more chimeric than the heart (P=0.032 and P=0.026, 
respectively).
Location and phenotype of chimeric cells
Chimeric cells appeared to be both parenchymal cells and hematopoietic cells. Figure 2 
shows photographs of slides with chimeric cells as observed in the various organs. In lungs, 
chimeric cells were incorporated into the alveolar septa, bronchiolar walls, and blood ves-
sels. In the spleen, chimeric cells seemed to be part of the hematopoietic cell population 
while in livers, chimeric cells resembled hepatocytes and were found in blood vessels. In 
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the kidney, chimeric cells occurred in tubules, glomeruli, and the endothelium of blood 
vessels. Male microchimerism was present in the cerebral cortex of all five women whose 
brain autopsy material was available. In the brain, chimeric cells appeared to be glial cells 
and possibly neurons and were also found in blood vessel endothelium. In hearts, chimeric 
cells resembled cardiomyocytes. 
Double staining was performed on tissue sections showing high positivity after in situ 
hybridization of the Y chromosome from 2 lungs, 1 spleen, 1 liver, 2 kidneys, 1 heart, and 
1 brain. In the lung, spleen, and kidney, some of the chimeric cells were CD3+, and in the 
lung, kidney, and liver, some were CD34+ (Figure 3). Also, following both double staining 
procedures, chimeric cells were found that did not show positivity for CD3 or CD34. In 
some instances, CD34+ chimeric cells lined a vascular wall, which could indicate that they 
are endothelial cells. Some of the CD34+ chimeric cells were found alone, which could 
imply that they have a stem cell phenotype.
Figure 1 Graph showing the numbers of Y chromosome-positive cells in maternal organs.
Lungs contained significantly more Y chromosome-positive cells corrected for cell density than any of the other organs 
studied (lung vs. any organ: P<0.001). * P<0.05. Horizontal lines represent median values, boxes represent 25th and 75th 
percentiles, whiskers represent 10th and 90th percentiles, circles represent outliers. 
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Figure 2 Y chromosome-positive nuclei in the lung (A), spleen (B), liver (C), kidney (D), brain (E), and heart (F).
Arrows indicate positively scored nuclei.
Figure 3 Double-staining by combination of in situ hybridization of the Y chromosome and immunohistochemical staining 
for CD3 and C34.
Cells that were both Y chromosome-positive and CD3+ (A) or CD34+ (B) were identified in kidney sections (A and B), 
as well as lungs, spleens, and livers (not shown). Y chromosome-positive, but CD3– (not shown) or CD34– (B, *) cells 
were also found after double staining.
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Tissue microchimerism in relation to injury
The sections used for the in situ hybridization were given injury scores by a pathologist, 
who identified 15 out of 19 pulmonary sections with signs of active injury (congestion and 
inflammatory infiltrates), while none of the pulmonary sections had chronic injury. Of the 
splenic sections, six out of 15 had signs of acute congestion while none had chronic injury. 
A total of 15 out of 19 hepatic sections had active injury (congestion and inflammatory 
infiltrates), and two out of 19 had chronic injury (steatosis). Three out of 19 renal sections 
with active injury were identified (lymphocytic infiltrate and erythrocytes in tubuli), as well 
as three out of 19 sections with chronic injury (calcifications). From the hearts, five out 
of 17 sections contained active injury (acute ischemia), and one of 17 sections showed 
chronic injury (fibrosis). From the brains, one out of five sections was identified with active 
injury (Purkinje cell degeneration). Neither the active injury score nor the chronic injury 
score was significantly correlated with tissue microchimerism (as expressed by number of 
Y chromosome-positive nuclei per million) when all organs were analysed together (active 
injury: ρ=0.077, P=0.5; chronic injury: ρ=0.017, P=0.9).  Active and chronic injury scores did 
not significantly correlate with quantities of microchimerism in organs studied individually, 
except for a significant correlation between active injury score and tissue microchimerism 
in the kidney (ρ=0.475, P=0.04).
Microchimerism in relation to pregnancy-related characteristics
The number of previous pregnancies did not associate with the amount of microchime-
rism (P=0.9). Women who died during pregnancy had on average more microchimerism 
than women who died after delivery; however, this difference failed to reach statistical 
significance (P=0.4). No relationship was found between gestational age and the amount 
of microchimerism (P=0.7), and the presence of preeclampsia/eclampsia did not differ 
relative to the amount of microchimerism (P=0.6). Only one woman had a known history 
of blood transfusion; therefore, the relationship between tissue microchimerism and blood 
transfusion history could not be evaluated. Women with a vaginal delivery had on average 
more microchimerism than women who delivered by Caesarean section; however, this 
difference was not statistically significant (P=0.1).
DISCUSSION
In this study, we investigated the frequency and distribution of chimeric cells in organs 
in a distinctive cohort of women who died during or shortly after pregnancy and of 
whom autopsy material was available. Male microchimerism occurred significantly more 
often in lungs, spleens, livers, kidneys, and hearts of women pregnant with sons than in 
non-pregnant women who had given birth to at least one son. We showed that some of 
the chimeric cells were CD3+ or CD34+. Moreover, we found a distribution pattern of 
microchimerism across organs of pregnant women that was similar to that identified in 
pregnant mice, with the lung being the organ in which microchimerism presented most 
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often and in greatest abundance.19
If microchimerism were mainly pregnancy-derived, one expected implication would be a 
negative correlation between the postpartum interval and the amount of tissue microchi-
merism. Moreover, because of the circulatory anatomical relationship between mother and 
fetus, the lung would be the candidate organ for having the highest amounts of microchi-
merism, as it contains the first capillary bed through which blood from the placenta passes. 
The current study has yielded two important observations that support the hypothesis 
that tissue microchimerism is mainly pregnancy-derived. First, tissue microchimerism occurs 
with higher frequency during pregnancy than in the years after pregnancy and is thus 
negatively correlated with the postpartum interval. Second, the lung harbours significantly 
more microchimerism than any other organ type after correction for cell density. 
It is fascinating that we found the same distribution pattern of microchimerism across 
organs in our study in humans as in mice during pregnancy,19 with the lungs being the 
organs in which microchimerism presented most often and in greatest abundance, followed 
by the spleen, liver, kidney, and lowest amounts of microchimerism found in the heart and 
brain. Because we corrected our data for cell density, they are comparable to the flow 
cytometry results for mice.19 In mice, frequencies of microchimerism as measured by flow 
cytometry targeting GFP ranged from 0 to 60 GFP-positive cells per million cells. In our 
study, the range of observed frequencies of Y chromosome-positive cells was wider by 
a factor 20, from 0 to 1200 Y chromosome-positive cells per million cells. This difference 
could be explained by differences in pregnancies between mice and humans, such as 
duration, litter size, and uterine anatomy, or by variation in the sensitivity of the detection 
methods. In our study, the amount of microchimerism is likely underestimated because 
not all nucleated male cells will give a Y chromosome-positive signal: in histologic 4 µm 
thick sections, the Y chromosome will be present in approximately 58% of all nuclei.9 Also, 
detection of tissue microchimerism from other sources in our study is limited to microchi-
merism derived from males. Microchimerism was also underestimated by Fujiki et al. using 
GFP in mice as a marker for microchimerism, as on average 48% of pups expressed GFP. 
Several explanations are possible for the distribution of microchimerism across organs. 
One is that fetal cells are passively trapped in the lungs, which contain the first capillary 
bed that cells must cross after entering the uterine venous circulation. Another possible 
explanation is that the distribution of chimeric cells reflects blood flow, as expressed by 
percentage of cardiac output received. In fact, the fractional distribution of cardiac output 
corresponds to the pattern of distribution of chimeric cells across the organs of pregnant 
women, with lungs receiving 100% of cardiac output, followed by the liver (22.7%), kidneys 
(17.5%), brain (11.4%), and heart (4.0%).23 Finally, chimeric cells could be actively accu-
mulated in specific tissues because of favourable microenvironments, much like the “seed 
and soil” theory in cancer studies.24 Accordingly, the high prevalence of microchimerism 
in the spleen and liver may arise from the sequestration of chimeric cells in these tissues. 
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In mice, allogenic fetal cells migrate to the spleen during pregnancy and may continue 
proliferation in the spleen long afterward.25 Numerous studies in humans and mice have 
shown a preferential homing of chimeric cells to sites of injury.26-29 Pregnancy-associated 
cardiovascular events often have significant effects on target tissues, such as the lung30 It 
could therefore be argued that the high prevalence of microchimerism in lungs of deceased 
pregnant women is due to injury. A significant number of our cases died of vascular 
causes such as pulmonary embolism or preeclampsia, in which pulmonary injury could be 
anticipated. Indeed, 15 out of the 19 pulmonary sections contained signs of active injury. 
However, correlations between quantities of chimeric cells corrected for cell density with 
active injury scores were not significant in the lung sections analysed. The only organ with 
a significant correlation between tissue microchimerism and active injury scores was the 
kidney. Of interest, in gentamicin-induced kidney injury, fetus-derived chimeric cells engraft 
in the kidney as tubular cells, suggesting a role in the repair process.27 In the setting of lupus 
nephritis, a repair function of microchimerism was recently supported by the demon-
stration of higher amounts of microchimerism in patients with better renal function.31 It 
is therefore conceivable that the kidney in particular is an organ prone to repair in the 
setting of microchimerism.
Chan et al. recently reported the existence of male microchimerism in the brains of 37 
out of 59 (63%) autopsied women as measured by real-time quantitative PCR, but the 
women included in that study were not pregnant and had an unknown reproductive 
history.32 To our knowledge, we are the first to describe male microchimerism in the 
brains of pregnant women, having identified it in all 5 women studied. Because of small 
sample size, we cannot draw conclusions on increased prevalence of microchimerism in 
the brain during pregnancy. Changes in the permeability of the blood-brain barrier have 
been described during pregnancy and could therefore explain the establishment of a fetal 
cell population in the maternal brain.33 In mice, Fujiki et al. did not observe fetal cells in 
the brain by flow cytometry.19 However, others using PCR have detected GFP+ fetal cells 
in the brains of mouse dams, resembling perivascular macrophages, neurons, astrocytes, 
and oligodendrocytes.34, 35
Our results support a role for microchimerism in several pregnancy-related conditions, 
including autoimmune disease, pregnancy complications, and certain malignancies. In the 
setting of autoimmune disease, the difference between men and women in the incidence of 
autoimmune diseases makes pregnancy-derived microchimerism an intriguing candidate for 
causing these diseases. It has been suggested that chimeric CD3+ cells have a pathogenic 
role in systemic sclerosis by inducing a graft-versus-host-like reaction.36 Because we found 
CD3+ chimeric cells in the tissues of pregnant women, it is possible that acquisition of 
these cells during pregnancy forms the basis for development of autoimmune diseases in 
which chimeric T cells are present. On the other hand, fetal CD34+ chimeric cells have 
been found in the circulation and tissues of healthy women many years after pregnancy, 
without the onset of autoimmunity,6, 37 and may therefore also be seen as innocent bys-
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tanders. Further study is necessary to unravel the impact of fetal cell microchimerism on 
maternal health and should include analysis of microchimerism in different immunologic 
background strains of mice. 
Concluding, we are the first to demonstrate the abundance of microchimerism in diffe-
rent tissues of pregnant women. Because we had a unique opportunity to study a group 
of women who died while pregnant or shortly after delivery, we could demonstrate 
that during pregnancy, a boost of pregnancy-derived chimeric cells is indeed observed in 
women, with a distribution across organs paralleling the distribution identified in a previous 
study in mice. Whether the distribution of chimeric cells across different organs reflects the 
occurrence of disease in these organs, as well as the immunologic mechanisms involved 
in the pathogenesis, will be the subject of ongoing research.
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Microchimerism may play a role in the pathogenesis of systemic lupus erythematosus 
(SLE). Using an innovative technique permitting more sensitive and specific detection of 
chimeric cells than previous studies, we aimed to determine the origin and amount of 
microchimerism in peripheral blood of women with SLE and controls. 
Methods
We investigated the relationship between microchimerism and disease onset, activity, and 
damage accrual. We included 11 SLE patients and 22 controls, their children, and if possible, 
their mothers. Quantitative PCR for insertion-deletion polymorphisms and null alleles was 
used to detect microchimerism in peripheral blood mononuclear cells and granulocytes. 
Results
Microchimerism was detected more often in patients than controls (54.4% vs. 13.6%, 
P=0.03). In 50% of SLE patients with microchimerism, it originated from multiple relatives, 
whereas in controls microchimerism was always derived from one relative.  Microchime-
rism was mostly of fetal origin, and the median number of fetal chimeric cells was 5/106 in 
patients and 2.5/106 in controls (P=0.048). We found no relationship between microchi-
merism and clinical or laboratory parameters. 
Conclusions
Apart from demonstrating that microchimerism occurs more frequently in SLE patients 
than in controls, this study provides novel, thought-provoking evidence that microchime-
rism in SLE can be derived from multiple relatives.
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INTRODUCTION
Microchimerism refers to the presence in an individual of a small number of genetically 
distinct cells of any type, originating from a different zygote. The most common (physio-
logic) source of microchimerism is pregnancy.1 During pregnancy, fetal cells can enter the 
maternal circulation leading to fetal microchimerism in the mother. When maternal cells 
cross the placental barrier to the fetus, this can lead to maternal microchimerism. Preg-
nancies of all terms, including both miscarriages and pregnancies resulting in (live) birth, 
may lead to microchimerism.2-5 
The role of microchimerism in health and disease is unclear. Microchimerism has been 
suggested to play a role in several autoimmune diseases, including systemic lupus erythe-
matosus (SLE).6-9 SLE is an autoimmune disease that mainly affects women and has a peak 
incidence in the reproductive years.10 Studies in mice showed that, in selected parent-to-F1 
combinations, injection of parental lymphocytes in their offspring led to a graft-versus-host 
response and a lupus-like disease.11, 12 These data suggest that pregnancy-acquired micro-
chimerism may be of pathogenic significance in the development of SLE.
Women with SLE have a significantly higher prevalence of fetal Y chromosome-positive 
chimeric cells in tissue than healthy controls.13-15 A number of studies showed that also in 
peripheral blood, there is an increased frequency of fetal microchimerism in SLE patients 
compared to controls,16, 17 whereas other studies showed no differences between patients 
and controls.18, 19 Previous studies on fetal microchimerism in SLE were limited to the detec-
tion of male microchimerism, thereby underestimating the total amount of microchimerism. 
Furthermore, because microchimerism was mostly studied in whole blood, the phenotype 
of the chimeric cells could not be determined. Maternal microchimerism in SLE in peripheral 
blood was studied by Kanold et al., and they did not find a difference between patients and 
controls.20 However, their sensitivity of detecting chimeric cells was relatively low.  In none of 
these studies were fetal and maternal microchimerism investigated together.
The aim of our study was to determine the presence and amount of microchimerism in 
peripheral blood of SLE patients and compare it to healthy controls. We studied peripheral 
blood mononuclear cells (PBMCs) and granulocytes separately to determine if microchi-
merism was present in either subset, or both. In our study we used insertion-deletion 
polymorphisms (indels) or null alleles for the detection of microchimerism, thus enabling 
us to study the origin of the chimeric cells: either fetal, maternal, or both. Also, we were 
able to establish whether microchimerism was derived from one relative or from multiple 
relatives. Furthermore, in order to find a clue as to the role of microchimerism in SLE, 
we investigated the relationship between disease activity and accumulated damage since 
the onset of SLE, and the presence of microchimerism. Finally, the temporal relationship 





This study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center (LUMC) (P09.047). All research was conducted in accordance with the 
ethical research standards of the LUMC and in compliance with the Declaration of Helsinki. 
Informed consent was obtained from all participants. The parents of minors gave written 
consent on their behalf. 
Patients and controls
Eleven female SLE patients and 22 female controls were studied. From 2010 to 2015 
SLE patients were recruited from four hospitals in the Netherlands: University Medical 
Center Groningen, Radboud University Medical Center Nijmegen, Bronovo Hospital 
The Hague, and Meander Medical Center Amersfoort. All included patients fulfilled at least 
four of the 1998 revised American College of Rheumatology Criteria for the classification 
of SLE.21 SLE disease activity was determined using the SLE Disease Activity Index 2000 
(SLEDAI-2K).22 Accumulated damage since SLE onset was measured using the Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology Damage Index 
(SDI).23 The control group consisted of women without a history of autoimmune disease. 
For inclusion in the study, probands (SLE patients and controls) were required to have at 
least one child of at least 18 years old. The probands’ children, as well as their mothers, were 
invited to participate. Peripheral blood samples were gathered from the probands, as well as 
either peripheral blood samples or buccal mouth swabs from their children and mothers.  All 
probands were asked to fill out a questionnaire including their age, ethnicity, reproductive his-
tory, history of blood transfusion, use of immunosuppressive medication, and medical history. 
Isolation of peripheral blood subsets
Peripheral venous blood samples were drawn in sodium-heparin solution vacutainer tubes 
(Becton Dickinson, Franklin Lakes, New Jersey) and processed to isolate peripheral blood 
mononuclear cells (PBMCs) by Ficoll amidotrizoate (pharmacy LUMC) with density gra-
dient centrifugation 1.077 g/mL. Erythrolysis (Qiagen, Hilden, Germany) was performed to 
remove the erythrocytes from the remaining granulocytes. Samples were stored in 10% 
dimethyl sulfoxide in fetal bovine serum at –180 °C until DNA extraction.
DNA extraction
DNA was extracted from PBMCs and granulocytes using the QIAamp DNA Blood Mini 
Kit (Qiagen) according to the manufacturer’s instructions with modifications. Briefly, we 
added 40 µL of proteinase K to 5*106 cells suspended in 200 µL phosphate-buffered 
saline. After adding 400 µL AL buffer, the suspension was incubated for 30 min (PBMCs) 
or overnight (granulocytes) at 56 °C. After adding 200 µL of ethanol, the mixture was 
applied to the Mini spin column. Buffers AW1 and AW2 were used to wash the column, 
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after which 100 µl AE buffer was added and incubated at 70 °C for 10 minutes to elute 
the DNA. The eluate was reapplied for an optimal yield. All DNA samples were stored at 
4 °C until quantitative PCR (qPCR). DNA extraction from buccal sterile OmniSwabs (GE 
Healthcare Life Sciences, Little Chalfont, United Kingdom) was performed with the same 
kit and according to the manufacturer’s instructions.
Allele informativity and genotyping
For the detection of fetal and maternal microchimerism a set of previously published indels 
and null alleles was used.24-26 In order to detect fetal and maternal microchimerism in the 
proband, and to discriminate between the proband’s children and mother, informative 
alleles to distinguish the different family members were required. Maternal DNA was 
available for six of 11 patients and eight of 22 controls. There was no fetal DNA available 
for any of the miscarriages. Genotyping by qPCR was performed using the same protocol 
as described below, but with a DNA input of 20 ng. Of the published sets of null alleles 
and indels, 19 were informative in our study population: GSTM1, GSTT1, SRY, RhD (null 
alleles), and S01a, S01b, S03, S04a, S04b, S05b, S07b, S08b, S09b, S10a, S10b, S11a, S11b, 
Xq28 and R271 (indels). The primer sequences are listed in Appendix 8.1. 
Detection of chimerism by qPCR
Fetal and maternal microchimerism were detected and quantified by qPCR. In all assays 
iQ SYBR Green Supermix (Bio-Rad, Hercules, California) was used, with 7.5 µM of each 
amplification primer.  The amplification and melting conditions for all primers consisted of 
incubation at 96.5 °C for 10 min, followed by 44 cycles of 96.5 °C for 30 s and 60 °C for 
1 min. The melting curve started at 65 °C for 5 s followed by 0.2 °C incremental increase, 
each lasting 5 s, to 95 °C.  Amplification and melting data were collected by a Bio-Rad 
CFX96 detector and analysed by Bio-Rad CFX Manager version 3.1. 
Primer specificity was ensured by Sanger sequencing of the amplification product and 
comparing the sequences to known genomic DNA sequences. Sensitivity was determined 
by testing serial dilutions of DNA positive for the indel or null allele in a background of 
DNA negative for the respective indel or null allele.  A sensitivity of one genome equivalent 
(gEq, based on 6.6 pg DNA content per cell) in 100,000 gEq was reached for all primersets. 
Four aliquots, each containing 660 ng DNA (100,000 gEq), were tested in each subset 
(PBMC or granulocytes) for every proband.  A standard curve for the specific assay was 
included to quantify the chimeric cells and validate the assay on each plate. The standard 
curve consisted of 100, 10, and 1 gEq spiked DNA per 100,000 gEq background DNA. 
Every sample was also tested for the housekeeping gene GAPDH. Results were expressed 
as the gEq of chimeric cells per one million gEq (gEq/106). Negative controls consisting 
of either a water control or background DNA not carrying the indel or null allele tested, 
were included in each qPCR plate. Negative controls were consistently negative across all 
experiments. If there was any doubt as to the specificity of the amplification product, the 
length of the PCR product was compared to that of the positive control using QIAxcel 




Strict anti-contamination procedures were employed during blood workup, DNA extrac-
tion, and qPCR preparation. Aerosol-resistant pipette tips and clean gloves were always 
used. The blood workup was performed in a laminar flow cabinet. Before DNA extraction 
or preparation of the qPCR, the cabinet used was thoroughly cleaned with DNA decon-
tamination reagent (Sigma-Aldrich, St. Louis, Missouri), and irradiated with UV light for one 
hour. All lab consumables were certified DNA free, and also irradiated with UV light for 
one hour. For the qPCR, 8-well strips with individual lids were used.
Statistical analysis
For the comparison of categorical data, Fisher’s exact tests were used (history of blood 
transfusion, presence of microchimerism). Student’s t-tests were used to compare normally 
distributed data (age proband, age eldest child, age youngest child, SDI). For the comparison 
of non-normally distributed numerical data, Mann-Whitney U tests were used (number of 
pregnancies, number of children, number of chimeric cells, SLEDAI-2K). A P-value <0.05 
was considered statistically significant. All analyses were performed using SPSS Statistics 
20.0 (IBM, Armonk, New York).
RESULTS
Baseline characteristics of patients and controls are shown in Table 1. SLE patients had 
microchimerism more often than controls (54.4% vs. 13.6%, P=0.03). When microchime-
rism was present, the median total number of fetal chimeric cells per proband was higher in 
the patient group than in the control group (5 gEq/106 vs. 2.5 gEq/106 [P=0.048]) (Table 2). 
When comparing patients and controls with and without microchimerism, there was no 
difference in age, number of children, number of pregnancies, history of blood transfusion, 
disease activity (SLEDAI-2K) or accumulated damage since disease onset (SDI) (Table 3). 
Also, there was no difference in the use of immunosuppressive medication between 
patients with and patients without microchimerism (data not shown).
All patients and controls, except one, with detectable microchimerism had fetal microchi-
merism (Table 4). Of the eight controls with maternal DNA available, one had detectable 
maternal microchimerism. Of the six SLE patients with maternal DNA available, one had 
detectable maternal microchimerism, three did not, and of two the possible maternal 
microchimerism was indistinguishable from the fetal microchimerism that was present, 
due to an overlap in indels and null alleles. 
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Table 1 Baseline characteristics of SLE patients and controls.
Characteristic SLE patients (n=11) Controls (n=22) P
Age proband, y 56.6 ± 5.5 57.2 ± 5.5 0.79a
Age eldest child, y 31.4 ± 5.2 28.9 ± 5.7 0.24a
Age youngest child, y 27.5 ± 5.3 24.4 ± 4.9 0.11a
Number of children 2 (1) 2 (1) 0.60b
Number of pregnancies 3 (2) 2.5 (1) 0.37b
History of blood transfusion, % 72.7 13.6 0.001c
SLEDAI-2K 0 (4) - n/a
SDI 2.2 ± 2.3 - n/a
Results are shown as mean ±SD or as median (interquartile range), unless otherwise specified. P-values were assessed 
with a Student’s t-test, b Mann-Whitney U test, or c Fisher’s exact test. SLE, systemic lupus erythematosus; SLEDAI-2K, SLE 
Disease Activity Index 2000; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology 
Damage Index.
Table 2 Microchimerism in SLE patients and controls.
Parameter SLE patients (n=11) Controls (n=22) P
Microchimerism present in PBMCs or granulocytes, % 54.5 13.6 0.03a
Microchimerism present in PBMCs, % 36.4 9.1 0.15a
Microchimerism present in granulocytes, % 40.0 (n=10) 10.0 (n=20) 0.14a
Total number of fetal chimeric cells/proband, when 
microchimerism is present, gEq/106 gEq
5 (8.1) (n=6) 2.5 (n/a) (n=3) 0.048b
Results are shown as median (interquartile range), unless otherwise specified. P-values were assessed with a Fisher’s exact 
test or b Mann-Whitney U test. gEq, genome equivalents; n/a, not applicable because number of cases is too low to provide 
an interquartile range; PBMCs, peripheral blood mononuclear cells; SLE, systemic lupus erythematosus.















Age proband, y 57.4 ± 5.2 56.0 ± 6.3 0.70a 57.6 ± 5.6 54.3 ± 4.3 0.33a
Number of children 2 (1) 2.5 (1.25) 0.84b 2 (1) 3 (n/a) 0.44b
Number of pregnancies 2 (1.5) 3.5 (2) 0.33b 2 (1) 3 (n/a) 0.71b
Blood transfusion, % 60.0 83.3 0.55c 10.5 33.3 0.37c
SLEDAI-2K 0 (2.5) 2 (5.5) 0.37b - - -
SDI 1.8 ± 2.0 2.5 ± 2.6 0.64a - - -
Results are shown as mean ± SD or as median (interquartile range), unless otherwise specified. P-values were assessed 
with a Student’s t-test, b Mann-Whitney U test, or c Fisher’s exact test. n/a, not applicable because number of cases is too 
low to provide an interquartile range; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SDI, 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
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Table 4 Origin of microchimerism in patients and controls.
Subject Relativesa Chimerism in PBMCs Chimerism in granulocytes Blood transfusion history SLEDAI-2K SDI
Origin Amount, gEq/106 Origin Amount, gEq/106
Patients
1 Mother, daughter 1, miscarriage (n/a), daughter 2, son Mother





n/a n/a Yes 10 4
2 Mother, daughter 1, 2 and 3 Daughter 1 5 Daughter 3






3 Mother, daughter, son Son 2.5 Daughter, and possibly mother 2.5 Yes 0 (1st blood 
drawb) 
2
- - 0 (2nd blood 
drawb)
2
4 Mother (n/a), miscarriages 1, 2 and 3 (n/a), daughter - - Daughter 15 Yes 4 7
5 Mother (n/a), daughter 1 (deceased, n/a), miscarriage (n/a), daughter 
2 (n/a), daughter 3
- - Daughter 3 5 Yes 0 1
6 Mother (n/a), son, daughter Daughter 5 - - No   0 1
Controls
1 Mother (n/a), daughter 1 and 2, son Daughter 2 2.5 Daughter 2 2.5 Yes - -
2 Mother (n/a), daughter, son - - Daughter 2.5 No - -
3 Mother, daughter 1, daughter 2, son Mother 2.5 - No - -
a Chronologically from old to young based on year of birth/miscarriage. b due to technical problems with the material from the 
first blood draw, a second blood draw was done approximately 1 year later. gEq, genome equivalent; n/a, no DNA available; 
PBMCs, peripheral blood mononuclear cells; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SDI, 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
Also, we determined if the microchimerism originated from one relative or more. In all 
three controls with detectable microchimerism, it originated from one relative (either one 
child or mother). In contrast, in at least three of the six SLE patients the microchimerism 
originated from more than one relative, either from multiple children or from a child and 
mother (Table 4). 
Finally, in patients with detectable microchimerism, we did not find a pattern in the temporal 
relationship between chimerism-causing pregnancies and the start of symptoms or diagnosis 
of SLE. One patient had her first symptoms prior to her first pregnancy, and experienced 
an exacerbation of symptoms during her first pregnancy, which resulted in a spontaneous 
miscarriage. Two patients experienced their first symptoms during their second pregnancy. In 
one of these patients, this pregnancy resulted in a spontaneous miscarriage. Therefore, it could 
not be determined if this pregnancy resulted in long-lasting microchimerism. In the other of 
the two patients, both her first and second pregnancy resulted in long-lasting microchimerism. 
Finally, three of six patients experienced their first symptoms one, seven, and ten years after 
the birth of their youngest child of whom microchimerism was detected.
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Table 4 Origin of microchimerism in patients and controls.
Subject Relativesa Chimerism in PBMCs Chimerism in granulocytes Blood transfusion history SLEDAI-2K SDI
Origin Amount, gEq/106 Origin Amount, gEq/106
Patients
1 Mother, daughter 1, miscarriage (n/a), daughter 2, son Mother





n/a n/a Yes 10 4
2 Mother, daughter 1, 2 and 3 Daughter 1 5 Daughter 3






3 Mother, daughter, son Son 2.5 Daughter, and possibly mother 2.5 Yes 0 (1st blood 
drawb) 
2
- - 0 (2nd blood 
drawb)
2
4 Mother (n/a), miscarriages 1, 2 and 3 (n/a), daughter - - Daughter 15 Yes 4 7
5 Mother (n/a), daughter 1 (deceased, n/a), miscarriage (n/a), daughter 
2 (n/a), daughter 3
- - Daughter 3 5 Yes 0 1
6 Mother (n/a), son, daughter Daughter 5 - - No   0 1
Controls
1 Mother (n/a), daughter 1 and 2, son Daughter 2 2.5 Daughter 2 2.5 Yes - -
2 Mother (n/a), daughter, son - - Daughter 2.5 No - -
3 Mother, daughter 1, daughter 2, son Mother 2.5 - No - -
a Chronologically from old to young based on year of birth/miscarriage. b due to technical problems with the material from the 
first blood draw, a second blood draw was done approximately 1 year later. gEq, genome equivalent; n/a, no DNA available; 
PBMCs, peripheral blood mononuclear cells; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SDI, 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
DISCUSSION 
Our study demonstrates that female SLE patients have detectable microchimerism in 
their peripheral blood more often than female controls. In almost all cases with detectable 
microchimerism, the origin of the chimeric cells was fetal. Additionally, in one patient and 
one control, maternal microchimerism was detected. The median total number of fetal 
chimeric cells in individuals with detectable microchimerism was higher in patients than 
in controls. Also, SLE patients often had chimeric cells originating from multiple relatives, 
in contrast to the controls, in whom the chimeric cells originated from only one relative. 
In accordance with our results, two previous studies found fetal microchimerism in perip-
heral blood more often in SLE patients than in controls,16, 17 while two other studies did 
not.18, 19 Differences in the blood compartment tested (PBMCs or whole blood), the 
specificities and sensitivities of the different techniques used, and the numbers of patients 
and controls included, may account for these conflicting results. In contrast to our study, 
previous studies did not demonstrate a difference between SLE patients and controls 
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in the number of chimeric cells present. However, a limitation of these studies was that 
exclusively the presence of the Y chromosome was investigated, thereby only detecting 
male microchimerism. Our approach allowed us to detect both male and female fetal 
microchimerism, as well as maternal microchimerism. If, in our present study, we had only 
investigated microchimerism using the Y chromosome in women with at least one son, we 
would not have found a statistically significant difference in the occurrence of microchi-
merism between patients and controls (data not shown). Only one study investigated the 
presence of maternal microchimerism in SLE and found no difference between patients 
and controls with maternal microchimerism occurring in 6% and 3%, respectively.20 This 
low prevalence of maternal microchimerism is in accordance with our results.
In the literature, there are indications that within one individual some sources of microchi-
merism lead to persistent microchimerism, while others do not. In one case report about 
a woman with hepatitis C, the detected chimerism in the liver seemed to originate from 
only one of her five pregnancies.27 Also, after blood transfusions, it was shown that in the 
majority of cases with transfusion-associated microchimerism, there was evidence of only 
one or two non-recipient HLA-DR alleles, suggesting that the microchimerism commonly 
involves only one donor despite some patients receiving blood products from multiple 
donors.28 However, in women with multiple children, it has not been systematically studied 
if there is a “favored-child” with regard to the persistence of microchimerism, i.e. if fetal 
microchimerism usually originates from one of the children, or from more children. Because 
we used indels and null alleles for the detection of microchimerism, we were able to show 
that at least half of the patients had persistent microchimerism from multiple relatives 
while all controls only had persistent microchimerism from one relative. The cause of this 
phenomenon is largely unknown. Studies in animals have demonstrated that syngenic or 
congenic matings resulted in more chimerism than allogenic matings, suggesting a role for 
HLA (mis)matches.29, 30 In humans, in certain autoimmune diseases mothers and children 
were shown to have fewer HLA disparities,31, 32 but these have not yet been significantly 
correlated to the presence of microchimerism.31 Nevertheless, having a certain HLA allele 
(HLA DQA1*0501) appears to be associated with the presence of fetal microchimerism.33, 
34 Interestingly, HLA DQA1*0501 has also been associated with SLE.35
The phenotype of a chimeric cell may affect the potential of a chimeric cell to result in to 
persistent microchimerism. We detected microchimerism in both PBMCs and granulocytes. 
Considering the relatively short half-life of granulocytes,36 it is likely that the chimeric cells 
detected in this compartment are derived from stem cells. The existence of chimeric fetal 
progenitor cells was demonstrated in several studies (reviewed by Seppanen et al.37). A 
higher prevalence of microchimerism in SLE patients than in controls can either mean that 
(i) more chimeric cells were acquired during pregnancy, (ii) more chimeric cells persisted 
after pregnancy, (iii) chimeric stem cells gave rise to more chimeric cells due to an unknown 
trigger, or (iv) a combination of aforementioned possibilities. 
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SLE patients had a blood transfusion in their history significantly more often than controls. 
However, within the groups of SLE patients and controls, we did not find a difference in 
blood transfusion history between subjects with and subjects without detectable microchi-
merism. In the literature, persistent chimerism was only described after blood transfusion 
following traumatic injury (reviewed by Bloch et al.38), which was not the indication for a 
blood transfusion in any of our subjects. Furthermore, a recent study in patients having 
received a blood transfusion in the peripartum period, like some of our subjects, did 
not show microchimerism at six weeks and six months after pregnancy.39 Therefore, it 
is unlikely that the difference in blood transfusion history between patients and controls 
explains our results.
In our study there was no difference in disease activity (SLEDAI-2K) or accumulated damage 
(SDI) between patients with and without microchimerism. The former result is in line with a 
previous study.19 Possible reasons for these findings are the absence of such associations or 
the small sample size.  Also, many of the SLE patients were in clinical remission. 
A limitation of our study is that we did not have maternal DNA available for all subjects. 
This means that we could not exclude a maternal source of the microchimerism in all 
cases. In a few patients of whom we did have maternal DNA available, it was not always 
possible to distinguish maternal microchimerism from the detected fetal microchimerism, 
due to an overlap in genetic markers. Furthermore, it was not possible to formally exclude 
all possible sources of microchimerism, such as unrecognised pregnancies or spontaneous 
abortions of which DNA was unavailable.
In summary, we detected microchimerism in peripheral blood more often and in higher 
numbers in female SLE patients than in female controls. The microchimerism detected was 
predominantly fetal in origin and was found in both PBMCs and granulocytes. Interestingly, 
this study provides the first evidence that SLE patients can have chimeric cells from mul-
tiple relatives, while all of the chimeric controls had chimeric cells from only one relative. 
Attempts to explain this phenomenon are speculative. It may depend on the immune 
response evoked by specific chimeric cells, possibly relating to HLA, or on the activation 
status of the immune system of the recipient in general. Future studies addressing the 
immunologic aspects of this phenomenon are called for. The exact role of chimeric cells 
in SLE is still unknown, but our data substantiate the hypothesis that chimeric cells do play 
a role in SLE.
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Summary and General discussion
SUMMARY
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease causing damage 
in multiple organ systems.  As a consequence, the clinical manifestations and outcomes 
of SLE are remarkably heterogeneous. In this thesis, issues relating to the diagnosis and 
prognosis of SLE were studied, focusing on the application of histopathologic evaluation in 
conjunction with clinical features in the setting of lupus nephritis (LN) and neuropsychiatric 
SLE (NP-SLE) in an effort to advance personalised medicine in SLE. 
Given the protean manifestations of SLE, the list of differential diagnoses is extensive. Tradi-
tionally, classification criteria for SLE have been developed to distinguish patients with SLE 
encountered in rheumatology clinics from other patients with mainly rheumatic diseases. 
Given the heterogeneity of SLE, it is not unthinkable that the performance of these criteria 
in patients presenting at nephrology clinics is different. In the first part of this thesis, issues 
concerning the diagnosis of LN were investigated in the setting of nephritis patients with full 
house glomerular immune deposits – a finding considered to be very characteristic of LN. 
In chapter 2, the diagnostic performance of the Systemic Lupus International Collaborating 
Clinics (SLICC) classification criteria as compared to the American College of Rheumatology 
(ACR) criteria was investigated in a cohort of patients with full house glomerular deposits, 
aiming to resolve whether such patients can reliably be classified as having SLE using the 
SLICC criteria. Hundred forty-nine patients with full house glomerular immune deposits 
were identified, 117 of whom had clinical SLE, and 32 had membranous nephropathy 
(anti-PLA2R-positive, n=1; cancer-related, n=3), IgA nephropathy (n=4), infection-related 
glomerulonephritis (n=2), anti-neutrophil cytoplasmic antibody (ANCA)-associated glo-
merulonephritis (n=2), and idiopathic non-lupus full house nephropathy (n=20). The SLICC 
classification proved to be useful with regard to diagnostic sensitivity among these patients, 
since all 117 patients with clinical SLE fulfilled the SLICC classification criteria. The ACR 
criteria had a lower sensitivity in this setting (95%), the difference being that the SLICC 
criteria include hypocomplementaemia, whereas the ACR criteria do not. However, of the 
117 SLE patients, none were classified as SLE according to the SLICC criteria because 
of its “stand-alone” criterion that allows classification of SLE in patients with biopsy-con-
firmed LN in combination with antinuclear or anti-double stranded DNA antibodies. Of 
the 32 patients with biopsies showing full house glomerular deposits and findings by light 
microscopy consistent with LN without clinical SLE, three met the SLICC criteria for SLE 
because of its “stand-alone” criterion, and none met ACR criteria. These findings sup-
port the usefulness of SLICC criteria with regard to diagnosing SLE among patients with 
nephritis, although the superior performance of the SLICC criteria (compared to the ACR 
criteria) was attributed to hypocomplementaemia as a criterion in the SLICC classification 
and not due to the “stand-alone” criterion.
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Chapter 3 involves the same cohort of patients with full house glomerular immune 
deposits as was investigated in chapter 2. Chapter 3 is focused on the distinction bet-
ween patients with nephritis and a renal biopsy showing full house glomerular immune 
deposits in the setting of clinically confirmed LN (lupus full house nephropathy [FHN]) 
and patients with this finding who do not have SLE and for whom the cause of full house 
immune deposits is idiopathic (idiopathic non-lupus FHN). In this chapter, a special focus 
is on the clinical, histopathologic, and prognostic differentiation between lupus and idio-
pathic non-lupus FHN, aiming to answer the question whether lupus and non-lupus full 
house nephropathy are clinically distinct entities. Of the 32 patients with non-lupus FHN, 
20 patients had idiopathic non-lupus FHN, and in 12 patients secondary non-lupus FHN 
due to membranous nephropathy, IgA nephropathy, infection-related glomerulonephri-
tis, and ANCA-associated glomerulonephritis was considered. Remarkable differences 
between lupus and idiopathic non-lupus FHN patients were noted: idiopathic non-lupus 
FHN patients were more frequently male, their renal biopsies more often showed a 
mesangial or membranous pattern of injury, and clinically they had more proteinuria, less 
erythrocyturia, and less complement consumption than lupus FHN patients. Most notably, 
multivariable analysis of patients with a LN class III or IV pattern of injury revealed that 
idiopathic non-lupus FHN compared to lupus FHN was an independent risk factor for 
end-stage renal disease. These results indicate that FHN is a pattern of renal injury most 
often encountered in SLE, but may also rarely be seen idiopathically as well as in a number 
of other diseases. The clinical recognition and distinction of idiopathic non-lupus FHN from 
lupus FHN is critical given the poor renal outcome of idiopathic non-lupus FHN. 
Like SLE itself, renal manifestations of the disease are highly variable in their clinical presen-
tation and outcome – as outlined in the second part of this thesis. This clinical variability 
parallels the broad spectrum of histopathologic abnormalities present in the renal biop-
sies of patients with LN. The glomerular histopathologic findings in renal biopsies of SLE 
patients are categorised according to the International Society of Nephrology/Renal Patho-
logy Society (ISN/RPS) classification of LN. The most severe classes of LN – class III and 
class IV – are defined as renal biopsies showing fewer or more than 50% of glomeruli with 
endo- and/or extracapillary hypercellularity by light microscopy.1 According to the current 
treatment guidelines for LN, patients with class III or IV LN – who are presumed to be at 
high risk of progression to end-stage renal disease – require aggressive immunosuppressive 
therapy consisting of a combination of corticosteroids and intravenous cyclophospha-
mide or mycophenolate mofetil. The categorisation of classes III and IV in the ISN/RPS 
classification reflects the notion that the severity and prognosis of LN are a function of 
the proportion of glomerular involvement and that there is a pathologic continuum from 
focal segmental to diffuse global glomerulonephritis. However, studies have shown that 
the lesions defining class III and IV LN themselves represent pathogenically heterogeneous 
lesions, with qualitatively and quantitatively different lesions of varied chronicity correspon-
ding to different clinical outcomes.2 The hypothesis that the definitions and assumptions 
inherent to the ISN/RPS classification may mask prognostic and pathogenic information 
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was investigated in chapters 4 and 5 of this thesis.
In chapter 4, the natural history of class III and IV LN was investigated, aiming to identify a 
subgroup of patients with a favourable prognosis eligible for treatment without cytotoxic 
immunosuppression. Hundred one patients with class III or IV LN were identified, three of 
whom did not receive cytotoxic immunosuppression according to guidelines. These three 
patients showed a favourable disease course during a follow-up period of 9–24 years. 
Importantly, the course of renal function during 10 years of follow-up in these three under-
treated patients was not different from that of 98 patients with class III or IV LN from the 
same historic cohort who received guideline-recommended immunosuppression. These 
three patients provide evidence for the existence of a subgroup of patients with class III or 
IV LN with a favourable natural history. Thus, current guidelines risk overtreatment of LN 
patients by considering patients with class III or IV LN to be representative of a category 
uniformly requiring cytotoxic immunosuppression and by disregarding clinical parameters. 
In chapter 5, the hypothesis that the lumped classes in the ISN/RPS classification may 
mask prognostic and pathogenic information was further explored by breaking down this 
classification and studying individual clinical and histopathologic variables in relation to renal 
outcome without preconceptions. Hundred five patients with class I–V LN were identified, 
and 50 histopathologic and 10 clinical variables were determined as candidate predictors 
for renal outcome. The results from this study clearly show that prognostication in LN 
may benefit from the specific assessment of lesions currently obscured in the classification. 
Normal glomeruli, cellular/fibrocellular crescents, fibrous crescents, and IF/TA were potent 
determinants of eGFR during follow-up. In addition, fibrous crescents, fibrinoid necrosis, 
and interstitial fibrosis or tubular atrophy predicted progressive renal function decline in 
the uniformly treated subset of patients with class III or IV LN. Importantly, these findings 
hint that these lesions were unresponsive, or incompletely responsive to the therapies 
given. Furthermore, clinical variables including ethnicity, age, renal function at baseline, and 
blood pressure may improve prognostication, warranting integration in clinical guidelines 
alongside the histopathologic classification of LN.
Whereas in LN knowledge about pathogenic mechanisms is central in establishing a his-
topathologic diagnosis and predicting the prognosis, little is known about the pathogenesis 
of NP-SLE. A major difficulty in the diagnosis of NP-SLE is the lack of clear diagnostic 
definitions, caused by a lack of pathognomonic features, inadequacy of diagnostic tools, 
and a vast heterogeneity of clinical symptoms. Due to the impracticability of performing 
a brain biopsy, histopathologic studies elucidating pathogenic mechanisms are limited, and 
a tissue diagnosis is generally not possible. 
In the setting of NP-SLE, the complement system as a pathogenic mechanism in NP-SLE 
was investigated to provide a possible link between thromboischemic injury observed in 
NP-SLE and autoantibody-mediated injury characteristic of SLE. In chapter 6, the presence 
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of classical complement deposition in cerebral tissue of patients with NP-SLE was exa-
mined, and the association between complement and thromboischemic cerebral injury 
was assessed. Cerebral autopsy tissue was collected from SLE patients with and without 
NP-SLE, as well as from controls. Complement deposition was strongly associated with 
both SLE and NP-SLE, but not with controls. The results from this study demonstrate that 
histopathologic lesions in NP-SLE represent a continuum, ranging from nonspecific lesions 
such as focal vasculopathy, to more specific lesions including diffuse vasculopathy, microin-
farction, macroinfarction, vasculitis, and C4d- and C5b-9-associated microthrombi related 
to clinical syndromes defining NP-SLE. Interestingly, the results from this study indicate that 
complement may be a key factor in the interaction between circulating autoantibodies and 
thromboischemic injury in NP-SLE and may have novel therapeutic potential. Furthermore, 
in one SLE and two NP-SLE patients, the correlation between cerebral post-mortem his-
topathology and ex vivo 7-Tesla MRI was investigated to evaluate whether histopathologic 
lesions may be detected clinically. 7-Tesla MRI could not detect most microvascular injury 
that was visible histopathologically, which is consistent with the clinicoradiological paradox 
of clinical symptoms in the absence of radiological findings by conventional MRI.  Thus, 
more accurate diagnostic tools for NP-SLE are warranted. 
Since making a diagnosis based on a common aetiology provides the highest level of 
conceptual understanding, we investigated microchimerism as a potential aetiologic factor 
involved in SLE. To substantiate ongoing research relating microchimerism to SLE, as well 
as to other autoimmune diseases, pregnancy complications, malignancies, response to 
injury, and transplantation outcomes, the occurrence and distribution of tissue microchi-
merism during human pregnancy was investigated in chapter 7. In situ hybridization of 
the Y chromosome was performed on paraffin-embedded autopsy samples of kidneys, 
livers, spleens, lungs, hearts, and brains that were collected from 26 women who died 
while pregnant or within one month after delivery of a son. Frequencies of chimeric cells 
were compared to those of a control group of non-pregnant women who had delivered 
sons.  Tissue microchimerism occurred significantly more frequently in lungs, spleens, livers, 
kidneys, and hearts of pregnant women than non-pregnant women. Remarkably, this dis-
tribution pattern replicates findings in pregnant mice, with the lungs being the organs in 
which microchimerism was present most often and in greatest abundance, followed by the 
spleen, liver, and kidney, with lowest amounts of microchimerism found in the heart and 
brain. Intriguingly, some of the chimeric cells were CD3+ or CD34+. Corrected for cell 
density, the lung was most chimeric, followed by the spleen, liver, kidney, brain, and heart. 
Data from this unique study group of women who died while pregnant or shortly after 
delivery provide important information about the amount and physiologic distribution 
of chimeric cells in organs of pregnant women and validate the use of mouse models to 
study microchimerism during pregnancy. 
 179
9
Summary and General discussion
In chapter 8, the relationship between microchimerism and SLE was further studied by 
investigating the origin and amount of microchimerism in peripheral blood of women 
with SLE and controls, as well as the relationship between microchimerism and SLE onset, 
disease activity, and damage accrual. Eleven SLE patients and 22 controls were included, as 
well as their children and, if possible, their mothers. Quantitative PCR for insertion-deletion 
polymorphisms and null alleles was used to detect microchimerism in peripheral blood 
mononuclear cells and granulocytes. Microchimerism was detected more often in patients 
than controls (54.4% vs. 13.6%) and was found in both peripheral blood mononuclear cells 
and granulocytes. In 50% of SLE patients with microchimerism, it originated from multi-
ple relatives, whereas in controls microchimerism was always derived from one relative. 
Microchimerism was mostly of fetal origin. No relationship was found between microchi-
merism and clinical or laboratory parameters. These results substantiate the hypothesis 
that chimeric cells play a role in SLE and provide novel, thought-provoking evidence that 
microchimerism in SLE can be derived from multiple relatives.
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GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES
In the early days of medicine, systemic lupus erythematosus (SLE) was diagnosed based 
upon a constellation of observable clinical findings in predominantly young females showing 
similar clinical courses. With advancing knowledge and techniques, it became possible to 
diagnose SLE more specifically – reflecting a higher level of conceptual understanding 
of underlying pathophysiology. Because of the frequently poor outcome of SLE patients, 
scientists have long searched to identify prognostic indicators at the time of diagnosis, 
which may inform the patient and the physician about the preferred therapeutic strategy 
and expected outcomes, and may also be modifiable targets for treatment. In the case of 
lupus nephritis (LN), a renal biopsy currently plays a central role in the diagnostic process. 
For LN, a renal biopsy currently provides the best reflection of the severity of the disease 
process and often allows the exclusion of other diagnoses. Furthermore, a renal biopsy 
may provide a wealth of prognostic information and identify patients who are most likely 
to benefit from treatment. However, the central role of the renal biopsy in the diagnosis 
of LN may not result in the overlooking of clinical findings: clinical factors may be valuable 
predictors of outcome, not all histopathologic lesions may have prognostic significance, and 
not all lesions that resemble LN may clinically represent SLE. This has important implicati-
ons for clinical practice and scientific research: a renal biopsy must always be interpreted 
in the setting of the clinical picture; and, in studying LN renal pathology, biopsy findings 
must always be interpreted in relation to clinical outcomes. In strong contrast with LN, 
neuropsychiatric SLE (NP-SLE) is a manifestation for which the performance of a biopsy 
of the affected tissue (the brain) is hardly feasible, and the pathology must therefore be 
assessed by less accurate diagnostic tools including radiological imaging. Nevertheless, 
the post-mortem histopathologic analysis of cerebral tissue is valuable to unravel patho-
genic mechanisms. In this thesis, challenges relating to diagnosis and prognosis based on 
histopathologic findings in conjunction with clinical findings were investigated in two of 
the most severe manifestations of SLE: LN and NP-SLE – the results and implications for 
personalised medicine of which will be discussed here.
The diagnosis of LN
Has the time come for diagnostic criteria for SLE?
The first challenge addressed in chapter 2 of this thesis relates to the diagnosis of SLE 
focusing on patients with renal disease. Since diagnostic criteria are absent for SLE, clas-
sification criteria for SLE are of central importance – allowing physicians to arrange the 
heterogeneous manifestations of SLE into comprehensive categories for research purposes 
and provide a means for communication. Ideally, a classification groups together patients 
with identical manifestations, prognosis, and response to treatment. Indeed, a classification 
that does not function as such becomes an impediment for research and communication. 
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Underlining the importance of an accurate classification, classification criteria for SLE have 
been universally used as inclusion criteria for clinical trials and thereby reflect the patient 
population for which therapeutic guidelines are composed. 
As emphasised in the introduction of this thesis, classification criteria for SLE are meant 
for research purposes and not for diagnosis. Theoretically, a diagnosis is not so much 
different from a classification in an individual patient. If classification criteria would have 
perfect sensitivity and specificity (100%), there would be no difference between diagnos-
tic and classification criteria, and every single patient would be correctly diagnosed using 
the classification criteria.3 However, because disease manifestations in SLE are clearly 
not identical among patients and current classification criteria have imperfect accuracy, a 
certain proportion of patients would be misdiagnosed using the classification criteria. In 
these cases, only experienced physicians can establish a diagnosis by considering individual 
patient features (beyond those represented in the classification criteria), as well as other 
factors including the local prevalence of conditions that appear in the differential diagnosis. 
In general, one must bear in mind that classification criteria, unless validated in multiple 
settings, reflect the applicability in the cohort of patients from which they were developed. 
Applying classification criteria in other settings requires consideration of the disease pre-
valence in a specific setting and the possibility of a different disease spectrum associated 
with particular organ manifestations. These elements were further elaborated in chapter 
2, in which the diagnostic performance of the recently published SLICC classification of 
SLE was tested in the setting of patients with renal disease selected from the nephro-
logy clinic. Here, the disease prevalence of SLE was relatively high and patients clearly 
had a different SLE disease spectrum than the SLE patients from the SLICC derivation 
cohort who were recruited from rheumatology clinics. Compared with patients in the 
SLICC derivation cohort, SLE patients with nephritis and full house nephropathy had a 
significantly lower frequency of alopecia, oral/nasal ulcers, and leukopenia, and a higher 
frequency of neurologic disorders, haemolytic anaemia, thrombocytopenia, anti-dsDNA 
antibodies, and hypocomplementaemia. These results are in agreement with those from 
a recently published large inception cohort comparing SLE patients with and without 
nephritis4 and support the notion that SLE is a disease with heterogeneous phenotypes.5 
The results described in chapter 2 provide evidence for the usefulness of SLICC criteria 
for the diagnosis of SLE in patients with nephritis, although the added value of the SLICC 
criteria (compared with the ACR criteria) was uniquely due to hypocomplementaemia as 
a criterion and not due to the low threshold “stand-alone” criterion of biopsy-confirmed 
LN in combination with antinuclear or anti-dsDNA antibodies. 
To resolve the inconsistencies of SLE classification criteria in different clinical settings, 
subspecialty-tailored criteria may be useful,6 taking into account the disease prevalence, 
differential diagnoses, and disease spectrum in each subspecialty. Thus, although evidence 
for the performance of the stand-alone criterion in the absence of at least four criteria 
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in the SLICC classification was missing,7 it may be that this criterion will indeed be useful 
to identify SLE patients among patients encountered in rheumatology clinics. Importantly, 
as investigated in this thesis, this low-threshold criterion in the setting of patients from 
the nephrology clinic with full house glomerular deposits compromised the specificity 
and should therefore be abandoned from SLE classification criteria used by nephrologists.
Non-lupus Full House Nephropathy: a red flag in the differential diagnosis of LN
Why should we be concerned about the suboptimal specificity (79%) of full house glo-
merular deposits for SLE and refrain from diagnosing LN in all patients with a seemingly 
renal-limited form of SLE? Making a clinical diagnosis only makes sense if patients have 
similar clinical features, a uniform prognosis, and response to treatment. In chapter 3, it 
was clearly demonstrated that patients with idiopathic and secondary non-lupus full house 
nephropathy (FHN) present with distinct clinical features and have a remarkably poor 
outcome as compared to lupus FHN patients. Here, the importance of taking note of the 
clinical characteristics rather than basing a diagnosis on tissue characteristics alone is clearly 
demonstrated. Besides the poor outcome of idiopathic and secondary non-lupus FHN 
patients, non-lupus FHN patients were clinically distinguished from lupus FHN patients by 
the absence of four or more clinical SLE signs and symptoms, higher levels of proteinuria, 
lower levels of erythrocyturia, and predominantly male sex.  Also on the tissue level, some 
salient features were identified, including a predominantly membranous pattern of injury 
and less intense immunofluorescence staining compared to lupus FHN. 
A number of factors may have contributed to the remarkably poor renal outcome of 
idiopathic non-lupus FHN patients. First, the severe clinicopathologic features at presenta-
tion and poor renal outcome in more than half of the patients with secondary non-lupus 
FHN raises the possibility that in some instances, idiopathic non-lupus FHN may represent 
severe forms of as yet unidentified other renal diseases that are accompanied by strong 
activation of the immune system, as has also been suggested previously.8-18 Second, idiopa-
thic non-lupus FHN patients had a relative lack of immunosuppressive treatment, higher 
levels of proteinuria, and a tendency towards a higher chronicity score – although these 
factors did not explain the difference in renal survival comparing idiopathic non-lupus 
FHN and lupus FHN in the statistical models in chapter 3.  The remarkably poor outcome 
of idiopathic non-lupus FHN urges future studies to unravel therapeutic strategies and 
aetiopathogenic mechanisms of immune complex deposition in idiopathic non-lupus FHN. 
The prognosis of LN
Personalised medicine versus guideline-based medicine in LN
Making a correct diagnosis of LN and distinguishing other diagnoses such as non-lupus 
FHN are crucial, since a diagnosis of LN has considerable clinical implications. Current 
guidelines recommend treatment with intensive immunosuppression in those cases with 
glomerulonephritis classified as class III or IV LN according to the International Society of 
Nephrology/Renal Pathology Society (ISN/RPS) classification. Standard care for patients 
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with class III or IV LN includes intravenous cyclophosphamide or mycophenolate mofetil 
in combination with corticosteroids.19-23 The intensive cytotoxic immunosuppressive regi-
mens have considerable short-term and long-term toxicities.24 Evidence-based guidelines 
for the treatment of LN are generated based on the body of clinical data available from 
therapeutic intervention studies in LN. The highest level of evidence in guidelines for LN 
is based on a number of landmark randomised controlled clinical trials (RCTs).19-23 His-
torically, the first large RCT including LN patients performed at the National Institutes of 
Health (NIH) was not based on a consensus histopathologic classification, but included 
SLE patients with “proliferative LN” and declining renal function.25 Since then, subsequent 
RCTs have formed the basis of current evidence-based treatment for proliferative LN, 
which generally included class III or IV (±V). It is of interest that the evidence for the cut-
offs defining patients with class III or IV (±V) LN is lacking, and that these cut-offs have 
never been validated. 
In general, RCTs have specific inclusion and exclusion criteria designed to represent a 
population large enough and sufficiently enriched regarding clinical abnormalities associated 
with an anticipated treatment effect to attain a number of end points and demonstrate a 
statistically and clinically significant difference in outcome. The usefulness of the guidelines 
may be questioned when individual patients within the heterogeneous population of LN 
patients in clinical practice differ in key characteristics from those of the trial population on 
which the guideline recommendation is based. In LN, inspection of the inclusion criteria of 
the landmark RCTs reveals that patients with only mildly disturbed renal function and/or 
mild proteinuria were frequently excluded from the RCTs,25-32 and in some RCTs inclusion 
criteria were stricter for patients with class III than for class IV LN.28-30 Consequently, results 
from these large RCTs cannot unequivocally be applied to all patients with LN in a clinical 
setting, creating a gap in the treatment guidelines for LN patients with predominantly mild 
clinical features. 
Since guidelines do not appear to be evidence-based across the clinical spectrum of LN, 
a guideline-based approach to the treatment of LN is problematic. As mentioned before, 
guidelines base their recommendations to initiate cytotoxic immunosuppressive treatment 
entirely on the lumped category of class III or IV (±V) LN. In chapters 4 and 5 of this thesis, 
it was demonstrated that this lumped category obscures prognostic information that is 
hidden in individual clinical and histopathologic characteristics. Furthermore, the RCT-based 
guidelines in LN do not address pharmacogenetic differences between individual patients, 
which may also be of clinical importance.33  The solution incorporating such characteristics 
of individual patients to predict outcome may be personalised medicine. Personalised 
medicine reflects the ability to classify individual patients into subpopulations who are 
similar in their clinical presentation, outcome, and response to treatment. Thus, the decision 
to initiate treatment is ideally focused on patients who will benefit from it, and be withheld 
from patients who will not. The toxicities of immunosuppressive regimens recommended in 
LN emphasise the importance of personalised medicine, to fulfil the physician’s obligation 
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“to do good or to do no harm”. On the one hand, overtreatment of benign renal lesions 
subjects patients to severe side effects including infections, risk of malignancy and prema-
ture ovarian failure. On the other hand, delaying therapy because of presumed mild disease 
may be associated with increased glomerular injury, progressive tubulointerstitial fibrosis, 
glomerulosclerosis, and therefore a lesser response to immunosuppressive drugs.34-36
Scarce evidence from an early landmark NIH trial in LN25 suggests that a subgroup of 
patients with class III or IV LN may be unlikely to benefit from cytotoxic immunosup-
pression. This hypothesis has never been tested prospectively in a separate clinical trial. 
Although a case for equipoise could be made for these cases, it is difficult to overcome 
the resistance of the medical community to actually investigate not treating these patients 
or choosing alternative treatment, since the guidelines recommend otherwise. Apparently, 
the development of evidence-based guidelines limits the subsequent application of perso-
nalised medicine. Clearly, the conflict between guideline-based and personalised medicine 
predominantly occurs in case of withholding recommended therapy.  As a first step, it was 
attempted to identify the subpopulation of patients with class III or IV LN who retros-
pectively did not receive cytotoxic immunosuppressive therapy in chapter 4.  The patients 
who were identified with class III or IV LN who did not receive immunosuppression 
according to guidelines provide evidence for the existence of a subgroup of patients for 
whom therapy regimens omitting cytotoxic drugs may suffice. Subsequent challenges will 
be to further characterise these patients eligible for milder therapy regimens and to test 
the utility of regimens omitting cytotoxic drugs in appropriate RCTs.  As an alternative 
to not treating patients, an intervention study may be conceived including a wait-and-see 
approach. In this study design, the renal biopsy would be followed by a period during 
which LN patients are closely monitored, and possible introduction of anti-inflammatory 
treatment with corticosteroids followed by suppression of autoimmunity using cytotoxic 
immunosuppression only if deemed necessary. Indeed, older studies have demonstrated 
that anti-inflammatory doses of corticosteroids alone were as effective as corticosteroids 
plus cyclophosphamide in the early phase of LN treatment.25, 37 
A new era for the histopathologic classification of LN
In spite of the success and worldwide acceptance of the ISN/RPS histopathologic classi-
fication of LN,38-40 it is apparent that patients fulfilling classification criteria may have very 
different outcomes. Furthermore, diagnostic disagreement is common among pathologists 
due to unclear definitions.41, 42 Thus, the characterisation of prognostic subgroups in LN 
warrants refinement. The ISN/RPS classification was designed by a group of pathologists 
and clinicians combining expert opinion with the best available evidence provided by stu-
dies that identified prognostic factors from candidate factors selected by reasoning and 
considering the hypothesised pathway from the onset of disease to subsequent outcome 
(“candidate approach”).  An evidence-based methodology in the design of a histopatho-
logic classification as inspired by the Oxford classification of IgA nephropathy has paved 
the way for a new era of clinical pathology, basing classification systems on prognosticators 
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with evidence-based significance identified in a “hypothesis-free” approach to discover 
possible unsuspected factors.  The prognosticators identified in chapter 5 that are currently 
obscured in the histopathologic classification of LN form a first step towards a revised 
histopathologic classification. An international initiative to revise the classification of LN 
must validate our results from chapter 5. It may well be that the time has come to refine 
historic classes, and incorporate a prognostic scoring system founded on lesions with 
evidence-based prognostic significance. This scoring system will likely include the lesions 
identified in chapter 5.
In the scoring system, it would be beneficial to specify the categories of prognostic signifi-
cance associated with different lesions. Essentially, the analysis of the different outcomes in 
chapter 5 uniquely revealed two categories of clinical and histopathologic prognosticators: 
(i) variables predictive of eGFR during follow-up; and (ii) variables predictive of progressive 
renal function decline, renal flare, and ultimately ESRD.  The first category of lesions repre-
sents injury that results in an irreversible loss of renal function that is not progressive or 
treated and halted successfully, whereas the second category of lesions represents injury 
resulting in progressive loss of renal function that is irreversible or impossible to halt using 
current treatment strategies. The results in chapter 5 suggest that particularly fibrinoid 
necrosis is a lesion in the latter category, raising the possibility that this lesion may have a 
different pathogenesis and may therefore benefit from treatment with a different thera-
peutic target.43-45 Similarly associated with progressive renal function decline, chronic lesions 
including fibrous crescents and interstitial fibrosis/tubular atrophy are unlikely to benefit 
from immunosuppressive therapy,46 and may more likely benefit from a renoprotective 
approach including antihypertensive therapy.
In addition to the benefit of a histopathologic scoring system, prognostication for patients 
with LN might improve by considering other prognosticators. In chapter 5, it was shown 
that clinical variables including age, ethnicity, blood pressure and renal function at the time 
of biopsy have prognostic significance. Ideally, a prognostic model would incorporate 
these clinical variables in addition to histopathologic variables, as well as other possible 
predictors that have yet to be identified. Presently, it is unknown how new biomarkers of 
persistent inflammation may change the classification and personalised medicine in LN in 
the future, for instance investigations using urinary proteomics to detect surrogate markers 
of unrecognised nephron loss,47 urinary flow cytometry to characterise the activation 
pattern of lymphocytes in persistent renal inflammation,48 or measuring urinary cytokine/
chemokine excretion.49 Similar to, for example, the implementation of prediction tools 
such as “Adjuvant! Online”50 and “PREDICT”51 in the clinical management of breast cancer, 
increasingly sophisticated prediction tools for LN may be on the horizon, incorporating 
a growing number of prognosticators and enabling a move from the categorisation of 
patients into broad prognostic groups to the realisation of providing survival estimates at 
the patient level. 
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The diagnosis of NP-SLE
NP-SLE as a spectrum
In marked contrast to LN, the lack of accurate diagnostic tools and a lack of knowledge 
about the pathogenesis challenge the diagnosis of NP-SLE. To gain insight into the patho-
genesis and the injury at the tissue level, an autopsy study was performed (chapter 6).  The 
results clearly illustrate that the injury and clinical manifestations of NP-SLE represent a 
continuum, ranging from relatively nonspecific lesions found in most SLE patients including 
focal vasculopathy, microinfarction, macroinfarction, and vasculitis – to specific and even 
pathognomonic lesions, including diffuse vasculopathy and microthrombi associated with 
clinical syndromes defining NP-SLE.52 Conceivably, thromboischemic injury occurs in all 
SLE patients but overt NP-SLE only ensues after a certain threshold of injury is reached. 
Since a brain biopsy to detect possible specific lesions such as microthrombi remains 
unfeasible in clinical practice, NP-SLE syndromes are diagnosed in SLE patients per exclusi-
onem supported by clinical and MRI findings. However, MRI often shows no abnormalities 
or nonspecific abnormalities such as small white matter hyperintensities53 in the presence 
of clinical symptoms, known as the clinicoradiological paradox. Thus, in the diagnosis of 
NP-SLE, there is a need for sensitive and specific diagnostic tools that can distinguish 
NP-SLE from other diseases in patients with a clinical neuropsychiatric syndrome. At the 
same time, these tools should improve the assessment of the extent of injury. 
In this thesis, the performance of 7-Tesla MRI was investigated as a diagnostic tool for 
NP-SLE as compared to histopathologic evaluation in two patients with NP-SLE and 
one patient with SLE without neuropsychiatric involvement. 7-Tesla MRI appeared to be 
less sensitive than histopathologic evaluation: post-mortem histopathologic evaluation of 
cerebral tissue of one NP-SLE patient revealed histopathologic injury in the absence of 
MRI findings. The specificity of both 7-Tesla MRI and histopathologic evaluation were lim-
ited: both revealed abnormalities in one patient without neuropsychiatric symptoms. The 
relevance of such subclinical injury in the setting of NP-SLE remains to be elucidated but 
the injury may well reflect the nonspecific histopathologic injury in SLE patients without 
neuropsychiatric syndromes. Future studies to determine the feasibility of, for instance, 
quantitative techniques such as volumetric magnetisation transfer imagining (MTI) detect-
ing specific lesions in SLE and NP-SLE patients are called for,54 as brain biopsies remain 
unattainable in routine clinical practice. Until then, the clinical evaluation will remain the 
mainstay in the diagnosis of NP-SLE.
The prognosis of NP-SLE
Because the heterogeneous manifestations of NP-SLE reflect a wide range of qualitative 
and quantitative lesions of which the diagnosis itself is often hampered, little is known about 
prognostic subgroups and factors that may be used to classify them. The identification 
of improved diagnostic tools and markers may pave the way for the identification and 
characterisation of prognostic subgroups in NP-SLE. 
 187
9
Summary and General discussion
An inflammatory and a thromboischemic pathogenic mechanism have been implicated 
as separate autoimmune pathogenic mechanisms for NP-SLE, the distinction of which is 
often not feasible.55 Cytotoxic immunosuppressive therapy is indicated in selected NP-SLE 
patients with a suspected inflammatory underlying disease mechanism. This therapy is 
relatively non-specific, anti-proliferative, and/or anti-metabolic in nature, and may therefore 
– like in LN – have severe systemic side effects, including sepsis, avascular bone necrosis, 
gonadal dysfunction, and malignancy.56 Antiplatelet and/or anticoagulation therapy is indi-
cated for patients with a suspected thromboischemic pathogenic mechanism. This type 
of therapy also carries the risk of significant haemorrhagic complications.57 Clearly, there 
is a need for better tools to distinguish these pathogenic mechanisms to enable better 
targeting of treatment. In addition, the development of targeted therapeutics that abrogate 
the pathogenesis of NP-SLE more selectively is warranted to maximise treatment efficacy 
and minimise side effects.
Aetiopathogenesis of SLE: the common ground
Because the diagnosis of SLE is challenged by the clinical heterogeneity and overlap with 
other diseases, the identification of underlying aetiopathogenic mechanisms may provide 
specific disease indicators assisting in making the diagnosis as well as providing potential 
modifiable therapeutic targets that could possibly prevent subsequent disease or halt its 
progression. 
Complement as a novel therapeutic target in NP-SLE
As described in the introduction of this thesis, the role of complement as a downstream 
effector of immune complex-mediated tissue injury in LN is well studied. In chapter 6, it 
was demonstrated that classical complement deposition is also strongly associated with 
NP-SLE and microthrombi in particular, providing a possible link between thromboischemic 
injury and inflammation in NP-SLE. Similar to what has been suggested in other entities 
such as thrombotic microangiopathy, accumulation of antibodies in small vessels most 
likely leads to activation of the classical complement pathway, endothelial injury, and the 
subsequent formation of microthrombi.58 In other fields, the complement system has 
recently been introduced as a promising therapeutic target. The finding in chapter 6 that 
C5b-9 deposits were present in 82% of patients with SLE and NP-SLE, suggests that at 
least this proportion of patients with NP-SLE – and perhaps also patients with SLE in the 
absence of neuropsychiatric symptoms – may benefit from treatment with the terminal 
complement inhibitor eculizumab. 
Eculizumab is a recombinant fully humanised IgG2/IgG4 monocolonal antibody that binds 
to complement component C5 and prevents the cleavage of C5 and thereby the formation 
of the anaphylatoxin C5a and the formation of the membrane attack complex (C5b-9). 
Eculizumab was shown to be efficacious in the prevention of erythrocyte lysis in paroxys-
mal nocturnal haemoglobinuria59 and in the treatment of atypical haemolytic uraemic 
syndrome.60 No RCTs have investigated the efficacy of eculizumab in the treatment of SLE 
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manifestations. However, animal studies have indicated that eculizumab may be beneficial: 
in lupus-prone mice, blockade of complement C5 has been shown to decrease proteinuria 
and renal dysfunction and prolonged animal survival.61 A number of case reports suggest 
that eculizumab may also be beneficial in the treatment of SLE in humans.62, 63 Clearly, the 
complement system is a promising target in NP-SLE urging RCTs to investigate the efficacy 
of eculizumab in SLE patients with NP-SLE. 
Chimerism in SLE
Little is known about the role of microchimerism in SLE, but the difference between men 
and women in the incidence of SLE makes pregnancy-derived microchimerism an intriguing 
aetiopathogenic candidate. In this thesis, microchimerism was investigated in association 
with SLE. In chapter 7, the rationale for studying microchimerism in SLE as well as a number 
of other pregnancy-related conditions, including other autoimmune diseases, pregnancy 
complications, and certain malignancies was investigated. Here, an increased occurrence 
of tissue microchimerism was demonstrated in women during pregnancy compared to 
after pregnancy, substantiating the rationale for investigating microchimerism in relation 
to SLE. Subsequently, the increased frequency (54.4% vs. 13.6%) of microchimerism in 
SLE patients was demonstrated in chapter 8.  The results in these chapters show that 
microchimerism is associated with SLE, but may also occur as a physiologic phenomenon 
without the advent of autoimmunity. 
The higher prevalence of microchimerism in SLE patients than in controls can be explained 
by (i) acquisition of more chimeric cells during pregnancy, (ii) persistence of more chimeric 
cells after pregnancy, (iii) chimeric stem cells giving rise to more chimeric cells due to an 
unknown trigger, or (iv) a combination of aforementioned possibilities. In chapter 8, an 
important difference between SLE patients and controls was that in 50% of SLE patients 
with microchimerism, it originated from multiple relatives, whereas in controls microchime-
rism was always derived from one relative. The increased frequency of microchimerism in 
SLE patients may be explained by HLA relationships. Studies in animals have demonstrated 
that syngenic or congenic matings resulted in more chimerism than allogenic matings, 
suggesting a role for HLA (mis)matches.64, 65 In humans, in certain autoimmune diseases 
mothers and children were shown to have fewer HLA disparities,66, 67 but these have not 
yet been correlated with the presence of microchimerism.66 
Concerning the hypothesis that pregnancy-acquired microchimerism may be an explana-
tion for the high incidence of SLE in women, it is remarkable that the results in chapter 7 
demonstrate that the lung was the organ harbouring most microchimerism in pregnant 
women, followed by the spleen, liver, kidney, brain, and heart. Remarkably, this distribution 
pattern replicates findings in pregnant mice, with the lungs being the organs in which micro-
chimerism presented most often and in greatest abundance, followed by the spleen, liver 
and kidney, with lowest amounts of microchimerism found in the heart and brain. These 
observations demonstrate the validity of mouse models to represent human fetomater-
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nal cell trafficking during pregnancy and substantiate the usefulness of mouse models to 
further unravel the impact of microchimerism on maternal health. In the pregnant women 
without autoimmune diseases who were studied, several factors including anatomy, cyto-
kine production, cell turnover, injury occurrence, and tissue metabolic rates could explain 
this distribution. The notable organ distribution raises the question whether the preferen-
tial occurrence of microchimerism in specific organs reflects the increased incidence of 
disease in these organs. 
A number of hypotheses have been proposed for the role of microchimerism in SLE, 
including a pathogenic role, a repair role, and an innocent bystander role of chimeric 
cells. Relating to the first hypothesis, the finding that male T cells (CD3+) were present in 
pregnant women (chapter 7) is compelling. Possibly, the acquisition of CD3+ cells during 
pregnancy forms the basis for development of SLE in which chimeric T cells are present. 
In the mouse model by Via and Shearer,68 the injection of chimeric T cells resulted in a 
graft-versus-host disease that resembles human SLE. Alternatively, the chimeric cells may 
not themselves be effector cells, but they may rather be the target of an immune reaction, 
and/or undergo cell death providing a source of DNA resulting in sensitisation and trig-
gering the development of antinuclear antibodies. The engraftment of the chimeric cells in 
tissues of pregnant women is intriguing in this setting, raising the possibility that these cells 
under specific circumstances become the target of an alloimmune response. Concerning 
the repair hypothesis, it has been demonstrated that in gentamicin-induced kidney injury, 
fetus-derived chimeric cells engraft in the kidney as tubular cells, suggesting a role in the 
repair process. In the setting of LN, a repair function of microchimerism was recently 
supported by the positive association between amounts of microchimerism and renal 
function.69 In chapter 8, no relationship between microchimerism and clinical or laboratory 
parameters was found. In SLE patients, it has been demonstrated that microchimerism 
occurs more often in organs from patients with SLE who had experienced injury than in 
normal control organs, irrespective of whether the injury was SLE-related, non-SLE-related, 
or both – supporting the hypothesis that tissue chimerism is the result of a repair process.70 
In chapter 7, the only organ with a significant correlation between tissue microchimerism 
and active injury scores was the kidney. It is therefore conceivable that the kidney is 
particularly prone to repair by chimeric cells. However, the latter observation could also 
be explained by the innocent bystander hypothesis, with the increased microchimerism 
being the result of nonspecific recruitment of inflammatory cells including chimeric cells. 
The innocent bystander hypothesis is supported by the occurrence of chimeric cells in 
healthy women (chapters 7 and 8), demonstrating that chimerism is also a physiologic 
phenomenon, and may only be pathogenic under specific circumstances. Further study 
is necessary to unravel the impact of fetal cell microchimerism on maternal health and 
conditions under which chimeric cells may induce SLE.
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Conclusion: towards personalised medicine in SLE
In the current thesis different challenges concerning the diagnosis and prognosis of SLE 
were investigated. A central conclusion from this thesis is that personalised medicine 
should be the framework of clinical care for SLE patients. A special focus should be on 
improving outcomes of individual SLE patients by considering prognostic factors and 
initiating treatment only in patients who will benefit from it and withholding treatment 
from those who will not. By this approach, the risk of adverse effects due to ineffective 
treatment is minimised. Thus, classifications should be developed starting with prognostic 
groups as identified by a constellation of clinical and histopathologic features. The finding 
of a prognostic difference between FHN patients with and without sufficient additional 
classification criteria for SLE (chapters 2 and 3) is the ultimate impetus to distinguish these 
patient groups by means of classification. Hence, patients with FHN without sufficient SLE 
criteria should not be regarded as representing a “renal-limited” form of SLE and should 
not be included in the classification. Currently, the ISN/RPS histopathologic classification 
of LN lacks accuracy in defining prognostic subgroups (chapters 4 and 5). For patients 
with LN receiving conventional immunosuppressive treatment, renal outcomes including 
progression to ESRD, renal flare, and eGFR during follow-up could be predicted by the 
histopathologic and clinical parameters described in chapter 5 – justifying the inclusion 
of these parameters in a revised version of the histopathologic classification. These para-
meters in fact define patients who were unresponsive or only partially responsive to 
conventional treatment. Future research may indicate that such patients may benefit from 
new therapeutic regimens focusing on different therapeutic targets.71 Insight in different 
pathogenic pathways may provide these new therapeutic targets. The complement system 
was identified as a promising therapeutic target in NP-SLE (chapter 6), and its role in LN 
may also warrant further investigation. Future research in the field of SLE should focus on 
the identification of aetiopathogenic factors and identification of new prognostic factors 
to define prognostic subgroups, to predict treatment response, to monitor disease pro-
gression, to improve stratification of patients in RCTs, as well as to develop new targeted 
therapies minimising the side effects.
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Systemische lupus erythematosus (SLE) of kortweg “lupus” is een auto-immuunziekte, 
dat wil zeggen een ziekte waarbij het immuunsysteem lichaamseigen stoffen aanvalt. SLE 
is een zeldzame ziekte (6 à 7 per 100,000 mensen) die met name jonge vrouwen treft. 
Het immuunsysteem zorgt ervoor dat we beschermd zijn tegen ziekmakende indringers, 
zoals virussen en bacteriën. Normaal gesproken is ons lichaam in staat om bestanddelen 
van lichaamsvreemde wezens te onderscheiden van lichaamseigen bestanddelen, maar in 
het geval van een auto-immuunziekte als SLE is dit onderscheidend vermogen gestoord. 
Als gevolg hiervan wordt het immuunsysteem geactiveerd, hetgeen onder andere leidt 
tot de vorming van afweerstoffen of “antistoffen” tegen lichaamseigen bestanddelen. In 
patiënten met SLE zijn deze antistoffen vaak gericht tegen bestanddelen van celkernen. 
Het aantonen van deze zogenaamde “antinucleaire antistoffen” (ANA, “nucleus” betekent 
celkern) vormt dan ook een belangrijke pijler om tot de diagnose SLE te komen. Deze 
afweerreacties en antistoffen kunnen verspreid door het hele lichaam ontstekingsreacties 
teweegbrengen, waardoor SLE uitingsvormen in veel verschillende organen kan hebben. 
Om deze reden is SLE ook wel “systemisch”, dat wil zeggen dat het hele lichaam of 
“systeem” betrokken kan zijn. De naam “lupus” stamt uit de Middeleeuwen, zo genoemd 
omdat de karakteristieke huidaandoening die bij een aantal lupuspatiënten kan worden 
gezien in het gelaat deed denken aan de beet van een wolf – ook wel lupus in het Latijn. 
Deze huidaandoening evenals een aantal andere huidaandoeningen bij lupus kenmerkt 
zich door een rode verkleuring, vanwaar de term “erythematosus” (rood) in de naam van 
deze ziekte is opgenomen. 
Door het systemische karakter kent SLE veel verschillende uitingsvormen. De diagnose 
SLE wordt gesteld op basis van een combinatie van symptomen en bloeduitslagen, waarbij 
andere ziektes moeten worden uitgesloten. Artsen kunnen bij het stellen van de diagnose 
zich richten tot classificatiecriteria voor SLE zoals opgesteld door de American College of 
Rheumatology (ACR) en meer recent door de Systemic Lupus International Collaborating 
Clinics (SLICC). De meest recente SLICC criteria staan vermeld in Tabel 1. Om de diagnose 
SLE te stellen moet een patiënt ten minste aan vier criteria voldoen, waarvan ten minste 
een “klinisch criterium” en ten minste een “immunologisch criterium”. Klinische bevindingen 
in deze classificatie zijn bevindingen met name op basis van de anamnese (het uitvragen 
van de klacht) en het lichamelijk onderzoek. Immunologische afwijkingen kan de arts door 
middel van laboratoriumbepalingen vaststellen. Los van de conventionele eis om aan 
minstens vier criteria te voldoen, kan de diagnose SLE laagdrempeliger gesteld worden 
in het geval van nierontsteking passend bij lupus (op basis van een nierbiopsie) en de 
aanwezigheid van ANA of anti-DNA afweerstoffen.
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Tabel 1  SLICC classificatiecriteria voor SLE. 
Criterium Uitleg
Klinische criteria
1. (Sub)acute cutane lupus Vlinderexantheem: rode uitslag over de wangen en de neusrug (vlindervormig)
Bulleuze lupus: huiduitslag met blaren passend bij lupus
Maculopapuleus exantheem: rode bobbelige huiduitslag passend bij lupus
Fotosensitiviteit: uitslag door zonlichtovergevoeligheid passend bij lupus
Toxische epidermale necrolyse: afsterven van de bovenste huidlaag met 
blaarvorming
Subacuut cutane lupus: huidafwijkingen lijkend op psoriasis
2. Chronische cutane lupus Discoïde lupus: discusvormige, schilferende, verdikte huiduitslag op het gezicht, 
de hoofdhuid, oren, borst of armen passend bij lupus
Lupus panniculitis: dieper gelegen huidontsteking
Slijmvliesafwijkingen
Chilblain lupus: door koude uitgelokte huidafwijkingen 
3. Zweertjes/aften Zweertjes (ulcera of aften) in de neus en/of mond
4. Niet verlittekenende alopecia Hoofdhaar dat verspreid dunner en/of breekbaarder wordt, waarbij gebroken 
haren te zien zijn
5. Artritis (≥2 gewrichten) Gewrichtszwelling 
Gewrichtspijnen en ten minste 30 minuten ochtendstijfheid
6. Serositis Pleuritis: ontsteking van het borstvlies (vlies om de longen) 
Pericarditis: ontsteking van het hartzakje (vlies om het hart)
7. Nefritis Ontsteking van de nieren, zich onder andere uitend in eiwit en/of bloed in de 
urine
8. Neuropsychiatrische afwijkingen Aantasting van het centrale zenuwstelsel (hersenen en ruggenmerg); onder 
andere epilepsie, concentratie-en geheugenproblemen en hallucinaties 
9. Hemolytische anemie Te weinig rode bloedcellen (bloedarmoede) door afbraak van rode 
bloedcellen
10. Leukocytopenie Te weinig witte bloedcellen met daarbij een verhoogd infectierisico
11. Trombocytopenie Te weinig bloedplaatjes met daarbij een verhoogd bloedingsrisico
Immunologische criteria
1. Antinucleaire antistoffen (ANA) Antistoffen tegen onderdelen van celkernen
2. Anti-dubbelstrengs DNA antistoffen 
(anti-dsDNA)
Antistoffen tegen DNA
3. Anti-Smith antisoffen (anti-Sm) Anti-Sm antistoffen zijn genoemd naar de eerste patiënte in wiens bloed 
ze zijn aangetoond (haar naam was Smith). Deze antistoffen worden bijna 
uitsluitend in SLE patiënten gevonden
4. Antifosfolipide antistoffen Antistoffen tegen het omhulsel van de cel. Aanwezigheid hiervan leidt tot een 
verhoogde stollingsneiging 
5. Laag complement Complementeiwitten worden gebruikt bij het opruimen van complexen met 
antistoffen in het bloed. Bij SLE kan het complement verlaagd zijn doordat het 
veel verbruikt wordt bij het opruimen van de antistofcomplexen.   





Buiten de verschijnselen die zijn opgenomen in de classificatiecriteria kent SLE nog een 
aantal andere uitingsvormen die minder voorkomen, zoals ontsteking van de hartspier, 
of die minder specifiek zijn voor SLE, zoals koorts en malaise. De grote variëteit aan 
uitingsvormen van SLE en overlap van deze symptomen met een aantal andere ziektes 
kunnen de diagnose bemoeilijken. De diagnose wordt gesteld op basis van het voorkomen 
van een combinatie van verschillende symptomen en er bestaat geen test die op zichzelf 
zekerheid geeft. In dit proefschrift zijn verschillende problemen onderzocht die verband 
houden met het stellen van de diagnose SLE op basis van weefselonderzoek en klinische 
bevindingen. Weefselonderzoek in dit kader bestaat uit het onderzoeken met behulp 
van een microscoop van weefsel dat is verkregen door het nemen van een biopsie 
of postmortaal verkregen weefsel via een obductie. Klinische bevindingen zijn gegevens 
die de arts verzamelt op basis van de anamnese (het uitvragen van de klacht) en het 
lichamelijk onderzoek. Zoals blijkt uit de classificatiecriteria, is natuurlijk ook aanvullend 
laboratoriumonderzoek bij de klinische evaluatie van een patiënt met SLE van groot 
belang. Verder is in dit proefschrift onderzocht hoe men de uitkomst van betrokkenheid 
van de nieren bij SLE beter kan voorspellen, strevend naar de toepassing van het concept 
van “gepersonaliseerde geneeskunde” (personalised medicine). Personalised medicine is 
het concept waarbij wordt geprobeerd afzonderlijke patiënten in zo specifiek mogelijke 
subgroepen in te delen die gelijk zijn wat betreft hun ernst van de ziekte, verwachte beloop 
en verwachte respons op behandeling. Op deze manier kan een betere en nauwkeurigere 
beslissing worden genomen om een individuele patiënt te behandelen die baat zal hebben 
bij de behandeling, terwijl op deze manier ook wordt voorkomen dat een patiënt onterecht 
wordt behandeld en daarmee wordt blootgesteld aan mogelijk ernstige bijwerkingen van 
medicijnen.
Nierbetrokkenheid bij SLE, ook wel lupus nefritis genoemd, is een van de meest ernstige 
uitingen van SLE. Minstens 50% van de patiënten heeft op enig moment tekenen van 
lupus nefritis als uiting van SLE. De nieren zorgen ervoor dat afvalstoffen uit het bloed 
gefilterd worden en in de urine terecht komen, de vocht- en zoutbalans gereguleerd 
worden en dat bepaalde hormonen en vitamines gemaakt worden. Voorbeelden hiervan 
zijn erythropoïetine (“epo” zorgt voor aanmaak van rode bloedcellen) en vitamine D 
(zorgt voor calciumstofwisseling). Bij nierschade door lupus nefritis kan het zijn dat de 
ontstoken bloedfilterlichaampjes, “glomeruli” genoemd, niet meer goed werken. Hierdoor 
kunnen eiwitten en/of bloedcellen in de urine terecht komen als teken van schade aan 
de glomeruli. Verder kunnen de nieren dan niet meer goed het bloed van afvalstoffen 
ontdoen, de vocht- en zoutbalans op peil houden en in een laat stadium door hun 
verminderde functioneren leiden tot bloedarmoede en botontkalking. De nierfunctie kan 
in het laboratorium geschat worden door het meten van het “creatinine” in het bloed. 
Deze stof is een afbraakproduct van spieren en wordt volledig via de nieren uitgescheiden. 
Als de nieren minder functioneren, kan creatinine dus minder goed worden uitgescheiden 
via de urine en ophopen in het bloed. De uitscheiding of “klaring” van creatine wordt 
gebruikt als maat voor nierfunctie. Als de nierfunctie of “creatinineklaring” minder dan 
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±15% bedraagt, is er sprake van eindstadium nierfalen. Op dat moment is dialyse of 
niertransplantatie noodzakelijk. 
Omdat SLE valt onder de zogenaamde “reumatische” ziektes, waarbij er veelal ontsteking is 
van gewrichten, botten, spieren of bindweefsel, worden patiënten met SLE veelal behandeld 
door reumatologen. Classificatiecriteria voor SLE zijn dan ook gebruikelijk ontwikkeld om 
patiënten met SLE te kunnen onderscheiden van patiënten zonder SLE zoals men deze 
zou kunnen treffen in de spreekkamer van de reumatoloog. Echter, ook andere medisch 
specialisten komen in aanraking met patiënten met SLE. Het is duidelijk dat de patiëntengroep 
waarvan patiënten met SLE bij andere specialismes moeten worden onderscheiden andere 
soorten ziektes heeft dan de patiëntengroep in de reumatologieklinieken. Bijvoorbeeld, een 
reumatoloog moet een patiënt met “reuma” en gewrichtspijn kunnen onderscheiden van 
een patiënt met SLE met gewrichtspijn, terwijl een dermatoloog een patiënt met huiduitslag 
ten gevolge van SLE moet kunnen onderscheiden van een patiënt met een huiduitslag en 
een andere huidziekte. Waarschijnlijk kunnen criteria voor SLE niet zonder meer worden 
toegepast door verschillende specialisten. 
In hoofdstuk 2 van dit proefschrift is onderzocht hoe de SLICC en ACR criteria voor 
SLE presteren als deze worden toegepast bij patiënten met nierziekten die worden 
gezien door artsen die gespecialiseerd zijn in nierziekten, zogenoemde “nefrologen”. De 
patiënten in deze studie hadden een nierziekte waarvoor een nierbiopsie werd verricht 
om de diagnose te stellen. Heel suggestief voor lupus nefritis is het “full house” patroon bij 
immunofluorescentie. Immunofluorescentie is een techniek waarbij antistoffen en andere 
eiwitten van het immuunsysteem zichtbaar kunnen worden gemaakt op weefselniveau 
door middel van fluorescentie. Omdat SLE wordt gekenmerkt door de aanmaak van 
veel antistoffen en andere eiwitten van het immuunsysteem leidt dit in veel gevallen tot 
een sterk positieve aankleuring bij immunofluorescentie – vandaar het zogenoemde “full 
house patroon”. In hoofdstuk 2 zijn 149 patiënten met een dergelijk patroon onderzocht. 
Een deel van deze patiënten bleek daadwerkelijk SLE (79%) te hebben en een deel 
niet (21%). Deze verdeling betreft zogenaamde “klinische diagnoses”, oftewel diagnoses 
gesteld door de arts op basis van ervaring en expertise – los van de classificatiecriteria. 
Vervolgens werd gekeken hoe deze klinische diagnoses zich verhouden tot de diagnoses 
die gesteld zouden worden op basis van de classificatiecriteria. De SLICC criteria bleken 
van nut te zijn om patiënten met SLE te kunnen detecteren: alle patiënten met de klinische 
diagnose SLE voldeden aan ten minste vier SLICC criteria. De ACR criteria daarentegen 
detecteerden 95% van de patiënten met SLE. Het laagdrempelige criterium van de SLICC 
classificatie, waarbij alleen de aanwezigheid van lupus nefritis in combinatie met ANA en/
of anti-DNA antistoffen genoeg is voor de diagnose, bleek niet van toegevoegde waarde 
te zijn. Er werden dus geen extra patiënten met SLE geïdentificeerd door het hanteren 
van dit laagdrempelige criterium die niet gedetecteerd zouden zijn geweest als er een 
hogere afkapwaarde (ten minste vier criteria zoals gebruikelijk) zou worden gesteld. Het 




resulteerde in het onterecht stellen van de diagnose SLE bij drie patiënten: deze patiënten 
hadden volgens de arts geen SLE, maar voldeden wel aan het laagdrempelige criterium. 
De bevindingen van deze studie laten zien dat de SLICC criteria nuttig zijn om SLE te 
diagnosticeren onder patiënten met nefritis in de nefrologiekliniek, alhoewel waakzaamheid 
is geboden bij het hanteren van het laagdrempelige niercriterium. 
In hoofdstuk 3 is dezelfde groep patiënten onderzocht als in hoofdstuk 2. De focus in 
hoofdstuk 3 lag op het onderscheid tussen patiënten met en zonder SLE. Het ging hier dus 
om een groep van 149 patiënten met een nierziekte waarbij de nierbiopsie met full house 
patroon zeer suggestief was voor lupus nefritis. Sommige artsen zouden wellicht stellen 
dat deze patiënten zelfs lupus nefritis hadden op basis van de bevinding bij nierbiopsie 
alleen.  Van deze groep bleek 79% daadwerkelijk SLE te hebben volgens de arts; deze groep 
patiënten werd in de studie de “lupus full house nefropathie (FHN)” groep genoemd. 
De overgebleven 21% van de patiënten bleek volgens de arts geen SLE te hebben. De 
oorzaak van de nierziekte met full house immunofluorescentie was in de meerderheid 
(63%) van deze patiënten onbekend. Deze groep patiënten zonder bekende oorzaak 
werd de “idiopatische non-lupus FHN” groep genoemd. De overgebleven (38%) patiënten 
had een nierziekte passend bij een andere diagnose dan lupus nefritis; er werd dus een 
oorzaak gevonden. Het onderscheid tussen patiënten met lupus nefritis (lupus FHN groep) 
en patiënten zonder bekende oorzaak van de nierziekte (idiopatische non-lupus FHN 
groep) is onderzocht op het vlak van klinische kenmerken, afwijkingen op weefselniveau 
en uitkomsten op de lange termijn. De vraag is of (i) idiopatische non-lupus FHN een 
vorm van SLE is die zich beperkt tot de nier, (ii) patiënten met idiopatische non-lupus FHN 
later in het beloop van hun ziekte kenmerken van SLE ontwikkelen en uiteindelijk voldoen 
aan classificatiecriteria, of (iii) dat patiënten met FHN zonder SLE een compleet andere 
vooralsnog onbekende ziekte representeren. Er werden opvallende verschillen gevonden 
tussen lupus en non-lupus FHN patiënten. Patiënten met idiopathische non-lupus FHN 
waren vaker van het mannelijke geslacht, hun nierbiopsieën lieten een ander patroon van 
schade zien, klinisch hadden ze meer eiwit en minder rode bloedcellen in de urine en 
minder vaak verlaagde complementeiwitten dan patiënten met lupus FHN (zie Tabel 1 
voor definities). Opvallend was dat patiënten met een bepaald patroon van schade waarbij 
ontsteking werd gezien eerder eindstadium nierfalen bereikten als zij idiopathische non-
lupus FHN hadden in vergelijking met lupus FHN. Deze resultaten laten zien dat hoewel 
het full house patroon een immunofluorescentiepatroon is dat het meest wordt gezien 
bij SLE, het van groot belang is te realiseren dat het bij een aantal andere nierziektes kan 
voorkomen evenals bij een idiopathische variant met een bijzonder slecht vooruitzicht 
wat betreft de nierfunctie. 
Net als SLE zelf is lupus nefritis erg variabel wat betreft de klinische verschijnselen en 
beloop. Deze klinische variabiliteit reflecteert het brede spectrum van afwijkingen die 
men kan zien op weefselniveau in een nierbiopsie onder de microscoop – zogenaamde 
“histologische” afwijkingen. De histologische afwijkingen in lupus nefritis zijn geclassificeerd 
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volgens de International Society of Nephrology/Renal Pathology Society (ISN/RPS) classificatie 
voor lupus nefritis. De meest ernstige klassen van lupus nefritis – de klassen III en IV – 
zijn gedefinieerd als nierbiopsieën waarbij respectievelijk minder of meer dan 50% van de 
glomeruli (bloedfilterlichaampjes) zijn ontstoken. Deze ernstige vorm van nefritis kan leiden 
tot eindstadium nierfalen en overlijden. Volgens de huidige richtlijnen voor de behandeling 
van lupus nefritis, moeten alle patiënten met klasse III/IV lupus nefritis worden behandeld 
met zware afweeronderdrukkende medicijnen, waaronder prednison en vormen van 
chemotherapie. Deze medicijnen kunnen gepaard gaan met ernstige bijwerkingen zoals 
onvruchtbaarheid, ontwikkeling van kanker en infecties. Echter, het op één hoop gooien 
van verschillende vormen en gradaties van ontsteking in klasse III/IV maskeert mogelijk 
kenmerken die wellicht zouden kunnen aangeven dat een patiënt een milder of juist een 
agressiever beloop van de ziekte zal hebben. Het gevolg van deze grote mengeling van 
afwijkingen in klasse III/IV is dat er wordt opgelegd dat alle patiënten behandeld moeten 
worden met deze zware medicijnen ongeacht de ernst van de ontsteking.  Als kenmerken van 
een milder of juist agressiever beloop zouden bestaan, zouden sommige patiënten wellicht 
een minder zware behandeling kunnen krijgen, terwijl andere patiënten misschien zelfs nog 
zwaarder behandeld zouden moeten worden. Deze hypothese is onderzocht in het tweede 
deel van dit proefschrift.
Het natuurlijke beloop (zonder therapie) van klasse III/IV lupus nefritis is onderzocht in 
hoofdstuk 4. Het doel van deze studie was om een subgroep aan te tonen van patiënten 
met een gunstige uitkomst die wellicht zouden kunnen profiteren van behandeling zonder 
de zware afweeronderdrukkende medicijnen. Uit de archieven zijn 101 patiënten met klasse 
III/IV lupus nefritis geïdentificeerd, waarvan drie patiënten in het verleden om verschillende 
redenen in strijd met de behandelrichtlijnen niet behandeld bleken te zijn geweest met 
afweeronderdrukkende medicijnen. Deze drie patiënten lieten een gunstig beloop zien wel 
9–24 jaar na nierbiopsie. Interessant genoeg was het beloop van nierfunctie van deze drie 
patiënten ook niet verschillend van het beloop van de andere 98 patiënten in de studie 
die wel waren behandeld met afweeronderdrukkende medicijnen. Deze drie patiënten zijn 
bewijs voor het bestaan van de subgroep van patiënten met klasse III/IV lupus nefritis met 
een gunstig natuurlijk beloop. De huidige richtlijnen leiden daarom in een aantal gevallen 
tot overbehandeling van patiënten met lupus nefritis. 
In hoofdstuk 5 is verder onderzocht welke kenmerken mogelijk van belang kunnen zijn 
om de uitkomst van patiënten met lupus nefritis te kunnen voorspellen. In deze studie zijn 
105 patiënten met verschillende klassen lupus nefritis volgens de eerdergenoemde ISN/
RPS classificatie onderzocht. Vijftig histologische kenmerken en tien klinische kenmerken 
werden getest of deze al dan niet verband hielden met verschillende uitkomsten. Deze 
uitkomsten waren de hoogte van de nierfunctie op de lange termijn, het doormaken 
van een opvlamming van lupus nefritis en het bereiken van eindstadium nierfalen. Dit 
onderzoek liet duidelijk zien dat het voorspellen van deze uitkomsten beter kan dan 




van de nierbiopsie, zoals de aanwezigheid van verlittekening en celdood, zijn met name 
van belang om een slechte uitkomst te voorspellen, evenals klinische kenmerken als niet-
westerse afkomst en hogere leeftijd. Een arts kan aan de hand van deze kenmerken dan 
bepalen of een patiënt waarschijnlijk een agressief beloop van de ziekte zal hebben en 
zware behandeling moet starten, of dat er een wat meer terughoudende aanpak op zijn 
plaats is.
In tegenstelling tot lupus nefritis, waarover relatief veel bekend is, is neuropsychiatrische 
lupus waarschijnlijk de minst begrepen uitingsvorm van SLE. Ongeveer 15–80% van de 
patiënten met SLE krijgt op enig moment een uiting van neuropsychiatrische lupus. Bij 
neuropsychiatrische lupus is er ontsteking van de hersenen of van zenuwen, hetgeen 
kan leiden tot uiteenlopende verschijnselen zoals hoofdpijn, epilepsie, psychose, een 
hersenbloeding of -infarct, depressie en aantasting van zenuwen in ledematen. De 
moeilijkheid om neuropsychiatrische lupus te diagnosticeren kan worden verklaard door 
de afwezigheid van duidelijke definities voor de diagnose, de afwezigheid van een test die 
met 100% zekerheid neuropsychiatrische lupus kan vaststellen en de grote verscheidenheid 
aan neuropsychiatrische symptomen. Omdat het nemen van een biopsie uit het brein vaak 
praktisch niet mogelijk en niet wenselijk is, is er ook weinig bekend over wat daadwerkelijk 
de patronen van schade en ontsteking zijn op weefselniveau.
In dit proefschrift is getracht om de schade op weefselniveau van neuropsychiatrische lupus 
beter in kaart te brengen (hoofdstuk 6). Hiervoor is een studie uitgevoerd gebruikmakend 
van hersenweefsel van overleden lupuspatiënten met en zonder uitingen in het centraal 
zenuwstelsel, alsmede van overleden patiënten zonder lupus. Opvallend is de schade bij 
neuropsychiatrische lupus gekenmerkt door de aanwezigheid van kleine stolsels in vaten 
en zuurstoftekort van het omliggende weefsel. Echte ontsteking met de aanwezigheid 
van immuuncellen, zoals in de nier vaak wordt gezien bij lupus nefritis, zijn in de hersenen 
vaak afwezig. Als mechanisme van ontsteking is het complementsysteem onderzocht, 
omdat dit systeem mogelijk een link kan zijn tussen ontsteking door antistoffen en het 
ontstaan van stolsel en zuurstoftekort. Zoals eerder genoemd worden eiwitten van het 
complementsysteem gebruikt bij het opruimen van verbindingen of “complexen” met 
antistoffen in het bloed (zie Tabel 1). In hoofdstuk 6 is beschreven dat de zogenaamde 
“klassieke” complementeiwitten in verhoogde mate werden gevonden in de hersenen 
van SLE-patiënten zowel met als zonder neuropsychiatrische manifestaties, maar niet in 
patiënten zonder SLE. Kleine stolsels werden alleen gevonden in breinen van patiënten 
met neuropsychiatrische lupus en niet in breinen van andere SLE-patiënten. Een belangrijke 
conclusie van dit onderzoek is dat het complementsysteem een belangrijke speler is 
betrokken bij het berokkenen van neurologisch schade in neuropsychiatrische lupus en 
mogelijk ook een belangrijk doelwit van behandeling kan zijn. Complementremmers 
worden momenteel al toegepast bij een aantal andere ziektes, maar kunnen mogelijk ook 
goed werken bij neuropsychiatrische lupus.
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Aangezien de oorzaak van SLE nog steeds onbekend is en beter begrip van oorzakelijke 
factoren kan helpen om de diagnose te stellen of om gerichte behandelingen aan te wijzen, 
is hier verder onderzoek naar gedaan. De observaties dat SLE met name voorkomt bij 
vrouwen in de vruchtbare levensfase en zwangerschap van invloed is op het ontstaan 
en beloop van SLE, zijn er veel theorieën over het verband tussen zwangerschap en het 
ontstaan van SLE. In de jaren 90 is voor het eerst aangetoond dat tijdens de zwangerschap 
cellen van het ongeboren kind of “foetus” via de placenta in de bloedstroom van de 
moeder terecht kunnen komen en wel tot 27 jaar na de bevalling daar kunnen blijven. 
Dit fenomeen wordt ook wel “chimerisme” genoemd, een fenomeen omschreven als 
het voorkomen van cellen in een individu die afkomstig zijn van een ander individu. De 
voornaamste bron van chimerisme is zwangerschap, waarbij er uitwisseling van cellen van 
moeder naar kind en vice versa plaatsvindt via de placenta. Bijna alle zwangere vrouwen 
zijn chimeer, maar ook jaren na de zwangerschap kunnen nog chimere cellen in de 
bloedstroom van de moeder worden gevonden. Zo is het mogelijk dat chimere cellen 
verkregen tijdens de zwangerschap een immuunreactie teweeg brengen, resulterend in een 
auto-immuun ziekte als SLE. Echter is nooit aangetoond dat de hoeveelheid chimere cellen 
daadwerkelijk is verhoogd in organen van zwangere vrouwen. In hoofdstuk 7 is gevonden 
dat de hoeveelheid mannelijke chimere cellen (met een Y chromosoom) in organen van 
vrouwen overleden tijdens de zwangerschap van een zoon is verhoogd ten opzichte van 
de hoeveelheid lang na de zwangerschap. Deze bevinding maakt chimerisme verkregen 
via de zwangerschap een intrigerende mogelijke oorzaak van een auto-immuunziekte als 
SLE. Opvallend was dat chimere cellen met name gevonden werden in de long, gevolgd 
door de milt, de nieren, het hart en het brein. Dit patroon van verdeling van chimere 
cellen over organen weerspiegelt het patroon dat al eerder is gevonden in een muismodel, 
hetgeen bevestigt dat proeven met muismodellen geschikt zijn om chimerisme tijdens de 
zwangerschap verder te onderzoeken in relatie tot ziekte.
De hoeveelheid chimerisme die achterblijft na de zwangerschap verschilt tussen vrouwen 
en is mogelijk gerelateerd aan de reactie van het immuunsysteem van de moeder op de 
cellen afkomstig van het kind. Weinig is bekend over hoe het immuunsysteem normaal 
reageert op cellen afkomstig van een kind en hoe de balans kan verschuiven in het geval 
van auto-immuunziekte. Het doel van de studie beschreven in hoofdstuk 8 was om het 
voorkomen en oorsprong van chimere cellen in vrouwen met SLE in kaart te brengen 
vergeleken met gezonde vrouwen. We vonden dat chimerisme vaker voorkwam in het 
bloed van vrouwen met SLE vergeleken met gezonde vrouwen. Chimerisme was in de 
moeders vaker afkomstig van hun kind dan van hun eigen moeder. In vrouwen met 
SLE kon het chimerisme afkomstig zijn van verschillende familieleden, terwijl in gezonde 
vrouwen het chimerisme altijd afkomstig was van slechts een familielid. Deze resultaten 




Conclusie: op naar “personalised medicine” bij patiënten met SLE
In dit proefschrift zijn verschillende uitdagingen onderzocht die verband houden 
met het stellen van de diagnose en het voorspellen van de prognose van SLE. Een 
belangrijke conclusie van dit proefschrift is dat “personalised medicine” de maatstaf 
moet zijn voor patiënten met SLE. Er moet speciale aandacht zijn om uitkomsten van 
individuele patiënten met SLE te verbeteren door het bestuderen van verschillende 
voorspellende of “prognostische” factoren die zijn geassocieerd met verschillende 
uitkomsten. Op deze manier moeten alleen patiënten behandeld worden die baat zullen 
hebben bij behandeling. Classificaties moeten daarom ontwikkeld worden uitgaande 
van prognostische subgroepen gekenmerkt door een combinatie van verschillende 
klinische en histologische kenmerken. Kennis over oorzakelijke factoren kan helpen 
bij het stellen van de diagnose, maar kan ook inzichten brengen met betrekking tot 
mogelijke gerichte behandelingen. Verder onderzoek zal zich moeten richten op de 
identificatie van oorzakelijke factoren die mogelijk ook doelwitten kunnen zijn voor 
gerichte therapie, nieuwe prognostische factoren die prognostische subgroepen beter 
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Appendix 2.1. Reclassification tables 
Reclassification tables of cases with and without SLE used for calculation of the net reclas-
sification improvement (NRI)
The NRI is based on reclassification tables constructed separately for patients with and 
without a reference standard clinical diagnosis of SLE ([SLE(+)] and [SLE(-)], respectively), 
and quantifies the correct movement in categories: [up|] for fulfilling classification criteria 
and [down|] for unfulfilling classification criteria as compared with reference classification 
criteria. The NRI can be expressed as follows: 
Σ up|SLE(+) – down|SLE(+)
NRI = +






Appendix 2.2. Prevalence of individual SLICC criteria
Prevalence of individual SLICC criteria in the full house cohort and the SLICC derivation 
cohort















SLICC clinical criteria n/total (%) % n/total (%) %
Acute cutaneous lupus 66/117 (56.4) 65.2 0.116 0/32 (0) 19.9 0.002
Chronic cutaneous lupus 14/117 (12.0) 19.7 0.065 0/32 (0) 6.4 0.242
Non-scarring alopecia 21/117 (17.9) 31.9 0.004 0/32 (0) 4.3 0.629
Oral/nasal ulcers 25/117 (21.4) 44.2 <0.001 3/32 (9.4) 7.9 0.734
Arthritis 86/117 (73.5) 79.0 0.243 1/32 (3.1) 56.4 <0.001
Serositis 44/117 (37.6) 35.2 0.652 1/32 (3.1) 2.8 1.000
Renal disorder 117/117 (100.0) 32.9 * 32/32 (100) 3.6 *
Neurologic disorder 18/117 (15.4) 5.5 0.002 0/32 (0) 1.0 1.000
Haemolytic anaemia 20/117 (17.1) 7.1 0.003 0/32 (0) 0.5 1.000
Leukopenia 36/117 (30.8) 46.4 0.004 0/32 (0) 5.2 0.385
Thrombocytopenia 28/117 (23.9) 13.5 0.013 0/32 (0) 2.0 1.000
SLICC immunologic criteria 
Antinuclear antibody 116/117 (99.1) 96.5 0.193 3/26 (11.5) 3.2 0.070
Anti-dsDNA 80/109 (73.4) 57.1 0.029 0/28 (0) 4.1 0.614
Anti-Sm 18/56 (32.1) 26.1 0.414 0/8 (0) 1.3 1.000
Antiphospholipid antibody 41/81 (50.6) 53.6 0.708 0/5 (0) 14.0 1.000
Hypocomplementaemia 94/109 (86.2) 59.0 <0.001 2/23 (8.7) 7.4 0.686
Direct Coombs’ test 25/75 (33.3) - - 0/13 (0) - -
SLICC validation cohort derived from Petri et al.1 Fulfilment of SLICC classification criteria in the full house cohort was 
registered up to and including the moment of renal biopsy. “Clinical SLE” refers to the reference standard clinicopathologic 
diagnosis of SLE. Anti-dsDNA, anti-double stranded DNA antibody. * Different by selection.
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Appendix 3.1. Clinical characteristics of patients with non-lupus full 
house nephropathy at the time of renal biopsy 
Patient 
number





1 Idiopathic minimal change-like nephropathy ANA(-), ASO(-) (-) (-) CS (-) 34
2 Idiopathic minimal change-like nephropathy ANA(-), ASO(-) (-) DM II† (-) HD (2), deceased (13) 11
3 Idiopathic mesangioproliferative nephropathy ANA(-), ASO(-) (-) DM II (27), hypertension (27) (-) (-) 38
4 Idiopathic proliferative glomerulonephritis ANA(-), HBsAg(-) Hypocomplementaemia* Alpha-thalassaemia* CS HD*, Tx (2) 24
5 Idiopathic proliferative glomerulonephritis ANA(dubious), anti-dsDNA(-), 
anti-GBM(-)
Nasal ulcers† Pulmonary silicosis†, nasal ulcers† CS CAPD*, Tx (1), deceased 
(11)
8
6 Idiopathic proliferative glomerulonephritis ANA(-), anti-dsDNA(-), HBsAg(-) Arthritis†, pleuritis* Seronegative RA* CS CAPD (1), deceased 
(11)
1
7 Idiopathic proliferative glomerulonephritis ANA(-), ASO(-) (-) (-) (-) Tx (2), deceased (20) 20
8 Idiopathic proliferative glomerulonephritis n/a (-) Migraines (11 years of analgesic use)†, DM II (36) (-) CAPD (26), Tx (29) 41
9 Idiopathic proliferative glomerulonephritis ANA(-), anti-dsDNA(-), anti-
GBM(-), ANCA(-), ASO(-)
(-) Haemoptysis (9) (-) CAPD (15) 24
10 Idiopathic proliferative glomerulonephritis ANA(dubious), ANCA(-), anti-
dsDNase B(-),
ANA (12) Pneumonia (Mycoplasma)*, gout*, pancytopenia (14) Cyclosporin 
+ CS
(-) 9
11 Idiopathic proliferative glomerulonephritis ANA(-) (-) Malignant hypertension†, primary Raynaud’s phenomenon (35) (-) Tx (39) 39
12 Idiopathic proliferative glomerulonephritis ANA(-), anti-dsDNA(-), ASO(-) Arthritis (9) RA†, episcleritis*, cutaneous vasculitis*, pleuritis (4), pericarditis 
(7)
AZA + CS Deceased (13) 13
13 Idiopathic MPGN + MN n/a (-) Return of MPGN in kidney graft (5, 20), myocardial infarction 
(18) 
AZA + CS CAPD (4), Tx (5), 
deceased (28)
28
14 Idiopathic proliferative glomerulonephritis ANA(-), ANCA(-) (-) (-) (-) CAPD (3), Tx (7) 26
15 Idiopathic MN ANA(-), HBsAg(-) (-) Migraine†, para-aortal lymphadenopathy (9) (-) Deceased (16) 15
16 Idiopathic MN + TIN ANA(-), HBsAg(-) (-) Hypertensive retinopathy†, CAD (2) CS (-) 2
17 Idiopathic MN ANA(-), ASO (-) (-) Coeliac disease (31), Hashimoto’s thyroiditis (31) (-) (-) 34
18 Idiopathic MN n/a (-) Erysipelas*, hypogammaglobulinemia*, cocaine/cannabis abuse 
(6)
AZA + CS CAPD (7), Tx (16) 21
19 Idiopathic proliferative glomerulonephritis ANA(-), anti-dsDNA(-), HBsAg(-) Serositis (2), arthritis (2) Myocardial infarction† (-) Deceased (16) 7
20 Idiopathic focal segmental glomerulosclerosis ANA(-), ASO(-) (-) Hashimoto’s thyroiditis (13) (-) CAPD (16), Tx (20) 34
Secondary non-lupus FHN
21 IgA-like nephropathy ANA(-), ASO(-) (-) IgA nephropathy in transplanted kidney (14), prostate 
carcinoma and renal mass (35)
CS Tx (14) 36
22 Crescentic IgA-like nephropathy HBV IgG(+)/IgM(-)/HBsAg(-) (-) IgA nephropathy in transplanted kidney (16), CAD (17), DM II 
(23), Guillain-Barré syndrome (32)
Unknown CAPD (14), Tx (16), 
deceased (36)
36
23 Crescentic IgA-like nephropathy ANA(-), HBsAg(-), anti-HCV(-), 
anti-HIV(-)
(-) Preeclampsia†, malignant hypertension*, IgA nephropathy in 
transplanted kidney (3)
(-) HD*, Tx (3) 12
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25 Infection-related glomerulonephritis Anti-dsDNA(-), anti-amoeba(+), 
anti-malaria(-), HAV IgG(+)/IgM(-)
(-) Malaria†, amoebic liver abscess *, DM II (20) (-) (-) 20
26 Infection-related glomerulonephritis n/a (-) Pyelourethral obstruction†, enterococcal sepsis*, 
cardiomyopathy (2), pericarditis (5)
(-) Tx (3), deceased (13) 13
27 ANCA-associated glomerulonephritis PR3-ANCA(+), ANA(-), anti-




Nasal ulcers*, cerebral vasculitis*, cavitating pulmonary lesions 
(15)
CYC + CS HD*, Tx (5) 19
28 ANCA-associated glomerulonephritis ANA(-), anti-ENA(-), anti-
cardiolipin(-), PR3-ANCA(+)
ANA† ([-] during FU), 
nasal ulcers*
ENT-limited PR3-ANCA-associated vasculitis* CYC + CS (-) 8
29 MN (anti-PLA2R) ANA(-), anti-PLA2R(+), aC1q(-) (-) Multiple pulmonary emboli* CS (-) 4
30 MN (cancer-associated) + FSGS ANA(-), ASO(-) (-) Squamous cell carcinoma lung* (-) Deceased (8) 0.4
31 MN (cancer-associated) + secondary 
glomerular sclerosis
ANA(+), anti-dsDNA(-), HBsAg(-), 
anti-HCV(-)
ANA*, ANA (4) Prostate carcinoma* (-) Deceased (9) 20
32 MN (cancer-associated) + minimal 
endocapillary proliferation
ANA(+), anti-dsDNA(-), aSS-A(+) ANA* (not tested during 
follow-up) 
Metastasised cervical carcinoma† CS Deceased (3) 3
Numbers in parentheses represent years since renal biopsy showing full house immunofluorescence. * indicates that the pheno-
menon occurred at the time of renal biopsy showing full house immunofluorescence; † indicates that the phenomenon occurred 
>6 months before the renal biopsy showing full house immunofluorescence; § Patients 2, 12, 22, and 31 died of cardiovascular 
disease, patients 30 and 32 of malignancy, patient 7 of terminal renal insufficiency, patient 13 of sepsis, and patients 4, 5, 15, 19, and 
26 of unknown causes.(+), present;(-), absent; n/a, not available; ESRD, end-stage renal disease; ANA, antinuclear antibody; ANCA, 
anti-neutrophil cytoplasmic antibody; ASO, anti-streptolysin O; AZA, azathioprine; CAD, coronary artery disease; CAPD, chronic 
ambulant peritoneal dialysis; CS, corticosteroids; CYC, cyclophosphamide; DM, diabetes mellitus; dsDNA, double stranded 
DNA; ENA, extractable nuclear antigen; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; 
HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, haemodialysis; HIV, 
human immunodeficiency virus; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; PLA2R, 












25 Infection-related glomerulonephritis Anti-dsDNA(-), anti-amoeba(+), 
anti-malaria(-), HAV IgG(+)/IgM(-)
(-) Malaria†, amoebic liver abscess *, DM II (20) (-) (-) 20
26 Infection-related glomerulonephritis n/a (-) Pyelourethral obstruction†, enterococcal sepsis*, 
cardiomyopathy (2), pericarditis (5)
(-) Tx (3), deceased (13) 13
27 ANCA-associated glomerulonephritis PR3-ANCA(+), ANA(-), anti-




Nasal ulcers*, cerebral vasculitis*, cavitating pulmonary lesions 
(15)
CYC + CS HD*, Tx (5) 19
28 ANCA-associated glomerulonephritis ANA(-), anti-ENA(-), anti-
cardiolipin(-), PR3-ANCA(+)
ANA† ([-] during FU), 
nasal ulcers*
ENT-limited PR3-ANCA-associated vasculitis* CYC + CS (-) 8
29 MN (anti-PLA2R) ANA(-), anti-PLA2R(+), aC1q(-) (-) Multiple pulmonary emboli* CS (-) 4
30 MN (cancer-associated) + FSGS ANA(-), ASO(-) (-) Squamous cell carcinoma lung* (-) Deceased (8) 0.4
31 MN (cancer-associated) + secondary 
glomerular sclerosis
ANA(+), anti-dsDNA(-), HBsAg(-), 
anti-HCV(-)
ANA*, ANA (4) Prostate carcinoma* (-) Deceased (9) 20
32 MN (cancer-associated) + minimal 
endocapillary proliferation
ANA(+), anti-dsDNA(-), aSS-A(+) ANA* (not tested during 
follow-up) 
Metastasised cervical carcinoma† CS Deceased (3) 3
Numbers in parentheses represent years since renal biopsy showing full house immunofluorescence. * indicates that the pheno-
menon occurred at the time of renal biopsy showing full house immunofluorescence; † indicates that the phenomenon occurred 
>6 months before the renal biopsy showing full house immunofluorescence; § Patients 2, 12, 22, and 31 died of cardiovascular 
disease, patients 30 and 32 of malignancy, patient 7 of terminal renal insufficiency, patient 13 of sepsis, and patients 4, 5, 15, 19, and 
26 of unknown causes.(+), present;(-), absent; n/a, not available; ESRD, end-stage renal disease; ANA, antinuclear antibody; ANCA, 
anti-neutrophil cytoplasmic antibody; ASO, anti-streptolysin O; AZA, azathioprine; CAD, coronary artery disease; CAPD, chronic 
ambulant peritoneal dialysis; CS, corticosteroids; CYC, cyclophosphamide; DM, diabetes mellitus; dsDNA, double stranded 
DNA; ENA, extractable nuclear antigen; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; 
HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, haemodialysis; HIV, 
human immunodeficiency virus; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; PLA2R, 
anti-phospholipase A2 receptor; RA, rheumatoid arthritis; TIN, tubulointerstitial nephritis; Tx, transplantation. 
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Appendix 3.2. Electron microscopy findings in patients with non-lupus 
(full house nephropathy) FHN 
Patient number Electron microscopy


































N/a, not available; mes, mesangial; sed, subendothelial; tm, transmembranous; sep, subepithelial. * Tubuloreticular inclusions 





Appendix 5.1. Histopathology definitions 
Definitions for glomerular lesions
Scorable glomeruli: Glomeruli that remained after excluding those which had less than 
3 mesangial fields because they were too small, on the edge of the biopsy and therefore 
incomplete, or otherwise artefactually damaged. 
Focal: Involving <50% of glomeruli.
Diffuse: Involving ≥50% of glomeruli.
Segmental: Lesion involving less than half of the glomerular area inside Bowman’s capsule. 
Global: Lesion involving more than half of the glomerular area inside Bowman’s capsule. 
Normal glomerulus: Glomerulus without a lesion. A normal glomerulus may show subtle 
changes as a result of ischemia.
Minimal leukocyte influx: Occurrence of <4 neutrophils, lymphocytes, or monocytes in 
an otherwise normal glomerulus, in the absence of endothelial cell swelling. 
Global sclerosis: Sclerosis of the entire glomerulus (obliteration of the capillary lumen by 
increased extracellular matrix, with or without hyalinosis or foam cells).
Segmental sclerosis: Less than 100% of the glomerulus is sclerosed (obliteration of the 
capillary lumen by increased extracellular matrix, with or without hyalinosis or foam cells).
Ischemic glomerulus: A glomerulus showing one or more of the following lesions: wrinkling 
of the glomerular basement membrane (GBM), collapse of the capillary tuft, thickening/
splitting of Bowman’s capsule. 
Mesangial hypercellularity: Four or more nuclei in the contiguous matrix of a peripheral 
mesangial segment. Note: mesangial hypercellularity is scored for each glomerulus by 
assessing the most cellular mesangial area. Mesangial areas immediately adjacent to the 
vascular stalk should not be scored. Scoring categories: (0) <4 nuclei; (1) 4–5 nuclei; (2) 
6–7 nuclei; (3) >7 nuclei.
Mesangial matrix expansion: Width of extracellular matrix exceeding 2 mesangial cell 
nuclei in ≥2 glomerular lobules.
Endocapillary hypercellularity: Hypercellularity due to an increased number of cells within 
glomerular capillary lumina (leukocytes or endothelial cells), causing narrowing of the 
lumina. Indicate whether lesion is segmental or global.
Endocapillary inflammatory infiltrate: ≥4 inflammatory cells in the glomerulus – either 
granulocytes, lymphocytes, or monocytes. 
Endothelial cell swelling: Prominence of endothelial cells in capillary lumens with narrowing 
of the lumen. 
Wire loop: Capillary wall thickening characterised by subendothelial immune complex 
deposits as demonstrated in the PAS staining.
Adhesion: Area of continuity between glomerular tuft and Bowman’s capsule separate 
from extracapillary lesion or from area of segmental sclerosis.
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Crescent: one of the following lesions involving >10% of circumference of Bowman’s capsule:
•	 Cellular crescent: Extracapillary cell proliferation of ≥3 cell layers with ≥50% of the 
lesion occupied by cells.
•	 Fibrocellular crescent: Extracapillary lesion comprising cells and extracellular matrix, 
with <50% cells and <90% matrix.
•	 Fibrous crescent: Extracapillary lesion composed of ≥90% matrix.  
•	 Segmental crescent: Lesion occupying less than 50% of the circumference of Bow-
man’s capsule.
•	 Circumferential crescent: Lesion occupying 50% or more of the circumference of 
Bowman’s capsule.
Fibrinoid necrosis: Disruption of the GBM with fibrin exudation and karyorrhexis. 
Karyorrhexis: Presence of fragmented nuclei including apoptosis.
Microthrombus: A microscopic clump of fibrin, platelets, and red blood cells.
Pseudothrombus: Eosinophilic, rounded aggregates in glomerular capillaries due to immune 
complex precipitates rather than fibrin, also known as hyaline thrombi.
Double contour/tram track: Double layer of GBM separated by clear zone on silver or 
PAS stains.
Spikes/vacuoles: Extensions of glomerular basement membrane between deposits (egg racks). 
Definitions of tubulointerstitial lesions
Interstitial infiltration: Inflammatory cells within the cortical interstitium in more than 5% 
of the cortical area. Specify dominant cell type of infiltrate: either lymphocytes, granulocytes, 
or other. Scoring categories: (0) <5%; (1) 5–24%; (2) 25–49%; (3) ≥50% of the cortical area.
Interstitial fibrosis: Extracellular matrix separating tubules in more than 5% of the cortical 
area. Scoring categories: (0) <5%; (1) 5–24%; (2) 25–49%; (3) ≥50% of the cortical area.
Focal cortical atrophy: Subcapsular ischemic cortical atrophy, sharply demarcated from 
normal cortex.
Tubular atrophy: Loss of cytoplasmic organelles, accompanied by a decreased diameter 
of tubules and thick irregular tubular basement membrane (TBM). Scoring categories: (0) 
<5%; (1) 5–24%; (2) 25–49%; (3) ≥50% of tubules.
Acute tubular injury: Necrosis of tubular epithelial cells (coagulation necrosis, karyorrhexis, 
pyknosis), swelling and clear vacuolation of tubular epithelium; can be accompanied by 
separation/detachment of tubular epithelium from TBM. 
Tubular casts: Presence of proteinaceous structures within the lumen of the tubules; may 
contain cellular debris; only scored when present in nonatrophic tubuli.
Tubular luminal macrophages: Presence of macrophages in tubular lumina; to be distinguish 
from sloughed epithelial cells. 
Tubular regeneration: Regeneration following acute tubular injury usually characterised 
by the presence of mitotic figures.
Tubular reabsorption droplets: PAS/silver-positive resorption droplets in the proximal 
tubular epithelium.




Definitions of vascular lesions 
Vasculitis: Inflammation in an arterial/arteriolar wall, characterised by the presence of 
inflammatory cells and/or fibrinoid necrosis.
Fibrinoid necrosis: Homogeneous, fibrin-like, deeply eosinophilic area with disruption of 
the architecture of the arterial/arteriolar vascular wall. 
Thrombosis: Total occlusion of vessel with fibrin.
Hyaline arteriolosclerosis: Accumulation of glassy, refractive, strongly PAS-positive material 
in the arteriolar intima and/or media.
Fibrous intimal hyperplasia: Cellular and fibroelastic intimal thickening with a fibrous intimal 
projection or cushion bulging into the lumen.
Arterial intimal fibrosis: Concentric thickening of the intima by deposition of collagen.
Appendix 5.2. Detailed study outcomes and statistical methods 
Outcomes were studied in two settings: (i) the complete cohort of patients with all obser-
ved LN classes who received various therapies and (ii) a subset of patients with class III 
or IV (±V) LN who received induction immunosuppression including cyclophosphamide 
(CYC), mycophenolate mofetil (MMF), or azathioprine (AZA). Prespecified variables for 
multivariable analyses were: variables from the reduced histopathology dataset; interaction 
terms of these variables with race, age, and induction immunosuppression; and the clinical 
variables sex, race, time since SLE diagnosis, age0, proteinuria0, erythrocyturia0, MAP0, induc-
tion immunosuppression, and decade during which the patient was biopsied. The models 
described below make no assumptions about the distribution of independent variables 
and the dependent variable, eGFR, was normally distributed; therefore, the variables were 
entered in the models without transformation. 
Renal flare and ESRD
The outcomes “renal flare” and “ESRD” relate to time-to-event analyses. We studied the 
time to a first LN flare in patients who achieved (partial) remission after induction therapy. 
Time to first renal flare was calculated from the date of biopsy until the date of flare for 
patients who reached this endpoint. For patients who did not, the follow-up time was from 
the time of biopsy until the last follow-up or until the patient reached ESRD. The definition 
of ESRD was dialysis-dependence for >3 months or renal transplantation. Time to ESRD 
was calculated analogous to time to renal flare. Patients who reached ESRD before the last 
follow-up were regarded as having eGFR=0 mL/min/1.73 m2 at the remaining time points. 
Outcomes were assessed using Kaplan-Meier analysis and Log-Rank tests. To ascertain 
independent predictors of ESRD and renal flare, multivariable Cox proportional-hazards 
models were designed including the prespecified variables. The multivariable models were 
simplified by stepwise removal of the least significant variables. Hazard ratios and 95% 
confidence intervals were estimated.
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eGFR during follow-up
The extent by which variables were associated with irreversible nephron loss was investi-
gated by modelling eGFR during follow-up.  An adjusted average level (intercept) and rate 
(slope) of decline of renal function during follow-up were modelled. Baseline variables were 
tested for their potential to predict a change in the intercept of this adjusted average level 
of decline in random intercept/slope linear mixed-effects models. Variables were tested 
in univariable models in the complete cohort (Table A5.2.1). A full model including the 
prespecified variables was designed and simplified by removing the least significant variables 
(Wald test) and comparing the goodness of fit of nested models (maximum likelihood 
ratio test). The distribution of data and the homogeneity of variance were assessed using 
graphical evaluation of residuals.
Progressive eGFR decline
To investigate progressive eGFR decline that did not necessarily result in ESRD and/or 
renal flare, variables were analyzed in association with progressive eGFR decline over 
1, 5, and 10 years relative to its linear prediction based upon eGFR0. The linear relati-
onship between eGFR0 and the predicted eGFR at time t (eGFRPredicted(t)) was defined as: 
eGFRPredicted(t)=eGFR0*β(t)+constant. Progressive eGFR decline relative to the eGFRPredicted(t) 
was assessed by calculating the corrected eGFR (eGFRCORR(t)), which was defined as the 
difference between the observed eGFR(t) and predicted eGFR(t).2 This procedure cre-
ated a corrected value that was independent of the starting value. Variables were first 
tested in univariable linear regression models for the outcomes eGFRCORR(1), eGFRCORR(5), 
and eGFRCORR(10) in the complete cohort (Table A5.2.2). For the complete cohort and the 
selected subset, a prediction model for these outcomes was designed using automated 
backward linear regression starting with the prespecified variables. 
Table A5.2.1 Univariable predictions of eGFR during follow-up up in 105 LN patients. 
eGFR in mL/min/1.73 m2 during follow-up†
Clinical variables β (95% CI)
Female sex −5.5 (−21.5; 10.4)
Age0, y −0.8 (−1.3; −0.4)*
Race Caucasian 0.5 (−13.1; 14.1)
Asian −0.8 (−16.3; 14.7)
Afro-Caribbean 0.3 (−19.3; 20.0)
Years since diagnosis SLE0 −1.2 (−2.3; 0.0)*
Proteinuria0, g/24h −0.4 (−2.1; 1.4)
Erythrocyturia0 >1+ −11.9 (−42.3; 18.5)
MAP0, mm Hg −0.5 (−0.9; −0.1)*
ACE inhibitor (after Bx) −2.2 (−19.1; 14.7)
Cytotoxic immunosuppressive (after Bx) −13.1 (−39.0; 12.8)




Table A5.2.1 Continued. 
Glomerular variables β (95% CI)
% Normal glomeruli/minimal leukocyte influx§ 0.4 (0.2; 0.7)*
% Global sclerosis −0.8 (−1.2; −0.4)*
% Segmental sclerosis 3.3 (−0.3; 6.9)
% Ischemic glomeruli −0.7 (−1.1; −0.2)*
% Mesangial hypercellularity 0.0 (−0.1; 0.1)
% Mesangial matrix expansion 0.1 (−0.3; 0.4)
% Endocapillary hypercellularity Any 0.0 (−0.2; 0.2)
Segmental 0.1 (−0.2; 0.4)
Global −0.1 (−0.3; 0.1)
% Endocapillary infiltration Lymphocytes 0.0 (−0.2; 0.2)
Monocytes 0.0 (−0.3; 0.2)
Granulocytes 0.1 (−0.4; 0.6)
% Crescents Cellular/fibrocellular§ −0.4 (−0.6; −0.1)*
Fibrous −1.6 (−2.8; −0.4)*
% Wire loops 0.0 (−0.3; 0.2)
% Adhesions –0.4 (−1.1; 0.3)
% Fibrinoid necrosis −0.2 (−1.1; 0.6)
% Karyorrhexis −0.1 (−0.6; 0.3)
% Double contours −0.1 (−0.5; 0.2)
% Spikes/vacuoles 0.1 (−0.2; 0.3)
Tubulointerstitial variables β (95% CI)
IF/TA 5−24% −3.9 (−14.0; 11.1)
25−49% −37.5 (−60.8; −14.2)*
≥50% −50.1 (−82.4; −17.7)*
Interstitial infiltration 5−24% −11.8 (−25.2; 1.6)
25−49% 13.1 (−20.7; 46.9)
≥50% −34.1 (−57.8; −10.5)*
Tubular casts −19.5 (−32.0; −7.1)*
Tubular macrophages −15.7 (−32.4; 0.9)
Tubular reabsorption droplets −10.2 (−23.2; 2.8)
Arterial intimal fibrosis −44.7 (−67.6; −21.7)*
β represents the mean change in the level of eGFR decline over time with one unit change of the variable. 
* P<0.05. † univariable random intercept/random slope mixed-effects models. § The composite variables “normal glome-
ruli/minimal leukocyte influx” and “extracapillary 2” were used rather than their individual components, as effect sizes of 
components were in strong accordance (data not shown).
Abbreviations: Bx, biopsy; IF/TA, interstitial fibrosis or tubular atrophy; MAP, mean arterial pressure.
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Table A5.2.2 Univariable predictions of progressive eGFR decline (in mL/min/1.73 m2) over 1, 5, and 10 years follow-up in 
105 LN patients.
eGFR decline over 1 
year (eGFRCORR(1))‡
eGFR decline over 5 
years (eGFRCORR(5))‡
eGFR decline 




Female sex −9.0 (−22.1; 4.1) 6.1 (−13.1; 25.2) −6.2 (−32.5; 20.1)
Age0, y −0.5 (−0.9; −0.1)* −0.9 (−1.5; −0.4)* −1.2 (−1.9; −0.4)*
Race Caucasian 10.2 (−0.8; 21.3) 11.2 (−7.1; 29.6) 13.7 (−11.2; 38.6)
Asian −2.9 (−15.7; 9.8) 5.3 (−10.8; 21.3) 3.5 (−18.6; 25.5)
Afro-Caribbean −16.6 (−32.6; −0.7)* −28.5 (−50.9; −6.1)* −28.5 (−59.1; 2.2)
Years since diagnosis SLE0 −1.0 (−2.0; −0.1)* −2.4 (−3.6; −1.2)* −2.2 (−3.9; −0.5)*
Proteinuria0, g/24h 0.2 (−1.3; 1.6) −0.5 (−2.5; 1.5) 1.2 (−1.5; 3.8)
Erythrocyturia0 >1+ 1.6 (−23.5; 26.8) −2.8 (−41.1; 35.5) −10.2 (−98.6; 78.2)
MAP0, mm Hg −0.1 (−0.4; 0.2) −0.3 (−0.8; 0.2) −0.9 (−1.4; −0.3)*
ACE inhibitor (after Bx) 0.0 (−13.9; 14.0) 2.1 (−17.9; 22.1) 9.9 (−18.9; 38.7)
Cytotoxic immunosuppressive (after Bx) 1.2 (−20.3; 22.7) 4.4 (−27.2; 36.0) 13.4 (−27.3; 54.1)
Biopsied after 2000 7.6 (−3.3; 18.5) 10.2 (−5.2; 25.6) 7.0 (−14.3; 28.2)
Glomerular variables
% Normal glomeruli/minimal leukocyte influx§ 0.0 (−0.2; 0.2) 0.1 (−0.2; 0.4) 0.1 (−0.3; 0.5)
% Global sclerosis −0.5 (−0.8; −0.2)* −0.7 (−1.1; −0.2)* −0.7 (−1.3; −0.1)*
% Segmental sclerosis −0.8 (−3.9; 2.3) 2.3 (−2.3; 6.8) 3.0 (−2.5; 8.5)
% Ischemic glomeruli −0.2 (−0.6; 0.2) −0.3 (−0.9; 0.3) −0.6 (−1.5; 0.3)
% Mesangial hypercellularity −0.1 (−0.2; 0.1) −0.1 (−0.2; 0.1) 0.0 (−0.2; 0.2)
% Mesangial matrix expansion −0.1 (−0.3; 0.2) −0.1 (−0.4; 0.3) 0.0 (−0.5; 0.5)
% Endocapillary hypercellularity Any 0.2 (0.0; 0.3) 0.2 (−0.1; 0.4) 0.3 (0.0; 0.6)
Segmental 0.0 (−0.3; 0.2) 0.1 (−0.3; 0.4) 0.4 (−0.1; 0.8)
Global 0.2 (0.0; 0.4) 0.2 (−0.1; 0.5) 0.1 (−0.3; 0.5)
% Endocapillary infiltration Lymphocytes 0.1 (−0.1; 0.3) 0.1 (−0.2; 0.3) 0.4 (0.0; 0.7)
Monocytes 0.2 (0.0; 0.4) 0.2 (0.0; 0.5) 0.4 (0.0; 0.7)*
Granulocytes 0.4 (0.0; 0.8)* 0.6 (0.0; 1.1)* 0.7 (−0.1; 1.5)
% Crescents Cellular/fibrocellular§ −0.1 (−0.3; 0.2) −0.1 (−0.5; 0.2) −0.1 (−0.6; 0.3)
Fibrous −0.6 (−1.6; 0.5) −0.9 (−2.4; 0.7) −1.0 (−3.2; 1.2)
% Wire loops 0.2 (−0.1; 0.4) 0.3 (0.0; 0.6) 0.3 (−0.1; 0.8)
% Adhesions −0.1 (−0.8; 0.5) −0.4 (−1.2; 0.5) −0.1 (−1.3; 1.0)
% Fibrinoid necrosis −1.0 (−1.7; −0.3)* −1.0 (−2.0; 0.1) −0.2 (−1.8; 1.5)
% Karyorrhexis 0.2 (−0.2; 0.5) 0.0 (−0.7; 0.6) −0.6 (−1.7; 0.5)
% Double contours 0.0 (−0.3; 0.3) −0.2 (−0.7; 0.3) −0.1 (−0.7; 0.4)





eGFR decline over 1 
year (eGFRCORR(1))‡
eGFR decline over 5 
years (eGFRCORR(5))‡
eGFR decline 




IF/TA 5−24% 3.2 (−9.3; 15.6) −6.4 (−23.8; 10.9) −13.5 (−37.0; 10.0)
25−49% −17.1 (−37.0; 2.8) −26.5 (−57.6; 4.6) −35.5 (−79.9; 9.0)
≥50% −27.9 (−55.4; −0.5)* −33.7 (−71.4; 3.9) −48.2 (−98.7; 2.3)
Interstitial infiltration 5−24% −2.5 (−13.8; 8.8) 0.7 (−15.2; 16.5) −5.5 (−27.0; 16.0)
25−49% 9.3 (−18.7; 37.2) 4.7 (−33.6; 42.9) 35.5 (−26.9; 98.0)
≥50% −11.7 (−31.8; 8.3) −22.5 (−53.8; 8.7) −30.2 (−81.6; 21.1)
Tubular casts −9.8 (−20.4; 0.9) −14.1 (−29.1; 0.9) −11.3 (−32.5; 9.8)
Tubular macrophages 8.4 (−5.8; 22.5) −3.6 (−23.6; 16.4) 10.6 (−16.3; 37.6)
Tubular reabsorption droplets −5.9 (−16.7; 5.0) −17.0 (−32.2; −1.9)* −15.9 (−37.1; 5.3)
Arterial intimal fibrosis −34.5 (−53.7; 
−15.3)*
−38.0 (−64.7; 
−11.3)* −31.1 (−63.5; 1.4)
Interpretation eGFRCORR1/5/10 (in mL/min/1.73 m2): β represents the change in eGFRCORR with one unit change of the 
variable. * P<0.05. ‡ Univariable linear regression models. § The composite variables “normal glomeruli/minimal leukocyte 
influx” and “extracapillary 2” were used rather than their individual components, as effect sizes of components were in 
strong accordance (data not shown).
Abbreviations: Bx, biopsy; IF/TA, interstitial fibrosis or tubular atrophy; MAP, mean arterial pressure. 
Appendix 5.3 Correlations between histopathologic variables
To prevent the inclusion of strongly correlated variables in our analyses of the various out-
comes, we assessed correlations between 29 glomerular and 9 tubulointerstitial variables 
(occurring in >5 patients), excluding normal glomeruli. Significant correlation coefficients 
between histopathologic variables after Bonferroni correction are shown in the table 
below. The following variables that were strongly correlated with other variables (r/ρ >0.8) 
were dropped: “mesangial 1” and “extracapillary 3/5” because of relatively laborious scoring; 
“endocapillary 3” because “minimal leukocyte influx” was encompassed by “normal glome-
ruli/minimal leukocyte influx”; “endothelial swelling”, “endocapillary inflammatory infiltrate”, 
and “endocapillary monocytes” because they were encompassed by “endocapillary 1/2/4”; 
“extracapillary 1” because cellular crescents were encompassed by “extracapillary 2”; and 
“interstitial lymphocytes” because they were encompassed by “interstitial infiltration”. 
“Interstitial fibrosis” and “tubular atrophy” were combined (whichever was the higher 
value) into a composite variable: “interstitial fibrosis/tubular atrophy” (IF/TA).  Thus, 29 
histopathologic variables remained to be tested in relation to outcomes. 
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Mes2 End2 End3 EndSw EndInf EndGran EndLym EndMon WL Extr1 Extr2 Extr3 Extr5 Necr DC TubAt IntInf IntLym IntGran IF ArtIF
GlobGS -0.5 0.5 0.5 0.4
Isch 0.5 0.4
Mes1 0.9 0.4
Mes3 0.3 0.4 0.4
MinLeu -0.4 -0.4
End1 0.5 0.6 0.5 0.5 0.3
End2 ─ 0.8 0.99 0.9 0.5 0.7 0.8 0.5
End3 ─ 0.8 0.8 0.6 0.6 0.5
EndSw ─ 0.9 0.5 0.7 0.8 0.5 0.4




Extr1 0.9 0.8 0.4





Because 666 comparisons were assessed, the significance was set to P=8∙10-5 by Bonferroni correction (P=0.05/666). 
Only correlation coefficients with P<8∙10-5 are shown. Numbers in the cells represent Pearson/Spearman correlation 
coefficients. Correlation coefficients >0.8 are bold-printed. Abbreviations: DC, double contours; End1/2/3: endocapillary 
1/2/3; EndInf, endocapillary inflammatory infiltrate; EndGran, endocapillary granulocytes; EndLym, endocapillary lymphocytes; 
EndMon, endocapillary monocytes; EndSw: endothelial cell swelling; Extr1/2/3/4/5: extracapillary 1/2/3/4/5; GlobGS, global 
sclerosis; IF, interstitial fibrosis; ArtIF, arterial intimal fibrosis; IntInf, interstitial infiltration; IntLym, interstitial lymphocytes; 





Mes2 End2 End3 EndSw EndInf EndGran EndLym EndMon WL Extr1 Extr2 Extr3 Extr5 Necr DC TubAt IntInf IntLym IntGran IF ArtIF
GlobGS -0.5 0.5 0.5 0.4
Isch 0.5 0.4
Mes1 0.9 0.4
Mes3 0.3 0.4 0.4
MinLeu -0.4 -0.4
End1 0.5 0.6 0.5 0.5 0.3
End2 ─ 0.8 0.99 0.9 0.5 0.7 0.8 0.5
End3 ─ 0.8 0.8 0.6 0.6 0.5
EndSw ─ 0.9 0.5 0.7 0.8 0.5 0.4




Extr1 0.9 0.8 0.4





Because 666 comparisons were assessed, the significance was set to P=8∙10-5 by Bonferroni correction (P=0.05/666). 
Only correlation coefficients with P<8∙10-5 are shown. Numbers in the cells represent Pearson/Spearman correlation 
coefficients. Correlation coefficients >0.8 are bold-printed. Abbreviations: DC, double contours; End1/2/3: endocapillary 
1/2/3; EndInf, endocapillary inflammatory infiltrate; EndGran, endocapillary granulocytes; EndLym, endocapillary lymphocytes; 
EndMon, endocapillary monocytes; EndSw: endothelial cell swelling; Extr1/2/3/4/5: extracapillary 1/2/3/4/5; GlobGS, global 
sclerosis; IF, interstitial fibrosis; ArtIF, arterial intimal fibrosis; IntInf, interstitial infiltration; IntLym, interstitial lymphocytes; 
IntGran, interstitial granulocytes; Mes1/2/3: mesangial 1/2/3; MinLeu, minimal leukocyte influx; TA, tubular atrophy; WL, wire 
loops.
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Correlations between histopathologic variables and the number of scorable glomeruli
None of the glomerular or tubulointerstitial variables were correlated with the number of 
scorable glomeruli. Patients who did not have more (≥) than 10 scorable glomeruli in their 
renal biopsies – as is the minimum biopsy requirement according to the ISN/RPS – had 
5 (n=5), 6 (n=3), 7 (n=2), 8 (n=6), or 9 (n=3) scorable glomeruli. A comparison bet-
ween patients with fewer (<) or more (≥) than 10 scorable glomeruli revealed  that only 
the distribution of karyorrhexis, endocapillary granulocytes, and monocytes was different 
between the groups (all P<0.05; higher scores in patients with ≥10 scorable glomeruli). 
Following these results, we decided to uphold our initial threshold of ≥5 scorable glomeruli. 
Karyorrhexis, endocapillary granulocytes, and endocapillary monocytes were not univari-
ably associated with any of the outcomes studied. These variables were not incorporated 
in our statistical models.
Appendix 5.5. Correlations between histopathologic variables and mean 
arterial pressure (MAP), eGFR, and proteinuria at the time of renal 
biopsy0 in 105 patients with LN
eGFR0, mL/min/1.73 m
2 Proteinuria0, g/24h MAP0, mm Hg
Glomerular variables r P r P r P
% Normal glomeruli 0.3 <0.001* −1.1 0.31 −0.2 0.02*
% Minimal leukocyte influx 0.3 <0.001* −0.2 0.06 −0.3 0.007*
% Normal glomeruli/minimal leukocyte 
influx
0.4 <0.001* −0.2 0.05* −0.3 0.001*
% Global sclerosis −0.2 0.02* 0.0 0.78 0.1 0.27
% Ischemic glomeruli −0.2 0.01* 0.0 0.82 0.0 0.78
% Endocapillary hypercellularity Any −0.2 0.11 0.2 0.02* 0.3 <0.001*
Segmental 0.1 0.36 0.0 0.85 0.2 0.08
Global −0.3 0.008* 0.3 0.007* 0.3 0.009*
% Wire loops −0.1 0.20 0.2 0.11 0.2 0.02*
% Cellular/fibrocellular crescents −0.2 0.03* 0.2 0.10 0.2 0.02*
Tubulointerstitial/vascular variables ρ P ρ P ρ P
IF/TA −0.3 0.001* 0.1 0.67 0.2 0.03*
Interstitial infiltration −0.3 0.002* 0.4 <0.001* 0.1 0.23
Tubular reabsorption droplets −0.1 0.34 0.2 0.07 0.2 0.03*
Tubular casts −0.3 0.007* 0.2 0.10 0.2 0.14
Tubular macrophages −0.3 0.008* 0.3 0.005* 0.1 0.18
Arterial intimal fibrosis −0.2 0.03* 0.0 0.78 0.2 0.04*
Only variables with any significant correlation with eGFR0, proteinuria0, and/or MAP0 are shown.*P<0.05. IF/TA, interstitial 
fibrosis or tubular atrophy; r, Pearson’s correlation coefficient; ρ, Spearman’s correlation coefficient.
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Appendix 5.6. Analysis of progressive eGFR decline
Results
Results for the complete cohort and the subset were comparable. In the complete cohort, 
a decline of eGFR over 1 and 5 years was independently predicted by non-Caucasian race 
(1 year : −17.7 mL/min/1.73 m2; 5 years: −17.8 mL/min/1.73 m2), age0 (1 year : −0.5 mL/
min/1.73 m2/year ; 5 years: −0.9 mL/min/1.73 m2/year), fibrinoid necrosis (1 year : −1.4 mL/
min/1.73 m2/%glomeruli; 5 years: −1.5 mL/min/1.73 m2/%glomeruli), fibrous crescents (1 
year : −1.2 mL/min/1.73 m2/%glomeruli; 5 years: −1.6 mL/min/1.73 m2/%glomeruli), and 
the presence of IF/TA ≥25% (1 year : −21.7 mL/min/1.73 m2; 5 years: −30.3 mL/min/1.73 
m2). Over 10 years follow-up, MAP0 was associated with eGFR decline (−1.1 mL/min/1.73 
m2/mm Hg), and endocapillary lymphocytes and wire loops were associated with eGFR 




Multivariable prediction models for progressive eGFR decline in mL/min/1.73 m2.
ISN/RPS Class I−V (n=105) ISN/RPS Class III/IV (±V)‡ (n=91) 
Progressive eGFR decline over 1 year (eGFRCORR(1))† (n=99)
Variables β (95% CI) β (95% CI)
(Constant) 30.6 (17.0; 44.1) 33.1 (18.2; 47.9)
Non-Caucasian −17.7 (−27.7; −7.7) −21.1 (−32.2; −10.0)
Age0, y −0.5 (−0.9; −0.2) −0.5 (−0.9; -0.1)
% Fibrinoid necrosis (glomerular) −1.4 (−2.0; −0.8) −1.4 (−2.0; −0.8)
% Fibrous crescents −1.2 (−2.1; −0.2) −1.3 (−2.3; −0.2)
IF/TA ≥25% −21.7 (−36.2; −7.2) −25.2 (−40.8; −9.5)
Tubular macrophages present 9.7 (−2.6; 21.9) 11.1 (-2.1; 24.4)
Progressive eGFR decline over 5 years (eGFRCORR(5))† (n=98)
Variables β (95% CI) β (95% CI)
(Constant) 45.7 (26.2; 65.2) 45.2 (24.4; 66.0)
Non-Caucasian −17.8 (−33.0; −2.7) −22.9 (−39.1; −6.6)
Age0, y −0.9 (−1.5; −0.4) −0.8 (−1.4; −0.3)
% Fibrous crescents −1.6 (−3.0; −0.2) −1.7 (−3.3; −0.1)
% Fibrinoid necrosis (glomerular) −1.5 (−2.5; −0.5) −1.5 (−2.6; −0.5)
IF/TA ≥25% −30.3 (−52.5; −8.1) −31.7 (−54.4; −9.1)
Progressive eGFR decline over 10 years (GFRCORR(10))† (n=71)
Variables β (95% CI) β (95% CI)
(Constant) 91.1 (40.4 ; 141.8) 93.6 (35.6; 151.6)
MAP0, mm Hg −1.1 (−1.6; −0.6) −1.1 (−1.7; −0.6)
% Endocapillary lymphocytes 0.4 (0.0; 0.7) 0.4 (0.0; 0.7)
% Wire loops 0.4 (0.0; 0.9) 0.5 (0.0; 0.9)
eGFRCORR(t) is the renal function deterioration (or improvement) in mL/min/1.73 m2 at t years relative to the expected 
value based on the eGFR at baseline and the unadjusted mean decline of eGFR over t years. eGFRCORR(t) = eGFRObserved(t) – 
eGFRPredicted(t). For a given patient, the eGFR at time t is given by: eGFRPredicted(t) + eGFRCORR(t). Estimations of eGFRPredicted(t) were: 
eGFRPredicted(1 year) = 29.9 + 0.67*eGFR0; eGFRPredicted(5 years) = 42.0 + 0.53*eGFR0; and eGFRPredicted(10 years) = 33.9 + 0.50*eGFR0. 
Estimations of eGFRCORR(t) are given in the table; e.g. eGFRCORR1 = Constant + βAge0*Age0 + β%fibrous crescents*%fibrous crescents 
+ β%fibrinoid necrosis*%fibrinoid necrosis + βnon-Caucasian (if Non-Caucasian) + βIF/TA ≥25% (if IF/TA ≥25%).
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Appendix 5.7
Interactions between histopathologic variables and race
Compared with patients with Afro-Caribbean race, spikes/vacuoles were more positively 
associated with eGFR in patients with Caucasian or Asian race (β=0.9 mL/min/1.73 m2 for 
each percent of glomeruli [95% CI, 0.2 to 1.5]). Moreover, the relationship between tubular 
reabsorption droplets on eGFR was different between ethnicities: Caucasian and Asian 
patients with tubular reabsorption droplets had a higher average eGFR than Afro-Carib-
bean patients (β=55.6 mL/min/1.73 m2 [95% CI, 16.8 to 94.4]).
Interactions between histopathologic variables and age
Age at the time of renal biopsy was significantly correlated with endocapillary granulocytes 
(r=−0.22, P=0.026), IF/TA (ρ=0.21, P=0.04), tubular casts (ρ=0.26, P=0.008) and arterial 
intimal fibrosis (ρ=0.31, P=0.001). A comparison between children (age <18 years) and 
adults revealed that children showed significantly less global glomerulosclerosis (P<0.001) 
and ischemia (P=0.03), and more endocapillary granulocytes (P<0.001). No differences 
in tubulointerstitial/vascular parameters were noted. No interactions between age and 
histopathologic variables were found. 
Interactions between histopathologic variables and therapy
To study whether cytotoxic immunosuppressive therapy influenced the predictive value of 
histopathologic lesions, induction therapy was divided in three categories: (i) no therapy/
prednisolone only; (ii) guideline-recommended therapy3-5 including intravenous cyclop-
hosphamide or mycophenolate mofetil (MMF); and (iii) azathioprine with prednisolone. 
No differences in the predictive value of histopathologic variables were noted between 
the treatment categories in mixed models for eGFR and in linear regression models for 
renal function recovery/deterioration in the complete cohort. In the subset of patients 
with class III or IV LN treated with cytotoxic drugs, analysis by treatment category for 
the outcomes ESRD and renal flare revealed no differences between predictive values 
of pathology variables, with one exception. Global glomerulosclerosis was significantly 
associated with ESRD for patients treated with azathioprine (HR 1.03 per %glomeruli, 
P=0.01), whereas in patients who received cyclophosphamide or MMF it was not. Time 
to first renal flare was not different between patients in each treatment category during 
10 years follow-up (P=0.5). Twenty-five of 53 patients with ≥10 years follow-up did not 
experience a first renal flare during 10 years follow-up: of these, 3 patients who received 
induction immunosuppression with azathioprine (n=10) and none of the patients in the 




Appendix 5.8. ISN/RPS classes in relation to outcome
Renal flare and ESRD
ISN/RPS classes were not significantly associated with overall renal survival (Log Rank test, 
P=0.7) and renal flare (Log Rank test, P=0.3) by Kaplan-Meier analysis (Figures below). 
eGFR during follow-up
The ISN/RPS class of LN (either I/II, III, IV-S [±V], IV-G [±V], or V) was significantly associated 
with the mean eGFR during follow-up (P<0.05). The lowest mean eGFR during follow-up 
was found in class IV-S LN. 
eGFR during follow-up in mL/min/1.73 m2 adjusted for ISN/RPS class (Mixed model analysis). 
Model β (95% CI)
(Intercept) 105.1 (76.3; 114.0)
(Time, y) −0.7 (−1.5; 0.02)
ISN/RPS class
  I/II −10.2 (−53.4; 33.0)
  III −18.3 (−49.5; 12.9)
  IV-S −36.8 (−67.6; −6.0)
  IV-G −21.9 (−52.9; 9.1)
  V* −
*Class V is the reference category; e.g. eGFR in class IV-S LN is on average 36.8 mL/min/1.73 m2 lower than eGFR in class 
V LN (which is 105.1 mL/min/1.73 m2 at the time of biopsy).
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Appendix 6.1. Case histories
Patient 1. NP-SLE, antiphospholipid syndrome, and cerebrovascular disease
This 57-year-old female had a 28-year history of SLE complicated by arthritis, endocarditis, 
epilepsy, cerebral infarctions, and antiphospholipid syndrome. She suffered an epileptic 
insult at home and was admitted to the hospital in a confusional state. An MRI scan (1.5-T) 
two weeks before her death revealed diffuse cortical atrophy, multiple previous cortical 
infarctions, and diffuse white-matter hyperintensities. The patient developed a myocardial 
infarction, severe pulmonary embolism, acute renal failure, and multiple cerebral infarctions. 
Antinuclear, anti-dsDNA, and antiphospholipid antibodies were repeatedly positive. The 
patient showed no sign of a central nervous system infection. The patient died in a coma 
from multiorgan failure due to active SLE and diffuse thrombotic complications. Autopsy 
revealed atrophy of the cerebral cortex, laminar cortical necrosis, old and recent micro-
infarctions, macroinfarctions, and diffuse vasculopathy.
Patient 2. NP-SLE, acute neurologic deterioration and vasculitis
This 38-year-old male had a 10-year history of SLE. He was admitted in a sub-comatose 
condition, a state that had developed the previous night. His SLE was associated with 
skin lesions, pleuritis, pericarditis, arthritis, and hypocomplementaemia. Antinuclear and 
anti-dsDNA antibodies were positive, whereas antiphospholipid antibodies were negative. 
All cerebrospinal fluid cultures at admission were negative. Ante-mortem CT and MRI 
(1.5-T) scans did not reveal any abnormalities. Upon the clinical diagnosis of NP-SLE, the 
patient was treated with high-dose immunosuppressive therapy (cyclophosphamide and 
prednisolone). However, the clinical course was complicated by the development of an 
opportunistic pulmonary infection with Klebsiella pneumoniae, and the patient died from 
respiratory distress in the intensive care unit. Autopsy revealed venous abnormalities 
consistent with venous vasculitis (invasion of lymphocytes within the vascular wall and 
fibrinoid necrosis) and diffuse vasculopathy. 
Patient 3. SLE, acute myocardial infarction, no neuropsychiatric symptoms
This 63-year-old female had a 30-year history of SLE complicated by arthritis, glome-
rulonephritis, pleuritis, and skin lesions. During the course of her disease, she did not 
develop neuropsychiatric symptoms. The patient was positive for antinuclear antibodies 
and anti-dsDNA antibodies, but negative for antiphospholipid antibodies.  Autopsy revealed 




Appendix 6.2. Post-mortem neuroimaging and evaluation of the acqui-
red images
Formalin-fixed brains were sectioned into approximately 1-cm-thick coronal sections and 
stored according to standard protocols. Remnants of the dura and vasculature were 
removed from the pial surface, and residual formalin was removed by immersion in phosp-
hate-buffered saline for at least one day to partially restore the transverse relaxation 
parameter.6 The brain specimens were placed between polymethyl methacrylate plates 
(170 mm long; 80 mm wide) and immersed in proton-free fluid (Fomblin LC55, Solvay). 
Post-mortem MRI scans were acquired using a whole-body 7-Tesla system (Philips Health-
care, Best, the Netherlands) fitted with a Nova Medical transmit coil with a 16-channel 
receiver array.
Images were acquired as described previously,7 with slight modifications; echo times (TE) 
ranged from 20–40 ms. After visual inspection, a TE time of 35 ms was found to provide 
the optimum combination of image quality and contrast; this TE was subsequently used for 
imaging all remaining brain specimens. Scan parameters were as follows: voxel resolution 
0.3 x 0.3 x 0.3 mm for a 3D T2*-weighted gradient echo sequence, with repetition time/
TE/flip angle = 60 ms/35 ms/10°. The number of slices was adjusted to match specimen 
size and ranged from 60−80 slices, resulting in scan duration of approximately 2.5 hours; 
seven signal averages were acquired to obtain sufficient image quality.
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Appendix 6.3. Relationship between C1q, C4d, and C5b-9 in SLE and 
NP-SLE
Twenty-five of 34 (74%) patients with SLE and/or NP-SLE had concurrent positive (either 
focal or diffuse) vascular staining of C1q, C4d, and C5b-9. Twenty-nine of the 30 patients 
with positive C4d staining (either focal or diffuse) had concurrent C1q deposits and 25 
had concurrent C5b-9 deposits (an overlap of 97% and 83%, respectively). Conversely, 29 
of the 33 patients with positive C1q staining (either focal or diffuse) had concurrent C4d, 
and 28 had concurrent C5b-9 staining (an overlap of 89% and 85%, respectively). Of the 
28 patients with positive C5b-9 staining, 25 (89%) had concurrent C1q and C4d staining.
C1q staining pattern C5b-9 staining pattern C4d staining pattern
SLE (n=18) No C4d staining Focal C4d staining Diffuse C4d staining
No C1q staining No C5b-9 0 1 0
Focal C5b-9 0 0 0
Diffuse C5b-9 0 0 0
Focal C1q staining No C5b-9 0 2 0
Focal C5b-9 2 4 1
Diffuse C5b-9 0 1 0
Diffuse C1q staining No C5b-9 0 0 0
Focal C5b-9 0 4 1
Diffuse C5b-9 0 2 0
NP-SLE (n=16) No C4d staining Focal C4d staining Diffuse C4d staining
No C1q staining No C5b-9 0 0 0
Focal C5b-9 0 0 0
Diffuse C5b-9 0 0 0
Focal C1q staining No C5b-9 1 0 0
Focal C5b-9 1 6 1
Diffuse C5b-9 0 1 1
Diffuse C1q staining No C5b-9 0 2 0
Focal C5b-9 0 1 0






Marker name Position 5’ Primer 3’
S01a F GGT ACC GGG TCT CCA CAT GA
S01b F GTA CCG GGT CTC CAC CAG G
S01a/b R* GGG AAA GTC ACT CAC CCA AGG
S03 F CTT TTG CTT TCT GTT TCT TAA GGG C
S03 R TCA ATC TTT GGG CAG GTT GAA
S04a/b F* CTG GTG CCC ACA GTT ACG CT
S04a R AAG GAT GCG TGA CTG CTA TGG
S04b R AGG ATG CGT GAC TGC TCC TC
S05b F AGT TAA AGT AGA CAC GGC CTC CC
S05b R CAT CCC CAC ATA CGG AAA AGA
S07b F GGT ATT GGC TTT AAA ATA CTC AAC C
S07b R CAG CTG CAA CAG TTA TCA ACG TT
S08b F GCT GGA TGC CTC ACT GAT GTT
S08b R TGG GAA GGA TGC ATA TGA TCT G
S09b F GGG CAC CCG TGT GAG TTT T
S09b R CAG CTT GTC TGC TTT CTG CTG
S10a F GCC ACA AGA GAC TCA G
S10b F TTA GAG CCA CAA GAG ACA ACC AG
S10a/b R* TGG CTT CCT TGA GGT GGA AT
S11a F TAG GAT TCA ACC CTG GAA GC
S11b F CCC TGG ATC GCC GTG AA
S11a/b R* CCA GCA TGC ACC TGA CTA ACA
GSTM1 F GAA CTC CCT GAA AAG CTA AAG CT
GSTM1 R GTT GGG CTC AAA TAT ACG GTG G
GSTT1 F TCC TTA CTG GTC CTC ACA TCT C
GSTT1 R TCC CAG CTC ACC GGA TCA T
RhD F GCC TGC ATT TGT ACG TGA GA
RhD R CAA AGA GTG GCA GAG AAA GGA
Xq28 F TGG GTT CCA ACC AGC A
Xq28 R ACT GAC AAT TAT CAC AGC TT
R271 F AGA GGA TTG ACT CGG G
R271 R GTT ACG TCT TAG ATG CCA G
SRY F TGG CGA TTA AGT CAA ATT CGC
SRY R CCC CCT AGT ACC CTG ACA ATG TAT T
F= forward, R= reverse, *common primer.
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